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PREFACE 
The purpose for any drug metabolism and pharmacokinetic (DMPK) study is to evaluate the 
characteristics of absorption, distribution, elimination and excretion from the body for a specific 
drug under certain conditions. The knowledge of DMPK is essential in understanding and 
evaluating drug concentrations and responses to ensure effective and safe drug use. 
 
I am particularly interested in evaluating the effects of the changes in body temperature (30-
35°C, mild therapeutic hypothermia) on drug metabolism and hepatic metabolizing enzyme 
activities. Our body temperature has a fundamental influence on nearly all aspects of 
physiological function. Forced cooling by therapeutic hypothermia potentially has side effects on 
multiple organ functions, including the activity of metabolic enzymes and therefore, has potential 
effects on the metabolism and elimination of xenobiotic substances. The work presented in this 
dissertation has been focused on a preclinical and clinical studies aiming to determine the 
activities of multiple drug metabolizing enzymes under therapeutic hypothermia conditions after 
critical illness. This work also focuses on the prediction of drug concentration under altered body 
temperature. Our findings are relevant to clinical and preclinical pharmacokinetic analysis study, 
resuscitation pharmacology, and clinical pharmacology. Furthermore, results from this study are 
expected to provide insightful information for the clinicians in their estimation of the effect of 
temperature alterations on drug metabolism and disposition.  Furthermore, results from this study 
are expected to provide insightful information for the clinicians in their estimation of the effect 
of temperature alterations on drug metabolism and disposition. 
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This work can be considered as the expansion of the current knowledge and advancement in 
topics of evaluating the effect of therapeutic hypothermia as well as cardiac arrest on drug 
metabolism. Both clinical and preclinical studies were carried out. This study has contributed to 
our understanding of the effect of hypothermia and cardiac arrest on the activity of specific CYP 
isoform, advanced cocktail bio-analytical assays development, and the utilization of microdosing 
PK methodology for critical ill patients. We have also performed population pharmacokinetic 
modeling and simulation analysis, in which the body temperature was considered as a possible 
statistical covariate of drug metabolism. Strong correlations have been found by establishing the 
mathematic PK model to best fit the observed data and proposed the physiological relationships.  
Results of this study are expected to provide rationale for drug dose adjustment to ensure a safer 
and more effective pharmacotherapy in this highly vulnerable patient population. We have 
elucidated the effects of hypothermia based on specific drug metabolic pathway, patients’ 
disease state, and specific temperature treatment and duration. 
Throughout my dissertation work, I have grown tremendously with the help from my dear 
family, friends, and my brilliant colleagues and mentors. I received a lot of help from many 
people in the field and therefore, I am very grateful, appreciative and thankful, especially to: my 
advisor Dr. Samuel Poloyac for his guidance and support throughout my tenure in his laboratory, 
to all my committee members Dr. Patrick Kochanek, Dr. Clifton Callaway, Dr. Robert Bies, and 
Dr. Wen Xie, from whom I have benefited greatly from their experience and their knowledge. I’d 
like to acknowledge and thank the research staffs from the School of Pharmacy, Emergency 
Medicine and Safar Center whom have all helped me thru the years, and I would like to share 
this achievement with my husband John, my parents and my sister and her family. Looking back 
now, I realize just how much I truly enjoyed this learning experience and I want to encourage 
   vi 
 
more students and scientists to further investigate disease related and treatment related drug 
metabolism and disposition.  
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Evaluation of the effects of therapeutic hypothermia and cardiac 
arrest on specific cytochrome P450 isoform activity 
 
Jiangquan Zhou, Ph.D. 
University of Pittsburgh, 2011 
ABSTRACT: 
Therapeutic hypothermia (TH, 32-35°C) mediated neuroprotection after brain ischemia has been 
demonstrated by both preclinical and clinical studies. Studies to identify the effects of mild 
hypothermia on CYP450 metabolism in humans are limited and the translational significance of 
the observations in the rat model remains to be identified. The goal of this study is to evaluate 
the effects of therapeutic hypothermia and relevant disease model cardiac arrest (CA) on hepatic 
drug metabolism. Specifically, this study evaluated the effects of therapeutic hypothermia on 
specific CYP450-mediated drug metabolism in preclinical and in translational clinical studies.   
 
There are several conclusions can be made based on our study results.  Mild hypothermia and 
cardiac arrest alter CYP activity in an isoform specific manner. Magnitude of the reduction is 
likely temperature, and extraction ratio specific. In animal model, the combination of 
hypothermia (33°C) and CA was most likely to be associated with isoform specific decrease of 
enzyme activities with greater changes observed for CYP3A and CYP2E1. Hypothermia 
decreased the volume of distribution of multiple probe substrates. In healthy volunteers, we 
found significant correlation between temperature and the clearance of CYP3A probe drug 
midazolam. Short duration hypothermia studies with hepatically eliminated drugs suggest ~11% 
reduction in clearance per °C change. Microdosed cocktail probes are likely to be very useful in 
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PK study design in critically ill patients due to the potential linearity of PK of probe drugs and no 
drug-drug interaction in the cocktail combination. In addition, our studies show that therapeutic 
hypothermia inhibited phenytoin metabolism in neonates with hypoxic ischemic encephalopathy, 
Km increase ~19% per °C and this likely due to the reduced activity of CYP2C9/CYP2C19, and 
reduced affinity between substrates and enzymes. In addition, effect of cooling on receptor 
dynamic response is unknown on the current data.  
 
In conclusion, our results have shown the effect of CA and hypothermia with interaction on 
isoform specific activity. Given the prominent role of mild hypothermia in the management of 
patients with CA, further translational studies using clinically relevant drugs and 
pharmacokinetics-pharmacodynamics modeling are vital for validation and prediction of drug 
dosing in different disease and temperature states. 
 
 
Key words: Therapeutic hypothermia, cardiac arrest, drug metabolism, critical care medicine, 
pharmacokinetics, in vivo probes, cytochrome P450, UPLC/MS/MS, population pharmacokinetic 
modeling 
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Hearts and brains, too good to die 
— Dr. Peter Safar, Father of CPR 
 
 
 
There's a way to do it better - find it. 
— Thomas A. Edison 
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1.0 INTRODUCTION 
  
1.1 CARDIAC ARREST AND BRAIN ISCHEMIA 
 
1.1.1 Cardiac arrest and global ischemic injury 
Cardiac arrest (CA) is the cessation of cardiac mechanical activity as confirmed by the absence 
of signs of circulation. More than 80% of sudden cardiac deaths occur in people with coronary 
artery disease. It is the number one natural killer among adults in the United States. 
Approximately half of all cardiac deaths can be classified as sudden cardiac arrest which 
accounting for approximately 300,000-450,000 deaths per year. Of these, 20-38% patients have 
ventricular fibrillation or ventricular tachycardia as the first recorded rhythm (Nichol 1999; 
Vaillancourt 2000). With the help of advanced cardiopulmonary resuscitation (CPR), only 37% 
of in-hospital cardiac arrests and 9% of out-of-hospital cardiac arrests can survive (Wright et al., 
2006).  
 
Brain injury starts to occur just about 4-6 minutes after the cardiac arrest. Brain injury can occur 
as a consequence of a reduction in cerebral blood flow (CBF) and subsequently loss of oxygen 
supply. The interruption of the blood flow and oxygen supply in the brain results in nutrition 
supply shortage, tissue death and loss of brain function, and severe neurological damage 
((Dearden 1985; Hertz 1981; Arai et al., 1984; Guercio et al., 1965). Brain ischemia in critical 
care medicine is associated with high mortality. Of all CA survivors, only between 3 and 10% 
are able to resume their former lifestyles and half experience persistent brain dysfunction 
(Wright et al., 2006). 
 
2 
 
1.1.2 Pathophysiology of brain ischemic injury 
After the interruption of circulation, multiple mechanisms of ischemic injury occur. Neuronal 
ischemic injury occurs rapidly with significant structure changes being observed within minutes. 
Siesjo et al. has reported that within 20 seconds of interruption of blood flow to the mammalian 
brain, under the conditions of normothermia, the EEG activity disappears, probably as a result of 
the failure of high energy metabolism. Within 5 minutes, high energy phosphate levels have 
virtually disappeared (ATP depletion) and profound disturbances in cell electrolyte balance start 
to occur (Siesjo et al., 1981). 
 
The loss of cellular high energy compounds during ischemia causes the loss of the Na+-K+ 
gradient, thus disrupting the cellular calcium homeostasis. This causes a massive and rapid influx 
of calcium into the cell. During ischemia, the NMDA (N-methyl-d-aspartate) receptor has been 
activated and they will also facilitate calcium entering into neurons (Berdichevsky 1983). 
Elevated intracellular calcium activates membrane phospholipases and protein kinases, leading 
to the production of free fatty acids including arachidonic acid. The degradation of membrane by 
phospholipase further reduces the efficacy of calcium pump, thereby leading to further calcium 
overload (Wolfe 1982).  
 
In addition, cerebral recovery from more than 5 minutes of cardiac arrest is greatly hampered by 
the secondary derangements of multiple organ systems after reperfusion (Safar 1985). After re-
introduction of the oxygen, the free fatty acids are metabolized into reactive oxygen species. 
Also, during ischemia, the hydrolysis of ATP via AMP leads to an accumulation of 
hypoxanthine. Increased intracellular calcium level enhances the conversion of xanthine 
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dehydrogenase to xanthine oxidase. Reactive oxygen species (ROS) will be generated by 
xanthine oxidase during reperfusion and oxygenation. Therefore, increased levels of several free 
radical species cause cell necrosis, apoptosis, DNA damage, altered mRNA selection and 
capillary membranes damage (Darwin, 1995; Tien et al., 1982; McCord 1985; Kleihues et al., 
1974). Calcium loading and free radical generation are the major contributors to mitochondrial 
structure changes (Frenkel et al., 1980). Mitochondrial stress leads to the release of cytochrome 
C, further inducing apoptosis and neuronal death.  
 
With the understanding of the mechanisms of the pathophysiology of cerebral ischemia, many 
possible pharmacological or non-pharmacological interventions have been tested to reduce brain 
damage. These interventions include: 1) calcium channel blockers, 2) reducing free radical, by 
pre- or post-insult treatment with nutritional antioxidant such as Vitamin E, selenium, vitamin C 
and beta carotene, 3) phospholipase inhibitor, 4) protection against the deleterious effects of 
excitotoxicity, NMDA glutamate receptor inhibitor, 5) increasing perfusion pressure, and 6) 
inhibition of inflammation (Darwin 1995).  
 
These possible interventions have been tested in the past decades but so far all of them have 
failed to demonstrate the neurological benefit after cardiac arrest in clinical trials. It has been 
proposed that the failure of individual agents is due to the fact that they typically target a single 
pathway in a multifactorial process of brain injury.  
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Figure 1-1: Brain ischemic cascade  
 
 
 
1.1.3 Drug concentration and metabolism in cardiac arrest and heart failure patients 
As previously discussed, cardiac arrest and heart failure incident leads to various 
pathophysiological disturbance in the body including hepatic ischemia, diminished intrinsic 
hepatic metabolic activity and changes in hepatic blood flow, and can associated with altered 
drug concentration and metabolism.   
 
Drugs with high extraction ratio such as morphine, lidocaine, and organic nitrates, can be 
affected by the significantly altered cardiac output and hepatic blood flow.  A previous study by 
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Stenson et al has demonstrated the correlation between decreased cardiac output, hepatic blood 
flow and increased steady state concentration of lidocaine (Stenson et al., 1971). A previous 
study has showed the prolonged half-live and metabolites for flosequinan in chronic cardiac 
failure compared to healthy volunteers, and this may also related to the changes of the flow 
(Nicholls et al., 1996).  
 
For oral drugs, reduced gastric emptying in heart failure patients delays absorption and decreased 
the peak plasma concentrations of furosemide, bumetanide and digoxin (Johnston et al, 1992).  
In addition, after an oral dose, the AUC and half-life of prazpsoin has doubled in congestive 
heart failure patients compared with healthy control subjects (Baughman RA et al., 1980). The 
decreased absorption and first pass metabolism can be offset by reduced hepatic and renal 
clearance, for oral drugs (Johnston et al, 1992).  
 
Previous study by Hepner et al tested aminophyrine as a probe drug for hepatic metabolic 
enzyme activity. The study found the significant reduced clearance of aminophyrine in heart 
failure patients compared with the control (29.7±7.1 vs 125.1±5.7 ml/min) (Hepner et al., 1978). 
The prodrugs ACE inhibitors such as enalapril, perindopril, ramipril, generally have lower than 
expected plasma concentrations in heart failure patients, indicating the potential biotransform 
activity decreased (Johnston et al, 1992). Quinidine, an antiarrhythmic, is extensively 
metabolized by the liver. Previous study has shown that in heart failure patients, quinidine 
concentration was 43% higher and the clearance decreased to 70% of the values in controls 
(Ueda et al., 1978). In addition, Tokola et al examined liver biopsy of patients of congestive 
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heart failure and found 30% decrease in the levels of drug oxidizing enzymes as compared to 
control (Tokola et al., 1973).  
 
The abnormal liver enzymes and liver function in congestive right side heart failure has been 
long recognized, and often time the acute heart failure is even worse than the chronic. This is 
thought to be due to direct centrizonal compression and hypoxic damage (Richman et al., 1961; 
Shibayama Y, 1987; Sokol et al., 2000). The mechanism is due to the fact that the liver gets to 
fixed amount of cardiac output, the decreases in flow is compensated for by an increase in 
oxygen extraction leading to anoxic necrosis in the centrizonal area. The increase in venous 
pressure caused by heart failure leads to atrophy of hepatocytes and causes perisinododial edema, 
which may lead to decreased oxygen diffusion (Sokol et al., 2000; Dunn et al., 1973). In 
addition, impairments of left ventricular function can also lead to marked liver enzyme 
abnormalities (Parisi et al., 1990; Cohen et al., 1974).  
 
Currently, the knowledge of impaired organ function, drug metabolism and distribution in 
cardiac arrest and other heart failure patients is very limited. 
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1.2 THERAPEUTIC HYPOTHERMIA 
 
1.2.1 Therapeutic hypothermia history  
The use of hypothermia for clinical purposes has ancient roots, beginning with its usage by the 
ancient Egyptians, Greeks, and Romans. Hippocrates (460-375 B.C.) advocated packing 
wounded patients in snow and ice to reduce hemorrhage. In early 1700, people already realized 
that cold could be used to kill the pain and deep hypothermia could improve the survival rate 
from various wounds. In the early nineteenth century (1814), Napoleon’s Surgeon General Baron 
Larrey observed that injured soldiers who became hypothermic and were put closer to a fire died 
more rapidly than those who remained hypothermic in the snow. The concept of hypothermia 
neuroprotection also dates back to ancient times, with the observation that infants abandoned and 
exposed to cold often remained viable for prolonged periods  (Mordecai et al., 1992; Polderman 
2004). 
 
In 1930s, Dr. Temple Fay used therapeutic hypothermia (TH) for 123 cancer patients to help 
with pain alleviation and to prevent further metastasis. In 1950s, Dr. Bieglow introduced TH to 
cardiac surgery patients. In 1960s, Dr. Rosomoff and Dr. Safar introduced TH to TBI and other 
neurological injuries. Most of these studies used relatively deep hypothermia (30 °C or lower). 
The clinical use of TH in critical care was discontinued for several years because of deep 
hypothermia‘s side effects, uncertain benefits and managment problems. From the early 1990s, 
mild to moderate hypothermia (30-35°C) was proven useful for treating focal and global 
ischemic brain injury in animal models and subsequently re-emerged as a therapeutic 
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intervention (Fay T, 1938; Alzaga, 2006; Bigelow et al., 1950; Shann F, 2003; Polderman 2004; 
Safar P, 1994; Safar and Bircher, 1994). 
 
1.2.2 Therapeutic hypothermia applications in critical care medicine 
Currently, the use of therapeutic hypothermia between 32-35°C has increased clinically based on 
the results from randomized controlled clinical trials, which have demonstrated decreased 
mortality and improved neurological outcomes after cardiac arrest in adults and hypoxic-
ischemic encephalopathy (HIE) in neonates.  
 
Due to the low survival rate and high incidence of brain dysfunction for post cardiac arrest 
patients, hypothermia provided the promising benefit for better neurological recovery and good 
outcome (Hypothermia after Cardiac Arrest Study Group, 2002; Bernard et al., 2002). Induced 
hypothermia after successful resuscitation leads to one additional patient with intact neurological 
outcome for every 6 patients treated (Kochanek and Bakken, 2009). Cardiac arrest patients 
especially if the initial rhythms of ventricular fibrillation are recommended to receive mild 
hypothermia at 32-34°C for 12-24 hours post resuscitation by American Heart Association and 
International Liaison of Committee for Resuscitation since 2003. Until 2009, more than fifty 
peer reviewed studies were identified investigating mild hypothermia during or after cardiac 
arrest in human adults. As of early 2011, there are over 200 published studies investigating 
hypothermia after cardiac arrest in human adult subjects.  
 
Therapeutic hypothermia is a promising therapy for neuroprotection for encephalopathy 
presumably due to hypoxic ischemia injury (Shankaran et al., 2010; Gluckman et al., 2005; 
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Thoresen et al., 2005; Polderman and Girbes, 2006). Neonatal HIE is one of the top reasons for 
infant deaths and brain damage. Neonates with moderate to severe encephalopathy have 
significant brain function deficits, memory impairment and increased risk of death (Shankaran 
2009). A relatively small reduction in temperature from 35°C to 32-30°C hypothermia in 
neonatal animals was associated with better maintenance of cerebral energy state during or 
immediately after ischemia (Shankaran 2008). Multiple multi-center clinical trials have 
consistently demonstrated that hypothermia was associated better outcome for neonatal HIE 
(Shankaran et al., 2008; Hoehn et al., 2008). 
 
Therapeutic hypothermia is also being evaluated in several other diseases including traumatic 
brain injury, focal brain ischemia, myocardial ischemia, spinal cord injury, hemorrhagic shock, 
pediatric cardiac arrest and encephalopathy due to acute liver failure (Schwab et al., 1998; 
Martinez-Arizala et al., 1992; Heinius et al., 2002; Stravitz, et al., 2009; Linares, et al., 2009; 
Kochanek et al., 2009). 
 
Therapeutic hypothermia is induced by lowering core body temperature via a wide array of 
surface cooling and intravenous cooling methods such as fans, cooling blankets, ice pack and 
intravascular cooling methods. Randomized controlled trials demonstrating neuroprotection have 
employed therapeutic hypothermia at 32-34°C for 12-24 hours in adults and up to 48-72 hours 
for pediatric patients (Bernard et al., 2002; Shankaran et al., 2010). Clinical implementation of 
therapeutic hypothermia can be divided into induction, maintenance and rewarming phases. 
Generally, rapidly reducing core body temperature, stable and controlled maintenance in the 
range of 32-35°C, and slow passive rewarming are suggested to be the key variables to yield 
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beneficial effects. In addition, it is important to identify eligible and ineligible patients and 
include key people from early in the planning stages to ensure success of therapeutic 
hypothermia (Oddo et al., 2006; Polderman 2004; Polderman and Herold, 2009; Seder et al., 
2009; Thoresen 2011; Callaway 2011).  
 
The success of therapeutic hypothermia in improving neurological outcomes has been attributed 
to the fact that reduced body temperature alters multiple pathogenic mechanisms simultaneously. 
Hypothermia inhibits multiple steps in the biochemical cascade that contributes to brain injury 
after insult including reduce excess glutamate, reduce mitochondrial stress, reduce cytochrome c 
release, reduce reactive oxygen species release and reperfusion injury, reduce lipolysis, reduce 
the changes of decreased protein synthesis and altered mRNA selection and positively interacts 
with postischemic repair processes (Polderman 2009;  Shintani et al., 2010; Silasi, et al., 2011, 
Kochanek et al., 2009; Busto et al., 1989).  It is the multiple pathway effects of hypothermia that 
are believed to underlie the success of therapeutic hypothermia as compared to single pathway 
pharmacologic agents in producing neuroprotective benefits.    
 
1.2.3 Thermoregulation  
Our body temperature has a fundamental influence on nearly all aspects of biological function, 
including the expression of genes, the activity of enzymes, the rate and force of contraction of 
muscles, the firing of neurons, and the habitats in which we can live (Blumberg 2002). All warm 
blooded animals, including humans, have a regulated/controlled body temperature. The normal 
body temperature for humans is 36.5-37°C. Humans can stay in very cold environments and 
maintain normal body temperatures. Many mathematical models of thermoregulation in humans 
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have been developed over the last 50 years (Grahn et al., 2011). Generally, we can consider that 
human thermal system consisting of core compartment and peripheral compartment. These two 
compartments regulate each other to adjust with temperature changes in the environment. The 
core temperature is regulated by limiting or increasing heat transfer to the periphery. Heat loss 
from the peripheral compartment is regulated through changes in skin perfusion (through 
vasodilation or vasoconstriction and radiation) and by increasing or decreasing the production of 
sweat (Polderman 2004).  
 
Our central thermoregulation, is believed to be mainly regulated by preoptic-
anterior/hypothalamus (POAH) in the brain, involves the afferent thermo-sensor spinal cord and 
involves nearly every part of autonomic nervous system (Benarroch 2007; Kurz 2008; Sessler 
2009). The normal set point is maintained when all thermoregulatory response are 
simultaneously turned on or off in response to hypothalamic temperature. Input temperatures 
outside the normal setting initiate regulatory responses. The core temperature triggering an 
afferent thermoregulatory response defines the threshold for central thermoregulatory response 
(Sessler, 2003; Sessler 2007). Body temperature regulation interference interacts with various 
physiological responses through the autonomic nervous system. In addition, autonomic nervous 
system is also related to the perception of pain, deep pressure, emotions and metabolic aspects, 
the endocrine functions as well as chronobiology related activities (Lungu et al., 1966; Haus 
2007).  
 
In many clinical situations, including disease states and drug therapies, the central set point for 
thermoregulation can be interrupted. General anesthesia markedly impairs normal control of 
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body temperature, reducing the threshold (triggering core temperature) for thermoregulatory 
vasoconstriction from 37°C to 34.5°C. Local anesthesia can also decrease the thresholds 
triggering vasoconstriction and shivering approximately 0.6°C (Sessler 2008; Sessler 2009). 
Consequently, most anesthesiologists consider mild hypothermia therapeutic during procedures 
(such as neurosurgery) in which cerebral ischemia is likely. In addition, sedatives, μ-opioid 
antagonist, biogenic amines, 5-hydroxytryptamine (5-HT), norepinephrine, α-adrenoceptor 
agonist, dopamine receptor antagonist and NMDA receptor antagonist all have been reported to 
affect thermoregulatory set point (Weant et al., 2010; Arpino et al., 2008; Chamorro et al., 2010). 
On the other hand, inflammation can cause hyperthermia, which most of time is also considered 
as a protective mechanism. Other physiological and pathological brain hyperthermia has been 
discussed in Kiyatkin, 2007. 
 
1.2.4 Physiological effect of therapeutic hypothermia 
Therapeutic hypothermia is a clinical based, forced, artificial cooling.  In this thesis research the 
work was focused on the clinically relevant temperature range from 32-35°C. Homeostatic 
mechanisms act to counter forced reductions in body temperature during therapeutic 
hypothermia and produce a series of physiological stress responses as well as cellular and organ 
function changes. These observed physiological responses can be temperature specific and time 
specific (Table 1-1).  
 
1.2.4.1 Thermoregulatory response  
The normal physiological response to hypothermia onset is peripheral vasoconstriction to 
preserve core normothermia (Warner 2009). Shivering often happens at the period of 
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hypothermia induction when body attempts to generate heat to counteract the cooling. A 
frequently cited threshold for shivering is 35.5°C. Shivering increases the total body metabolic 
rate by 2-4 fold, therefore raise concerns for myocardial stress in patients with vascular disease 
and hypothermia induction efficiency (Warner 2009). Shivering is readily inhibited with 
neuromuscular blockers, and combination of opioids, sedative, general anesthetics and may 
require mechanical ventilation (Doufas et al., 2004; Doufas 2003). 
 
1.2.4.2 Cardiovascular system 
Hypothermia induction may trigger the thermoregulatory and cardiovascular response such as 
shivering and increased heart rate. A core temperature reduction of 1°C in normal volunteers is 
associated with 20% increase in myocardial perfusion and 33% increase in heart rate, which is 
predicted parallel by increases in plasma norepinephrine and epinephrine (Frank et al., 2003; 
Warner 2009). Normally, tachycardia is observed when temperatures are above 35°C and 
bradycardia when temperatures are below 35°C (Polderman 2004). Mild hypothermia at 
temperatures below 35°C, decreased heart rate and the slowed metabolic demand accompanied a 
decrease in cardiac output of about 25% (Polderman 2004). Hypothermia is associated with 
changes in myocardial function. The cardiac index is transiently suppressed while systemic 
vascular resistance is transiently increased during hypothermia induction. These changes 
spontaneously correct by 6-18 hours after hypothermia onset (Bernard et al., 2002; Warner 
2009). In addition, hypothermia induced arrhythmia may occur for temperatures lower than 
30°C.  
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1.2.4.3 Blood system 
Watts et al. showed the slowed enzyme activity and decreased platelet function contributing to 
hypothermic coagulopathy in patients when temperature below 34.0°C. There was no change in 
fibrinolysis within the studied temperature range from 33-36°C (Watts et al., 1998). Lower pH 
has been found during hypothermia as the solubility of CO2 in blood increases at lower 
temperatures. In addition, lactic acid levels increase with shivering during hypothermia. A 
previous study also indicated that hypothermia and acidosis impair thrombin generation and 
fibrinogen availability (Martini 2009). Future study in this area is still needed for confirmation.  
 
1.2.4.4 Renal function 
As measured by creatinine clearance, renal function is impaired during hypothermia, but this 
appears to be reversible after rewarming (Arpino 2008). In a previous review paper, van den 
Broek et al. proposed that if the synthesis of creatinine decreases, the renal function may not be 
well predicted by creatinine clearance (Broek et al., 2010). Urine output usually increases in mild 
hypothermia initially, due to an increase in renal blood flow of vasoconstriction. Then with 
falling temperature, the increase in urine output may due to a loss of distal tubular ability to 
reabsorb water and a resistance to action of vasopressin (Polderman 2004; Mallet 2002). The 
cold induced diuresis is accompanied by an increase in urinary electrolyte excretion, probably as 
a result of reduced tubular sodium re-absorption (Atterhog 1975). Serum levels of K+, Mg2+, 
Ca2+ and phosphorus are significantly reduced during hypothermia. Compared with other organs, 
renal oxygen consumption is most rapidly reduced in hypothermia (Wong 1983). Renal blood 
flow reducing during hypothermia has been suggested, and it may be attributed to an increase in 
renal vascular resistance or decreased cardiac output, which may also related to specific 
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temperature range (Wong 1983). Previous study by Nishida et al. observed that GFR (glomerular 
filtration rate) did not decrease until the core temperature was below 32°C (Nishida et al., 2007).  
This study suggests that kidney is able to maintain GFR in spite of possible variations in the 
systemic circulation.  
 
1.2.4.5 Hepatic and metabolic 
The liver’s functions of detoxification and conjugation are believed to be depressed during 
hypothermia, therefore, affecting the half-life of many drugs, and prolonged effect of ethanol 
(Wong 1983). Liver enzyme activities have been shown to be temperature dependent; therefore 
decreases in activity are predicted during systemic hypothermia (Wong 1983). Oxygen 
consumption is reduced about 6% for every degree C fall in temperature indicating the general 
metabolism rate is reduced in parallel. The basal metabolic rate can be reduced by as much as 
50% at 28⁰C. Cardiac arrest injury related hepatic ischemia might also affect liver metabolism. 
Hepatic metabolism decrease coupled with decreased renal blood flow will result in decreased 
drug clearance depending on the degree to which the given drug is extracted by liver enzymes.  
These alterations in liver enzyme activity can lead to overtreatment or delayed awakening for 
anesthesia drugs (Diaz, 2011). 
 
1.2.4.6 Gastrointestinal 
Intestinal motility decreases below 34⁰C. The absorption of medication given orally or by 
nasogastric tube can be impaired during hypothermia (Polderman 2004; Mallet 2002). The 
gastric erosions and submucosal hemorrhages have found in hypothermia patients, although the 
authors suggested it was not clinical significant (Reuler 1978).  
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1.2.4.7 Others 
Mild hypothermia suppresses insulin release and cause insulin resistance. Peripheral uptake of 
insulin at the tissues is impaired (Polderman and Herold 2009; Polderman 2009). Possible airway 
infections, wound infections and prolonged healing were observed (Polderman 2004). 
Hypothermia also influences the immune system, which has not yet proven to contribute to 
hypothermia neuroprotection, but it may relate to the increases the risks of infection. More 
studies are needed for conclusion (Polderman 2004; Meybohm et al., 2009; Scumpia et al., 
2004). These physiology changes might be time dependent, with forced cooling change to 
regulated hypothermia, the body will tend to adapt the environment with adjusted physiology 
parameters. In addition, a series of complex physiological changes will be observed under a 
combination of disease injury and hypothermia effect.  
 
1.2.5 Rewarming  
Rewarming, normally using a heating air blanket is initiated after the recommended period of 
induced therapeutic hypothermia, to increase body temperature back to normothermia. 
Rewarming is one of the important variables in the therapeutic hypothermia. Physiological 
effects and cerebral effects of rewarming following a prolonged hypothermia are not fully 
understood. Most studies suggested a slow rewarming is most beneficial. In the cases of which 
intracranial hypertension is controlled only with hypothermia, a slower rewarming period should 
be established (Varon 2008). Although the optional rewarming rates remain to be determined, it 
is likely depends on the disease process and the presence or absence of brain swelling 
(Kochanek, 2009). Comparing literature reported rewarming rate in different patients population, 
the fastest rewarming rates are used in cardiac arrest patients (no faster than 0.5°C per hour), 
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slower rewarming rates are generally used in TBI (no faster than 0.25°C per hour) and even 
slower are used in stroke patients (Kochanek, 2009).  
 
Therapeutic hypothermia over the range of 32-35°C affects multiple physiologic processes 
including reduced metabolic rate, changes in pH and renal function, bradycardia and slowed 
gastrointestinal function and so on. Each of these physiological processes are also involved in 
determining a given drugs dispositional characteristics (Table 1-1).  It is this fact that led us to 
propose that TH would have a significant effect on drug disposition and effect.   
 
 
 
 
 Table 1-1: The effect of hypothermia on major organ systems 
Organ system Hypothermia effect Affected drug group 
Cardiovascular 
 
Renal 
 
Hepatic 
Gastrointestinal 
Metabolic 
Blood 
flow↓ in disease state, hypertension/hypotension, tachycardia >35°C, 
bradycardia <35°C, CO↓ <35°C 
 diuresis, vascular resistance↑, <35°C vascular resistance↑, electrolytes 
disorder, renal oxygen consumption↓, tubular dysfunction 
<35°C flow↓, liver enzyme activity ↓, liver function impairment in disease 
Intestinal motility↓, Gastrointestinal impairment 
Metabolic demand↓, CO2 production↓, O2 consumption↓ 
Platelet system interrupted<34°C 
High hepatic extraction drug 
 
Renal secretion drug,  
hydrophilic drugs 
Liver enzyme dependent drugs 
Orally given drugs 
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1.3 THE EFFECTS OF HYPOTHERMIA ON DRUG METABOLISM AND DRUG 
RESPONSE 
 
Zhou J and Poloyac SM The effect of therapeutic hypothermia on drug metabolism and response: 
cellular mechanism to organ function. Expert Opinion of Drug Metabolism and Toxicity, 
2011:7(7):1-14. 
 
The focus of this thesis is to determine the effect of hypothermia and cardiac arrest on drug 
metabolism. As previously discussed many of the enzymes and transporters involved in drug 
absorption, distribution and metabolism are temperature dependent. Therapeutic hypothermia has 
been utilized clinically without a full understanding of the effects on drug metabolism and drug 
disposition. The extensive pharmaco-therapeutic regimen employed in the critically ill patients, 
coupled with the difficulty identifying adverse drug reactions in these patients, creates a high 
likelihood of unrecognized therapy–drug interactions. For clinicians and health professionals to 
better understand the best method of applying hypothermia during pharmacological 
management, an understanding of the effect of hypothermia on current knowledge of drug 
disposition and response is necessary. In this chapter, a literature review of previous preclinical 
and clinical evidence and potential implications of altered drug disposition during mild and 
moderate hypothermia (30-35°C) is presented.  
 
1.3.1 Pharmacological interventions involved in therapeutic hypothermia  
A wide variety of medications are employed in critically ill patients who receive therapeutic 
hypothermia. These medications include analgesics/sedatives, muscle relaxant, cardiovascular 
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drugs, anti-arrythmics, anti-hypertensive, anti-convulsant, anti-platelets, antimicrobial and anti-
inflammatory drugs (Arpino et al., 2008; Chamorro et al., 2010). We summarized the list of these 
medications in Table 1-2 with their pharmacological effects, related specific metabolic and 
elimination pathways, liver extraction ratios, protein binding and half-lives (Chernow, 1989; 
Kim 2002; Kalliokoski 2009). Many of these drugs have narrow therapeutic windows and have 
not been thoroughly studied under conditions of therapeutic hypothermia. Adverse drug effects 
in critically ill patients are known to cause hypotension, increased ICU stay, prolonged 
cardiovascular support, prolonged respiratory depression and hematologic side effect (Devlin et 
al., 2010; Lazarou et al., 1998). These adverse effects have the potential to diminish the overall 
efficacy of therapeutic hypothermia.  
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Table 1-2: Pharmacological interventions involved in critically ill patients and their 
pharmacokinetic characteristics 
ANALGESICS/SEDATIVE Half life 
Protein 
binding 
Hepatic extraction 
ratio to blood flow CYP3A CYP2C9/19 CYP2D6 
Renal 
elimination 
Transporter/ 
OTHERS 
Fentanyl  2.5-6.5mins  80-85%  High √     √   
Propofol 30-60mins   95-99%  High       √  CYP2B/UGT 
Alfentanil 1.5-2 hrs   92%  Low √     √   
Midazolam 1.8-6.4hrs   95%  Low/Intermediate √     √   
Morphine 2-3hrs   30-40%  High     √  UGT 
MUSCLE RELAXANT                
Vecuronium 51-80mins  30%  Low  √     √  PGP 
Pancuronium 1.5-2.7hrs   77-91%  Low       √ +Bile   
ANTI-ARRYTHMICS             √   
Lidocaine 1.5-2hrs   61-80% High √     √  CYP1A2 
Amiodarone 15-142 days   33-65%  Low  √    Bile   
Digoxin 38-48hrs   25%  Low       √  PGP 
Procainamide 2.5-4.5hrs  15-20%  Intermediate     √ √   
Bretylium 7-8hrs   N/A  N/A       √ only   
ANTI-HYPERTENSIVE                
Verapamil  2.8-7.4hrs  90%  Intermediate √  √     PGP 
Enalapril 11hrs  N/A  Intermediate       √  OATP/ MRP2 
Metoprolol 3-7hrs   15%  Intermediate/high    √ √   
Propranolol 4-5hrs   88%  High     √    
Atenolol  6-7hrs  6-16%  Low       √    
Valsartan 6hrs  95%  N/A       √+Bile  OATP/MRP2 
Pravastatin 77hrs  50%  Intermediate/high       √ 
 OATP1B1 /  
OATP2B1 
RESUSCITATION/ 
INCREASE HEART RATE                
Epinephrine  2mins  N/A  N/A       √ MAO/COMT 
Dopamine 9mins N/A  N/A     MAO/COMT 
ANTI-CONVULSANT                
Phenytoin 6-24hrs   90%  Intermediate   √   √+Bile  UGT 
Phenobarbital 2-7 days   20-45%  N/A  √   √  CYP2C19/UGT 
Carbamazepine 25-65hrs   76%  Low    √     PGP/UGT 
MISCELLANEOUS                
Warfarin  30-60hrs  99.5%  Low   √ (S-,R-)   √  CYP1A2(R-) 
Mannitol 100mins   N/A  N/A       √ only   
Gentamicin      2 hrs  0-10%  N/A       √   
Rifampin 1.5-5hrs  90-95%  N/A       √  Esterases 
Ranitidine 2-3hrs   15%  N/A      √ √  PGP 
Famotidine 8-12hrs  10-28%  N/A       √   
Corticosteroids  Varies  varies  N/A √     √   
Magnesium Sulfate  N/A  NA  N/A       √ only   
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1.3.2 Metabolism and hepatic clearance alterations during therapeutic hypothermia  
In this section, we reviewed the current literature on the alterations in either drug concentrations 
or metabolism during hypothermia within the temperature range 30-35°C. It has been shown that 
hypothermia increases drug concentration and prolongs drug response in multiple clinical and 
animal studies. Based on the classic Pang et al. paper describing the well-stirred model (Pang 
and Rowland, 1977), factors that affect the hepatic clearance of a drug include: 1) blood flow to 
the liver; 2) intrinsic clearance; and 3) the fraction of drug bound to protein. Drugs can be 
classified into three categories according to the well-stirred model equation CLh=Q× 
[Fu×CL’int/(Q+Fu×CL’int)]: 1) Flow limited: in the case when intrinsic clearance (CL’int) is 
very large in comparison to blood flow (Q) , hepatic clearance (CLh) proximately equals blood 
flow, CLh=Q; 2) Capacity limited binding sensitive: for drug highly bound to plasma protein, a 
displacement from binding sites will significantly increase the concentration of drug at the 
hepatic enzyme site and the rate of metabolism will increase, CLh=Fu×CL’int; 3) Capacity 
limited binding insensitive: When CL’int is very small comparison to hepatic blood flow, 
assigning drug protein binding did not change during the therapeutic range, CL=CL’int. 
Therefore, in this section, we divided all the drugs into three categories based on the flow 
limited/hepatic extraction ratio, protein binding and their specific metabolic pathway (Table 1-3).  
 
1.3.2.1 Flow limited drugs in therapeutic hypothermia  
Flow limited drugs have a high hepatic extraction to blood flow ratio. Upon i.v. administration, 
the systemic clearance is highly dependent on the liver blood flow. Propofol and fentanyl are two 
examples of flow-limited drugs. During hypothermia at 34°C, propofol steady state 
concentrations during constant infusion increased 28% compared with normothermia at 37°C in 
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human volunteers (p < 0.05). In addition, the effect of hypothermia on propofol concentration 
was more significant in the beginning (3.34 ± 1.62 vs 1.99 ±1.30 pg/ml at 2 min), with 
diminishing magnitude of change at later time points. The three-compartment model was used to 
estimate the pharmacokinetic parameters of propofol. The clearance of propofol at 34°C 
decreased 25% compared with normothermic condition (0.59 (95% CI 0.24 - 1.38) vs 0.79 (0.58 
- 1.08) L/min). A significant association was found between hypothermia and the inter-
compartment clearances (1.73 (95% CI 1.40 - 2.15) vs 3.51 (3.40 - 3.63) L/h for shallow, p < 
0.005, and 2.13 (95% CI 1.83 - 2.47) vs 2.63 (2.15 - 3.22) L/h for deep, p < 0.05). Hepatic blood 
flow decreased in both groups (33 ± 11% in hypothermic volunteers and 23 ± 11% in 
normothermic group); however, this trend did not reach statistical significance (Leslie et al., 
1995).  
 
Similarly, in an animal study, Fritz et al. showed that fentanyl plasma concentrations are 
significantly elevated by 25±11% in 31.6°C as compared with normothermic group in pig model. 
Fentanyl was given infusion at a constant rate during a 6-hour period of hypothermia at 
31.6±0.3°C. Fentanyl plasma concentration at the end of the cooling was 7.0±0.6 ng/mL, which 
was significantly elevated as compared with normothermic group (< 6.0ng/mL). The authors 
suggested that the porcine model has similarities between swine and humans in the basic 
cardiovascular variables, as well as regional distribution of blood flows. Significant reduction in 
cardiac output and reduced flow to multiple organs were found during hypothermia. However, 
there was no significant alteration in hepatic artery flow during hypothermia (Fritz et al., 2005).   
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Meanwhile, in two animal studies, the metabolism and elimination of indocyanine green (ICG), a 
commonly used marker for liver function, especially hepatic blood flow and biliary excretion has 
been tested in hypothermia. Daemen et al. has shown that the plasma disappearance ICG was 
delayed in hypothermia 32.5°C and the clearance of ICG was significantly reduced from 
normothermia in male Wistar rats (Daemen et al., 1986). Pentobarbitone anesthesia was used in 
the study. ICG clearance decreased in the normothermia group as well (4.3±0.6 vs 8.0±1.7 
ml/min in conscious rats). Hypothermia further reduced the clearance of ICG to 0.9±0.1ml/min, 
which was almost an 80% decrease from normothermic group clearance. Mean resident time 
(MRT) increased two-fold in hypothermia. In addition, Nishida et al. has shown that during 
hypothermia at 32°C, significantly elevated ICG plasma concentration, increased area under the 
curve (AUC), and the decreased total clearance of ICG were found (Nishida et al., 2007). ICG 
was given IV at 1mg, plasma AUC at hypothermic group increased approximately two-fold 
compared to the AUC from control group (550±63.3 vs 271.4±53.4 µg×min/mL). Total 
clearance of ICG in hypothermic group decreased to 47% compared to those in normothermia 
(2.28±0.26 vs 4.83±0.70 ml/min).  
 
Based on these results, it is evident that the clearance of the high extraction ratio drugs, propofol 
and fentanyl are significantly reduced during hypothermia. Although this alteration is likely due 
to a reduction in hepatic blood flow, inconsistent results have been published demonstrating 
either no change or a decrease in hepatic blood flow during cooling. These inconsistent changes 
in blood flow may due to the different assessment methods. In addition, at specific time or 
specific temperature, blood flow pattern compared to normothermia might be different. Mild 
hypothermia initially may have no effect on blood flow, but with sustained low temperature 
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during prolonged cooling, reduced blood flow is more likely observed due to a lower metabolic 
demand. Definitive studies employing more precise experimental methods of assessing hepatic 
blood flow are needed for full elucidating the mechanisms that underlie changes in fentanyl or 
propofol clearance. 
 
1.3.2.2 Capacity limited binding sensitive drugs in therapeutic hypothermia  
Phenytoin is an example of capacity limited binding sensitive drugs. It is metabolized through 
CYP2C9 and CYP2C19 isoforms. Phenytoin metabolism and protein binding have been tested in 
mild hypothermia in the study by Iida et al. in patients (Iida et al., 2001).  Fourteen traumatic 
brain injury patients were cooled to 34°C for 72 hours. Phenytoin AUC was increased by 180% 
(46.3±30.2 vs 16.6±7.3 min·mg/mL, p<0.02) and mean residence time was prolonged by 180% 
(194±130 vs 69±28 minutes, p<0.01) during hypothermia compared with the corresponding 
values after rewarming. The clearance of phenytoin was decreased by 67% (1.11±0.86 vs 
3.42±2.67 L/h, p<0.02) and elimination constant (Ke) was decreased by 50% (0.10±0.06 vs 
0.20±0.15 h-1, p<0.05) during hypothermia. In addition, plasma concentration of metabolite 5-
pHPPH was found to be significantly lower during hypothermia in comparison with after 
hypothermia (p<0.05). Phenytoin protein binding did not change during hypothermia. Therefore, 
these results demonstrated that phenytoin metabolism was inhibited by mild therapeutic 
hypothermia in the study, whereas protein binding was not altered, thereby implying that 
hypothermia decreased the specific activities of CYP2C9 and CYP2C19. 
 
In a cardiac arrest animal model, our lab has shown that protein binding for chlorzoxazone at 
30°C did not change from normothermia values (Tortorici et al., 2006). A confounder in 
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assessment of protein binding was discussed by van den Broek et al. who has pointed that the in 
vitro protein binding test might not be accurate because hypothermic blood has been warmed up 
to 37°C. Therefore, the drug protein binding formed a new equilibrium before the analysis was 
carried out, which would introduce errors in predicting the temperature effect (van den Broek et 
al., 2010). However, in our lab previous observation with chlorzoxazone, careful temperature 
control was conducted throughout experimentation to decrease the likelihood of this confounder. 
Lin et al. has suggested that use of the ratio of cerebrospinal fluid (CSF) drug concentration to 
plasma drug concentration to determine the drug binding in vivo, since CSF is a very low-protein 
fluid, drug in CSF is considered to be primarily unbound (Lin et al., 1997). Future studies 
providing available data from both blood and CSF concentrations during hypothermia will be 
helpful in further evaluating the protein binding change in vivo.   
 
Collectively, the current evidence suggests that mild to moderate hypothermia does not 
significantly alter drug protein binding. However this conclusion is based on studies in a limited 
number of drugs, therefore future research is needed to determine the magnitude of hypothermia 
effect on protein binding across substrates.  
 
1.3.2.3 Capacity limited binding insensitive drugs in therapeutic hypothermia  
The clearance of capacity limited drugs is highly dependent on the hepatic intrinsic clearance, 
including, hepatic drug metabolism by CYP enzymes. Many drugs used in critical care medicine 
are metabolized by various isoforms of the CYP450 enzyme (Table 1-1). In this section, we 
reviewed the published evidence on evaluating drug concentration and pharmacokinetic 
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alterations. Individual drugs have been divided by their specific metabolic CYP pathway (Table 
1-3). 
 
1.3.2.3.1 CYP3A 
CYP3A is one of the most important CYP isoforms. CYP3A has broad substrate specificity, 
metabolizing a wide array of compounds such as the small molecules acetaminophen through the 
large molecule such as cyclosporine. A typical substrate structure includes lipophilic, 1-2 H-bond 
donor/acceptors at 5.5-7.5Å and 8-10Å from the binding site (Kumar et al., 2001). Commonly 
used drugs in critical care metabolized by CYP3A include midazolam, fentanyl, alfentanil, 
cardiovascular drugs such as lidocaine, calcium channel blockers vecuronium and the majority of 
corticosteroids. Since CYP3A is present in both liver and intestine, the changes in activity of 
CYP3A in the intestine could also affect both bioavailability and systemic clearance. 
 
Midazolam is a well-known CYP3A4/5 substrate. A previous study by Fukuoka et al. has 
reported a five-fold increase in plasma concentration of midazolam in hypothermic patients 
compared with the normothermic patients at steady state (Fukuoka et al., 2004). The highest 
concentration was found at 96 hours which was close to 10,000ng/mL in hypothermic group, 
while the concentration at steady state in normothermic group was less than 2000ng/mL. The 
hypothermic patients were maintained for 48 hours and slowly rewarmed. The complete sample 
collection time was 216 hours after ICU administration. There was greater than 100-fold 
decreases in clearance of midazolam in these brain injured patients when subjects’ core 
temperature were lower than 35°C. In addition, the calculated volume of distribution in 
hypothermia was 84% higher than normothermia. In later part of this thesis, we will discuss one 
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of our human studies in Chapter 4. In this study, we evaluated midazolam clearance in normal 
healthy volunteers during mild hypothermia. We found that the midazolam clearance and inter-
compartment clearance were associated with temperature reduction. Systemic clearance of 
midazolam has been estimated to decrease 11.1% per °C reduction in body temperature (Hostler 
et al., 2010). Therefore, the significant increases in midazolam concentration and decreased 
clearance observed in the studies are likely due to the depressed CYP3A intrinsic clearance. 
Similarly, neuromuscular blocker vecuronium is metabolized by CYP3A and the clearance of 
vecuronium was estimated to decrease 11.3% per °C in healthy human volunteers by Caldwell et 
al. (Caldwell et al., 2000).  The percentage alteration in plasma clearance per °C reduction in 
body temperature can be very helpful in developing dosing guidelines in patients receiving 
therapeutic hypothermia.  
 
The decreased CYP3A activity in vitro has been reported by Fritz et al., in which ethyl morphine-
N-demethylation experiment showed strong temperature dependence of CYP3A activity 
(p<0.01) (Friz et al., 2005). Hepatic CYP3A4 activity decreased to 69±1% at 32°C when 
compared with the CYP3A4 activity in normothermic control (p<0.001). Future in vitro study 
testing different concentrations of substrate as well as different temperatures will be helpful.  
 
Collectively, these studies suggest that the metabolism of the drugs that depend on CYP3A 
activity would be inhibited due to the acute effect of hypothermia on CYP3A functional activity. 
The magnitude of the alteration is still open for debate given the data suggesting from 100-fold 
to as little as 20% changes during mild to moderate hypothermia. Future studies are warranted to 
determine the magnitude and clinical implications of these changes in CYP3A function.   
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1.3.2.3.2 CYP2C9 and CYP2C19 
The CYP2C9 and CYP2C19 isoforms are involved in the metabolism of many commonly used 
medications in critically ill patients. Typical CYP2C9 substrate characteristics are weak acid, 
lipophilic, 1 or 2 H-bond donor/acceptors at 5-8Å from the site of metabolism. CYP2C9 also 
displays polymorphism in humans (Kumar et al., 2001; Stearns et al., 1995). CYP2C9 
metabolizes drugs including phenytoin, carbamazepine, warfarin, tolbutamide, neostigmine and 
losartan. Typical substrates of CYP2C19 are neutral or weakly basic, 2-3 H-bond done/acceptors 
at 4.5Å apart and 5-8Å from the site. CYP2C19 is also involved in metabolizing phenytoin, 
phenobarbital and carbamazepine. In addition, it metabolizes omeprazole, diazepam and 
propranolol. 
 
The metabolism of phenytoin has been discussed in the previous section, in which significant 
metabolism inhibition during hypothermia has been reported (Iida et al., 2001). Neostigmine is 
metabolized by CYP2C9 and CYP3A. Heier et al. demonstrated that at normothermia condition, 
the clearance and central volume of distribution of neostigmine were 696 ± (SE 175) ml/min and 
5590 ± (SE 926) ml in healthy human volunteers. During mild hypothermia at 34.5°C, there was 
a 38% reduction in the central volume of distribution of neostigmine, and no significant 
alteration of total clearance was found (Heier et al., 2002). In this case, the reduction of volume 
of distribution can describe the plasma concentration-time profile better than the reduction of 
clearance. Acenocoumarol is also metabolized by CYP2C9. Acenocoumarol is an anticoagulant 
that functions as a vitamin K antagonist. In the animal study, clearance of S-acenocoumarol 
decreased significantly during hypothermia at 32.5°C in male Wistar rats (Daemen et al., 1986). 
At normothermia 37.5 °C, pentobarbitone anesthesia decreased clearance of acenocoumarol from 
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those in conscious rat (4.9 ± (SE 0.4) vs 3.4 ± (SE 0.3) ml/min). Hypothermia further reduced the 
clearance to 2.5 ± 0.2 ml/min, which was around 49% decrease from normothermia conscious 
state rats and 26.5% decrease from normothermia anesthesia group.  
 
Phenobarbitone is metabolized by CYP2C19. Kadar et al. performed a study in critically injured 
children and found that the reduction in body temperature influenced the rate of metabolism, 
urinary excretion and the volume of distribution of phenobarbitone (Kadar et al., 1982). Urine 
excretion for metabolite hydroxyphenobarbital at hypothermia 30-31°C was significantly 
decreased to 48% (1.87±0.71 vs 4.50±.90 µmol/h, p<0.005) while the urinary excretion rate of 
the parent drug was 52% higher (12.01±3.38 vs 6.25±1.25 µmol/h, p<0.05) during hypothermia. 
Volume of distribution increased around 25% in hypothermia. Relatively large inter-individual 
variability was observed in the study; however the change in the relative concentration of 
phenobarbitone and metabolites in urine was influenced primarily by body temperature. 
Collectively, these data suggest that hypothermia likely decreases the activity of CYP2C19 and 
rate of metabolism of its substrates.  
 
Collectively, the metabolism and distribution for CYP2C9 and CYP2C19 substrates phenytoin, 
S-acenocoumaril and phenobarbitone were significantly altered during hypothermia. Clinically, 
based on the narrow therapeutic window for anticoagulants and anticonvulsant, carefully clinical 
drug monitoring is warranted for these drugs during hypothermia.  
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1.3.2.3.3 CYP2D6 
While CYP2D6 constitutes only about 2% of the total CYP content, it is an important isoform 
due to its role in the metabolism of a large number of pharmaceutical agents such as 
antiarrhythmics, CNS agents, codeine and anticancer drugs. CYP2D6 also exhibits genetic 
polymorphisms in humans. While CYP3A4 can accommodate molecules that are structurally 
very diverse, CYP2D6 has a very strict structure requirement. Substrate normally have at least a 
basic nitrogen, have a flat hydrophobic area near the site of oxidation, be relatively hydrophilic, 
and have two potential hydrogen bonding groups in order to bind to the CYP2D6 active site 
(Kumar et al., 2001).  
 
Biotransformation of pentobarbital involves CYP2D6 and CYP2B6. The pharmacokinetics of 
pentobarbital during hypothermia (<32°C) was examined in 11 children with Reye syndrome, 
hypoxic encephalopathy, or acute head injury. A significant decrease in the systemic clearance 
and a 20% decrease in volume of distribution at steady state of pentobarbital were observed in 
hypothermic patients when compared to previous data in normothermic adult volunteers 
(Schaible et al., 1982). The diminished systemic clearance of pentobarbital may result from the 
decrease in intrinsic enzyme activity that accompanies hypothermia, as well as hepatic 
dysfunction in patients with Reye syndrome, hypoxic encephalopathy, or acute head injury. In 
the animal model, the metabolism of pentobarbital-2-C14 during hypothermia at 30°C was 
studied by Kalser et al. (Kalser et al., 1968).  Since liver is the only site of metabolism of 
pentobarbital, the disappearance of the unchanged pentobarbital from the blood, after initial 
uptake by the liver, is primarily due to its liver metabolism. This study showed that the hepatic 
clearance decreased to 50% and the metabolite concentration in blood decreased 32% during 
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hypothermia. In addition, bile clearance of pentobarbital decreased 71% and less metabolite 
excreted in bile as well. Therefore, hypothermia markedly decreased the amount of metabolites 
appearing in blood and bile as well as liver itself.  
 
Rocuronium is partially metabolized through CYP2D6 and CYP2C19 and large amount of 
rocuronium is excreted unchanged in bile and urine. Beaufort et al. study showed that 
hypothermia at 30.4±0.8°C reduced the plasma clearance of rocuronium around 50% (from 4.26 
±0.50 to 2.17±0.62 mL/ kg/ min), and prolonged the mean residence time approximately 1.9-fold 
(from 56 ±19 to 108 ± 39 min) in nineteen neurosurgical patients (Beaufort et al., 1995). The 
significant reduction in the clearance of pentobarbital and rocuronium are likely due to the 
reduction in the metabolic rate. Studies designed to determine the effect of hypothermia on the 
metabolism and pharmacokinetics of other CYP2D6 substrate drugs are needed to support these 
results for further conclusion on the effect of hypothermia on the activity of CYP2D6 isoform.  
 
1.3.2.3.4 CYP2E1 
CYP2E1 comprises 7% of total P450 content. It is implicated in the metabolism of volatile 
anesthetics, acetaminophen, ethanol, and a small number of therapeutic agents. CYP2E1 active 
site is relatively restricted compared to the large and open bonding pocket of CYP3A4. The 
active site contains two phenylalanines at alignment position 78 and 88 which appears to be able 
to adopt a coplanar arrangement of the phenyl rings, possibility represent an access channel for 
planar aromatic substrates (Carrière et al., 1996).  In addition, humans exhibit wide inter-
individual variability in concentrations of CYP2E1 mRNA and protein. The CYP2E1 activity 
ranges four to five- fold differences from different individuals. 
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Chlorzoxazone is a well-known CYP2E1 probe. Rate of chlorzoxazone-6-hydroxylation was 
significantly correlated with concentrations of immunochemically measured CYP2E1 level 
(Carrière et al., 1996). Our laboratory demonstrated that hypothermia at 30°C decreased the 
systemic clearance of chlorzoxazone in cardiac arrest rats (1.26±0.34 vs 0.580±0.37 mL/min). 
Significant decreases in 6-hydroxychlorazoxone formation clearance and increases in plasma 
AUC of chlorzoxazone were found in temperature at 30°C compared to normothermia at 37°C 
(Tortorici et al., 2006). In vitro analysis demonstrated that Michaelis-Menten constant (Km) was 
significantly increased at 30°C compared to 37°C (551±150 vs 255±52 µM), and CYP2E1 
enzyme capacity (Vmax) was not altered. It was concluded that these alterations were due to the 
reduced intrinsic metabolic clearance produced by a decrease in enzyme substrate affinity and 
were not due to the alteration in drug protein binding.  
 
Despite the limited number of studies, the results have consistently demonstrated the reduced 
intrinsic clearance and depressed enzyme activity, including multiple CYP isoforms during mild 
and moderate hypothermia.  
 
1.3.3 Phase II enzymes function in therapeutic hypothermia 
The activities of Phase II enzymes are important for drug biotransformation and elimination. 
UDP-glucuronosyltransferase (UGT) is one of the most studied phase II enzymes. Endogenous 
substrates of UGT enzymes include bilirubin, thyroxin, and steroid hormones. Commonly known 
UGT substrate drugs include benzodiazepines, morphine, propofol, phenobarbital, propranolol, 
aspirin, acetaminophen and valproic acid (Kumar et al., 2001).  
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Morphine is primarily metabolized by UGT2B7, with little to no contribution by Phase I enzyme 
in the morphine elimination. Two major metabolites are morphine-3-glucuronide (M3G) and 
morphine-6-glucuronide (M6G). M6G binds to μ-receptors and is a more potent analgesic than 
morphine (Wittwer et al., 2006). The effect of mild hypothermia at 33-34°C on morphine 
concentration in infants with hypoxic-ischemic encephalopathy was studied by Róka et al. (Róka 
et al., 2008). The study found that the mean morphine concentration in hypothermia was 
significant higher than normothermic group at 72 hours after birth. More notably, 6 of 7 infants 
in the hypothermia group vs 1 of 6 infant in the normothermia group demonstrated a 
concentration above the 300ng/mL. The clearance of morphine in hypothermia was significantly 
decreased from 0.89 (0.65-1.33) to 0.69 (0.58-1.12) mL/min/kg. The results showed that plasma 
morphine concentration were more likely to be elevated to potentially toxic concentrations in 
HIE patients receiving therapeutic hypothermia.  
 
In the animal model, a previous study by Bansinath et al. showed a significantly higher 
concentration of morphine in both plasma and in cerebrospinal fluid (CSF) during hypothermia 
(30°C) in dogs (Bansinath et al., 1998). Morphine sulfate was given IV bolus at dose 1mg/kg. 
Total clearance and volume of distribution of morphine were significantly decreased in 
hypothermia (25±4 vs 84±11 ml/min/kg, and 5.7±0.8 vs 8.5±0.7 L/kg, respectively) compared to 
those in normothermia at 37°C. Meanwhile, the elimination half-life and mean residence time 
were significantly increased during hypothermia (184±21 vs 81±8 minutes, and 3.6±0.8 vs 
1.5±0.17 hours, respectively).  
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Collectively, these results demonstrated that morphine metabolism is inhibited during 
hypothermia, and careful monitoring the drug concentration and response is necessary. The 
reduced activity of UGT during hypothermia is a likely mechanism underlying the inhibition of 
metabolism. However, study on alternative UGT substrates, morphine pharmacodynamics during 
hypothermia will be necessary for further confirmation.  
 
1.3.4 Transporter function in therapeutic hypothermia 
A growing body of evidence has demonstrated a significant role of various transporters as 
effectors of both drug distribution and excretion. The major drug transporters, the ATP binding 
cassette (ABC) family are the major family involved in drug distribution, which include 
transporter ABCB1 or MDR1 P-glycoprotein (PGP). PGP has considerable influence on the 
systemic absorption and pharmacokinetics of drugs, especially for many calcium blockers and 
antiarrhythmic drugs used in critical care medicine. A previous study by Jin et al. demonstrated 
that MDR1-mediated transport of digoxin was decreased in vitro at temperatures of 32°C (Jin et 
al., 2006). The transporter net ratio from basal side to apical side direction for digoxin decreased 
approximately 50% in lower temperature (7.5 vs 14), suggesting that MDR1 transport activity 
was reduced at 32°C. No significant difference in passive diffusion process was observed at 
32°C in this study. In addition, the transport of inulin, as a marker of paracellular pathway, 
showed no effect of temperature at 25°C, suggesting that the tight junction was not affected 
during therapeutic hypothermia. Therefore, this study indicated that therapeutic hypothermia 
cause a suppression of active MDR1 transporter, whereas, no alterations in passive diffusion 
occurs at 32°C. 
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Previously discussed liver blood flow marker ICG is also a transporter substrate. ICG is excreted 
into bile through multiple different transporters including organic anion transporter (OATP), and 
multidrug resistance associated protein (MRP2). Biliary clearance of ICG decreased significantly 
to 46% in hypothermia at 32°C (1.94 ± 0.26 vs 4.18 ± 0.63 ml/min) (Daemen et al., 1986). 
 
Collectively, these studies suggest that the activity of PGP reduces during hypothermia, while 
passive diffusion is not altered by cooling. ABC transporters require energy in the form of 
adenosine triphosphate (ATP) to translocate substrates across cell membranes. Thereby, these 
results suggest that there is a reduction in energy dependent processes during hypothermia. More 
studies are needed for determining the effect of hypothermia on transporters MDR1, OATP and 
others. 
 
1.3.5 Renal elimination in therapeutic hypothermia 
Renal elimination function can be divided into filtration, active secretion and re-absorption. The 
balance between renal clearance and metabolism is determined by physical-chemical properties 
of the drug (Smith et al., 1996). Gentamicin is a commonly used IV antibiotic that is eliminated 
largely by passive filtration with a minor contribution by tubular secretion. A previous study by 
Liu et al. evaluated gentamicin in infants with HIE (Liu et al., 2009). This study showed that the 
mean trough serum gentamicin concentration of hypothermia and normothermia groups were 
similar (2.19±1.7 vs 2.30±2.0 mg/L). The clearance of gentamicin was not altered by 
hypothermia at 33.5°C. As expected, a significant correlation was found between high serum 
gentamicin concentration and impaired renal function. Plasma creatinine concentrations were 
closely correlated (r2=0.36) with trough serum concentration in both hypothermia and 
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normothermia groups. In an animal study, gentamicin pharmacokinetics was studied during 
hypothermia at 35°C in hypoxia piglets. Pharmacokinetics was evaluated after three gentamicin 
doses: before hypoxia-ischemia, after hypoxia-ischemia during mild hypothermia or 
normothermia, and during normothermia 48 h after the first dose. The study found that hypoxia-
ischemia altered the renal function and the gentamicin clearance correlated with the creatinine 
plasma concentration (r=0.89) as well as kidney pathology score (r=0.55). There was no 
significant change in gentamicin pharmacokinetic parameters at 35°C compared to 39°C. 
Therefore, mild hypothermia after hypoxia-ischemia does not affect gentamicin 
pharmacokinetics over clinically employed therapeutic hypothermia temperatures (Satas et al., 
2000). Although studies which evaluated temperatures below 30°C have shown reduced 
gentamicin clearance due to a reduced cardiac output and decreased GFR (Koren et al., 1985), 
these reductions are not expected over the clinically relevant 32-35°C temperature range.  
 
Pancuronium is another drug that is primarily excreted through kidney filtration. Sixty to eighty 
percent of pancuronium is excreted through the kidneys and the remainder is metabolized in the 
liver and excreted in the bile. In a cat model, pancuronium was studied by Miller et al. in cat at 
39°C, 34°C and 29°C (Miller et al., 1978). Volume of distribution of central compartment and 
total volume of distribution of pancuronium at steady state were both decreased at 34°C 
compared to 39°C. Total plasma clearance was found to be significantly reduced at 29°C 
compared to 39°C, while there was no difference of pancuronium clearance at 34°C vs 39°C 
(10.7±0.9 vs 10.9±1.5 ml/kg/min) observed. There was a markedly reduced urinary and biliary 
excretion of pancuronium only when temperature was below 30°C. Fluorescein isothiocyanate 
(FITC)-dextran (FD-4), an index of GFR has been evaluated in the rat model during therapeutic 
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hypothermia at 32°C (Nishida et al., 2007). FITC-dextran is eliminated by passive diffusion. 
Plasma concentrations were almost equal at all time points between 37°C and 32°C. The total 
clearance and renal clearance at 32°C and 37°C were also comparable ( 2.10±0.14 vs 1.88±0.13 
ml/min for total, and 1.57±0.09 vs 1.45±0.05 ml/min for renal), while both were significantly 
decreased only at a temperature of 28°C (Nishida et al., 2007). Collectively, these studies 
suggested that the kidney is able to maintain GFR during mild and moderate therapeutic 
hypothermia (30-35°C) in spite of possible variations in the systemic circulation. Therefore, 
renal passive filtration is not likely to be altered by mild hypothermia.  
 
With respect to renal tubular secretion, PSP (phenolsulfonphthalein), a hydrophilic dye, has been 
used as a tool to assess renal function in preclinical studies. PSP is excreted into the bile and 
urine as a free form or conjugative metabolite. A previous study by Nishida et al. has shown that 
the plasma concentrations of PSP were increased significantly in the hypothermic groups (at both 
32°C and 28°C) compared to the normothermic group at 37°C (Nishida et al., 2007). The plasma 
AUC of PSP in hypothermic group at 32°C was significantly larger than those in the 
normothermic group (1487.9±227 vs 788.6±0.9 µg·min/mL). The total clearance of PSP 
decreased about 42% at temperature 32°C (0.87±0.1 vs 1.51±0.15ml/min).  In addition, both 
plasma MRT and bile MRT of PSP in the hypothermic group were significantly longer than 
those in normothermic group (95.1±15.7 vs 49.9±4.7 minutes for plasma MRT and 88.2±12.1 vs 
49.5±0.9 minutes for bile MRT). Furthermore, biliary and urinary recovery rates of PSP 
metabolite excretion were calculated as 37°C (66%, 34%) vs 32°C (75%, 25%), showing a 
tendency of decrease in urinary contrition by low body temperature.  Therefore, PSP clearances 
(bile, urine and metabolites) in the hypothermic group were decreased, suggesting that 
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hypothermia reduces active tubular secretion of PSP (Nishida et al., 2007). In addition, this study 
also suggested that active renal transporter would be attenuated at 32°C due to a failure in energy 
dependent drug secretion. 
 
In summary, these studies suggest that active, energy requiring processes such as tubular 
secretion are reduced during therapeutic hypothermia, whereas passive filtration is not 
significantly altered in mild and moderate hypothermia at 30°C-35°C.  The effect of hypothermia 
on hepatic metabolic pathway, phase II enzyme, transporter and renal elimination based on the 
current evidence has been summarized in Figure 1-2. 
  
1.3.6 Current evidence on drug response changes during therapeutic hypothermia 
Besides the effect of hypothermia on drug metabolism and pharmacokinetics, drug response 
changes during hypothermia have been reported in both clinical and preclinical studies (Table 1-
4).  
 
The drug responses to neuromuscular blockers including vecuronim, atracurium, neostigmine, 
rocuronium and tubocurarine have been evaluated during hypothermia. Previous study by Heier 
et al. has demonstrated that mild hypothermia increased the duration of action and time for 
spontaneous recovery from vecuronium-induced neuromuscular blockade in patients undergoing 
elective surgery (Heier et al., 1991). Decreasing core temperature correlated with an increasing 
duration of action of the second infusion of vecuronium (R2=0.58, p<0.005). There was no 
difference between hypothermic and normothermic subjects as measured by the steady state 
concentration producing 50% depression of twitch tension on the train-of-four test. Thus this 
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study has suggested that hypothermia mediated increases in the duration of action of vecuronium 
was not due to the pharmacodynamics response, but more likely due to a change in 
pharmacokinetics of vecuronium. Similarly, a previous study by Caldwell et al. has also 
demonstrated the increased duration of action of vecuronium during hypothermia (Caldwell et 
al., 2000). Hypothermia decreased the rate constant for vecuronium equilibration between 
plasma and effect site (0.023 per °C/min), and increased the slope of the concentration-response 
relationship by 0.43 per C indicating that recovery of neuromuscular function has been delayed 
by hypothermia. This study suggested that reduced metabolism and rate of effect site 
equilibration both contributed to the prolonged response.  Previous study by Leslie et al. has 
shown that mild hypothermia at 34°C increased the duration of atracurium significantly (Leslie 
et al., 1995). Core hypothermia prolonged the time to recovery of the first twitch in the train-of-
four to 10% of its control value (Tl = 10%) after atracurium administration by -60% (p< 0.05), 
from 44± (SE 4) min to 68 ± (SE 7) min. Beaufort et al. has shown that hypothermia at 30.4 
±0.8° C prolonged the duration of action of rocuronium and delayed spontaneous recovery. The 
altered pharmacokinetics, such as a decreased clearance was a primary contributor (Beaufort et 
al., 1995). Ham et al. reported a prolonged duration of action d-tubocurarine at body temperature 
of 35.8°C and 31.9°C in neurological patients (Ham et al., 1978). Meanwhile, the efficacy of 
neostigmine as an antagonist of vecuronium induced neuromuscular block was not altered by 
mild hypothermia at 34°C and clearance of neostigmine was not changed (Heier et al., 2002). 
When temperature was reduced below 30°C, pancuronium neuromuscular block was prolonged 
because of an increased sensitivity of the neuromuscular junction to pancuronium and delayed 
biliary and urinary excretion (Miller et al., 1978). A 2°C reduction in body temperature may 
double the duration of neuromuscular blockage. Collectively, these studies suggested that 
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reduction in body temperature to mild and moderate hypothermia may prolong the duration of 
neuromuscular blockers. It is important for clinical practitioners to be aware of this prolonged 
response and to increase pharmacodynamics monitoring of these patients in both the cooling and 
rewarming phases of therapeutic hypothermia.  In addition, the observed prolonged response of 
neuromuscular blockers during hypothermia is more likely due to the reduced metabolism and 
increased drug concentrations during hypothermia. Interested reader can further refer to Heier et 
al. review paper in 2006 which has focused on the response to neuromuscular blocking drugs 
(Heier et al., 2006). 
 
           Besides neuromuscular blockers, the responses for anesthetics isoflurane and morphine have been 
evaluated during hypothermia. Liu et al. observed a reduction in isoflurane dosing requirements 
in children by 5.1% per °C. Isoflurane minimum alveolar concentration (MAC) values were 
1.69±0.14%, 1.47±0.10%, and 1.22± 0.15% at 37° C, 34° C, and 31° C, respectively (Liu et al., 
2001). Isoflurane pharmacokinetics was not evaluated in this study. Therefore the 
pharmacokinetic change in clearance and volume of distribution as it relates to the effect is 
unknown. In addition, isoflurane is metabolized by CYP2E1 enzyme, and a decrease in 
metabolism by CYP2E1 may underlie the prolonged drug response and reduced dosage 
requirement. However, additional studies are needed to determine the correlation between 
CYP2E1 activity and isoflurane response.  
           
           Previous study by Puig et al. has shown that the potency of morphine was significantly decreased 
at 30°C and increased at 40°C when compared with its potency at 37°C in guinea pig ileum (Puig 
et al., 1987). This study demonstrated that there was a large decrease in the affinity of morphine 
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for its receptor as was evidenced by a six-fold increase in the dissociation constant at 30°C. This 
study suggested that the affinity of morphine for the µ-receptor decreased as temperature 30°C. 
In another animal study by Bansinath et al., morphine response during hypothermia has been 
evaluated in dog model. After a single intravenous bolus injection of 1 mg/kg, morphine resulted 
in a significant and sustained decrease in mean arterial pressure in hypothermia, but not in 
normothermia. The hypotension was observed throughout the experiment in 30°C group but not 
in the normothermic group. During hypothermia, 10 minutes after morphine administration, the 
MAP was 35±5 mm Hg vs 114±5 mm Hg in normothermia. The decrease in MAP observed in 
30°C was statistically different from 37°C until 3.5 hours. The correlation coefficient between 
plasma morphine levels and the mean percentage decrease in MAP was 0.98 for the hypothermic 
group. Similarly, the correlation coefficient for CSF morphine levels and percent decrease in 
MAP was 0.95 in the same experimental group. Therefore, this drug response change was likely 
possibly due to the reduced morphine metabolism. Collectively, reduced body temperature in 
therapeutic hypothermia range prolonged the anesthetic drug response. Hypotension has been 
observed as one of the most common side effects for hypothermic patients. Prolonged ICU stay 
and prolonged respiratory depression may mask and alter the benefit effect from hypothermia. 
Clinical drug monitoring for side effects of series of anesthetics is warranted until a full 
understanding of drug PK and response during TH is determined.  
             
            β-Adrenoceptor response during hypothermia was studied by Han et al. The study has shown that 
the physiological cardiovascular responses mediated by the β-adrenoceptor were significantly 
diminished during core hypothermia at 33°C (Han et al., 2008). In this study, the dose dependent 
positive inotropic and chronotropic effects of isoproterenol observed at 37°C were diminished as 
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core temperature lowered to 33°C or below. The lack of ability to increase cardiac output in 
hypothermia may also partially due to the increase in total peripheral resistance at temperature 
below 33°C. The changes of binding affinity or downstream intracellular signaling related to 
cAMP (cyclic adenosine monophosphate) alteration have been suggested as the underlying 
mechanism of this effect (Han et al., 2008). However, previous study by Williams et al. has 
shown that the positive inotropic responses to orciprenaline of paced left atria and papillary 
muscles were actually potentiated at the lower temperature at 30°C (Williams et al., 1982). A 
similar hypothermia-induced supersensitivity was observed for the positive chronotropic 
response of right atria. While the β-adrenoceptor has two types β1 and β2, these studies suggest 
that hypothermia-induced supersensitivity occurs only at the β1-adrenoceptors not β2, indicating 
a fundamental temperature-dependent difference between the two receptor types.  
 
In summary, the changes of drug response for neuromuscular blockers, volatile anesthetics, 
opiates, and β-adrenoceptor blockers have been observed during hypothermia. Reduced 
metabolism and clearance may explain part of the response changes. The reduced affinities to µ-
receptor and changes in downstream signaling to the specific effect on β1-adrenoceptors have 
been reported. Careful clinical pharmacotherapeutic monitoring during hypothermia treatment is 
necessary to prevent the potential therapy-drug interaction and toxicity caused by the changes in 
both drug concentration and in drug response during hypothermia. 
 
1.3.7 Rewarming  
The third step of therapeutic hypothermia is passive rewarming. During the rewarming phase, 
physiological functions are restored in homeothermic organism after they have been suppressed 
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by cold. The effect of hypothermia on drug metabolism is also reversible after rewarming. A 
theoretical time course model of CYP activity during hypothermia and after rewarming was 
suggested by Tortorici et al. (Tortorici et al., 2007). The aforementioned phenytoin study 
demonstrated that the clearance in the rewarming phase was significantly increased from 
hypothermic values (Iida et al., 2001). Similarly, phenobarbitone, the metabolite rates of 
excretion (hydroxyphenobarbitone, conjugated hydroxyphenobarbitone and phenobarbitone-N-
glycoside) increased substantially (increase 141, 63 and 114%, respectively), during rewarming 
(Kadar et al., 1982).  It is recommended that the body may be rewarmed slowly at a temperature 
of 0.3 - 0.5°C (1 -- 2°F) every hour to a target temperature of 36°C (Tran et al., 2010; Oddo et 
al., 2006; Arpino et al., 2008). It may take more than 8 h for passive rewarming. The plasma 
concentration  of fentanyl at 6 h after rewarming remained increased compared with baseline 
(6.3 ± 0.6 vs < 6.0 ng/ml, p < 0.05) (Fritz et al., 2005). This suggests that the alterations of drug 
metabolism may exist during rewarming periods. Currently there is lack of studies that focused 
on the rewarming phase. Instead, many clinical study results combined both effects during 
hypothermia and after rewarming. For long half-life drugs, the rewarming phase might be even 
more important due to prolonged elevations in drug concentration even after restoration of drug 
receptor responsivity. 
 
1.3.8 Conclusion 
Our current understanding suggests that hypothermia has multiple beneficial effects after global 
ischemic injury. Besides the benefit of hypothermia, the possible side effects associated with 
hypothermia are unavoidable. The effects of hypothermia on drug metabolism and disposition 
may increase the probability for unanticipated toxicity, which could limit the putative benefit of 
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this novel therapy. Recent evidence suggests that the specific alterations of drug metabolism and 
the magnitude of the change observed during hypothermia can be metabolism and elimination 
route specific. The effects of hypothermia on drug response including muscle relaxant, volatile 
anesthetics, opiates and β-adrenoceptor agonist have been reported. Pharmacokinetic and 
pharmacodynamic alterations during hypothermia may both contribute to the resultant effect. 
Available evidence demonstrates that mild hypothermia decreases the clearance of a variety of 
drugs with apparently little change in drug protein binding. Future studies on specific CYP 
probe’s metabolism and receptor response are needed. By defining the impact of mild 
hypothermia on drug metabolism, disposition, and response in experimental models as well as 
thorough clinical research is needed. In doing so, drug dosing during therapeutic hypothermia 
can be optimized to facilitate the maximal benefits and minimize side effects of this therapeutic 
intervention.  
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Table 1-3: Drug concentration and pharmacokinetic alterations in therapeutic hypothermia with 
their specific metabolism and elimination pathway 
Metabolic 
pathway 
Temperature/subject 
population 
Investigated Drug concentration/PK parameters estimates 
Flow/CYP2B/UGT 
Flow/CYP3A 
Flow/bile/OATP 
Flow/bile/OATP 
34°C/healthy volunteers 
31.6°C/piglets 
32.5°C/ male Wistar rats 
32°C/ rats 
Propofol  
Fentayl  
ICG  
ICG  
Css↑ 28%, Inter-compartment CL↓ with temperature 
Plasma conc↑25±11%, temperature and CYP3A4 dependency 
CL↓80%, MRT↑ 2-fold 
Total CL↓ to 47%, AUC↑2-fold,  CLb↓  
CYP3A 
CYP3A 
CYP3A/PGP 
CYP3A 
Moderate 32-34°C/TBI patients 
35.5-36.5°C /healthy volunteers  
<35, 35-35.9,36-36.9°C/volunteers 
32°C /In vitro microsome 
Midazolam  
Midazolam  
Vecuronium 
Ethylmorphine  
Plasma concentration ↑, Vd↑83%, CL↓, Ke↓ 
CL↓ 11% per degree 
CL↓11.3% per degree 
Temperature dependent reaction, CYP3A4 activity ↓ to 69% 
CYP2C9/CYP2C19 
CYP2C9/3A 
CYP2C9/Renal 
CYP2C19/UGT  
34 °C/ brain damage patients  
34.5°C/ healthy volunteers 
32.5°C/ male Wistar rats  
30-31°C /TBI  children  
Phenytoin  
Neostigmine  
S-acenocoumarol  
Phenobarbital  
AUC↑180%, MRT↑180%, CL↓67% and Ke↓50% 
V1↓38%, no change in CL 
CL↓26% 
Ke↓, renal metabolite excretion↓, Vd↑25% 
CYP2D6/2B 
CYP2D6/2B 
CYP2D6/Renal  
Server <32°C/9 out of 11 children 
30°C/perfused rat liver 
30.4°C/ neurosurgical patients 
Pentobarbital 
Pentobarbital-2-c14  
Rocuronium  
CL↓, Vd↓20%, no change in T1/2  
CLh↓50%, CLb↓ 71% 
CL↓ to 51%, MRT↑1.9 fold 
CYP2E1 30°C/cardiac arrest rats Chlorzoxazone  Km↑116%, Clint↓44%,CL↓ 54%, Ke↓66% 
UGT 
UGT 
33-34°C/ HIE infants 
30°C/dog 
Morphine  
Morphine  
CL↓, potential toxic concentration in hypothermia 
Conc in plasma and CSF↑, CL↓ 70%,T1/2β↑2-fold, MRT↑, Vd↓ 
Transporter PGP 32°C /in vitro kidney epithelial cell Digoxin  Direction from B to A ↓50% 
Renal filtration 
Renal filtration 
Renal filtration/CYPs 
Renal filtration/GFR 
Renal tubular secretion 
33.5°C/HIE infants 
35°C/hypoxia newborn pig 
32°C/cats 
32°C/ rats 
32°C/ rats 
Gentamicin 
Gentamicin  
Pancuronioum  
FD-4  
PSP  
No change in CL, high concentration related to renal impairment 
No change in CL 
No change in CL, Vss↓ 
No change in pharmacokinetics 
Total CL↓ 42%, plasma AUC↑2-fold,  MRT↑, renal secretion ↓ 
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Table 1-4: Current evidence on drug response change in therapeutic hypothermia 
 Pharmacological 
effect 
Temperature/subject 
population 
Investigated Drug Drug response/PD estimates 
Muscle relaxant 
Muscle relaxant 
Muscle relaxant 
Muscle relaxant 
Muscle relaxant 
Muscle relaxant 
34.5°C/patients undergoing surgery 
<35, 35-35.9,36-36.9°C/volunteers 
34°C/healthy volunteers 
34°C/healthy volunteers 
30.4°C/ neurosurgical patients 
31.9°C/neurological patients 
Vecuronium 
Vecuronium 
Atracurium  
Neostigmine  
Rocuronium 
D-tubocurarine  
Recovery time↑, duration of action↑ 
Response↑, equilibration rate↓ 
Response↑, duration of action↑ 
No change in efficacy and duration  
Duration of action↑ 
Duration of action↑ 
Volatile anesthetic 
Opiate anesthetic 
Opiate anesthetic 
34, 31°C/children 
30°C /dog 
30°C/ guinea pig ileum 
Isoflurane  
Morphine  
Morphine  
Dose requirement↓ 5.1%  per °C. MAC↓ 
Hypotension incidence↑ 
IC50↓, the affinity to µ-receptor↓ 
β-adrenoceptor agonist 
β2-adrenoceptor agonist 
33°C/rats 
30°C/ guinea-pig 
Isoproterenol  
Orciprenaline  
HR↓, CO↓, SV↓, LV dP/dtmax↓ 
β1 adrenoceptor sensitivity↑ 
 
 
 
 
 
 
 
 
 
 
 
   Figure 1-2: The effect of hypothermia on drug metabolism and elimination pathway 
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1.4 SIGNIFICANCE AND SPECIFIC OBJECTIVES OF THE THESIS RESEARCH 
 
1.4.1 Significance 
Mild therapeutic hypothermia is emerging clinically as a neuroprotection therapy for cardiac 
arrest victims and other critical illness. However the effects of therapeutic hypothermia in 
combination with the critical illness on drug disposition and response have not been fully 
elucidated. The effects of hypothermia on drug metabolism and disposition may increase the 
probability for unanticipated toxicity, which could limit the putative benefit of this novel 
therapy. Previous studies have found significant elevated drug levels and prolonged drug 
response during hypothermia, for drugs such as phenytoin, neostigmine, vecoronium, morphine, 
propofol, and fentanyl. With new interventions comes an increase in the care of optimizing drug 
therapy through rationale concentration based dosing adjustments in order to prevent side effects 
in these highly vulnerable patients. By defining the impact of mild hypothermia on drug 
metabolism, disposition and enzyme regulation in experimental models as well as through 
clinical translational research, drug dosing during therapeutic hypothermia can be optimized to 
facilitate the maximal benefits and minimize side effects of this therapeutic intervention. 
 
In addition, during hypothermia post CA, the alterations in normal drug metabolism, can be quite 
complex due to suppressed effects from heart failure, multiple organ dysfunction and 
temperature. Various pathophysiological disturbances including hepatic ischemia and changes in 
hepatic blood flow may significantly alter the PK behavior of drugs. Therefore a thorough 
understanding of both the temperature and CA pathophysiologic interaction on individual CYP 
isoform activity is necessary to delineate the alterations in drug metabolism and disposition. 
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Surprisingly, the specific/quantitative changes of drug metabolism and disposition during 
hypothermia after CA are largely unknown. Therefore, to investigate the possible alteration on 
drug metabolism caused by CA injury as well as CA-temperature interaction is necessary. 
 
Currently population based pharmacokinetic modeling (nonlinear mixed effect modeling) has 
been recognized useful in critical care pharmacology, anesthesia and pediatric pharmacology. 
Population PK modeling describes the complex relationship between multiple factors (such as 
diseases, treatment, temperature, drug combination covariates) and drug metabolism and 
disposition from various clinical and animal studies. In order to gain new insight into optimizing 
pharmacotherapy in these critical ill patients, it is the also a goal of this thesis research to 
develop population PK models that serves as a mathematic representation of physiological and 
pharmacological phenomena and provide the estimation and prediction of the hypothermia effect 
as well as disease interaction on drug metabolism and distribution.  
 
1.4.2 Specific objectives of this research 
The current understanding of the possible TH effect on drug concentrations led to the need for 
evaluation of multiple CYP isoforms in one set of studies with a disease model. Therefore, the 
first objective of the study is to investigate hypothermia CYP isoform specific effect (CYP2C, 
CYP2D, CYP3A and CYP2E1) and disease interaction by studying multiple hepatic metabolic 
enzymes and the PK of their substrates during hypothermia in experimental cardiac arrest rat 
model. This objective is addressed in Chapters 2 and 3. The study utilized advanced analytical 
assays, in vivo probe drug metabolism analysis, asphyxia CA model and population modeling 
analysis.  
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Within all CYP isoforms, CYP3A4 is the important isoform, therefore, the second objective of 
this study is to investigate the effect of mild hypothermia on the single isoform CYP3A activity 
in healthy human volunteers. This objective has been completed in Chapter 4. This study utilized 
the well-known probe drug midazolam metabolism profile, approach to induce mild hypothermia 
in healthy volunteers and population modeling and simulation for a mathematic prediction of the 
correlation between the changes of temperature and midazolam clearance.  
 
Realizing the difficulty of conducting a further PK study with critical ill patients, the third 
objective of this study investigated the feasibility and accuracy of using microdosed probe 
cocktail approach in evaluating the phenotyping of multiple CYP enzymes (CYP1A2, CYP2C19, 
CYP2D6 and CYP3A4) and renal secretion in healthy human volunteers. This objective has been 
described in Chapter 5. This study utilized advanced analytical assays, PK simulation, clinical 
pharmacology study design, as well as a summary of literature reported PK parameters for each 
probe drug used in higher dose. The result will be greatly useful for further clinical study design 
determining the drug metabolism and disposition change in critical ill patients. 
 
Finally, as an extension of our previous research with CYP probe drugs, we sought to evaluate 
the effect of therapeutic hypothermia on the disposition of clinically relevant drugs in susceptible 
patient populations. Phenytoin is widely used clinically, has a narrow therapeutic index, and 
follows non-linear pharmacokinetics. Therefore, the fourth objective of this study is to determine 
the effect of therapeutic hypothermia on population pharmacokinetics of phenytoin in pediatric 
traumatic brain injury patients. This objective has been described in Chapter 6. This project was 
focused on determining the hypothermia effect on phenytoin nonlinear elimination, the 
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estimation of the temperature correlation with Km and Vmax by population modeling and 
prediction simulation. The result of the study is greatly helpful in providing rational for possible 
dosage adjustment guidelines for phenytoin in clinics. 
 
Overall, this thesis research provided an essential proof of concept to support subsequent clinical 
studies aimed at optimizing the specific dosage guidelines in the critically ill patient population 
receiving therapeutic hypothermia based on specific drug metabolic pathways, the patient disease 
states and specific temperatures and durations of hypothermia (Figure 1-3). It also provided 
essential translational tools and methodology tools for others who interested in clinical and 
preclinical PK study design and data analysis.  
 
 
 
Figure 1-3: Rational for future pharmacotherapy for critical ill patients receiving hypothermia 
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2.0   MULTIPLE PROBE DRUGS BIOANALYTICAL ASSAY BY 
UPLC/MS/MS-FOUR DRUG COCKTAIL 
 
2.1 INTRODUCTION 
 
Analytical methods play a vital role in supporting every facet of the drug research, discovery and 
development and approval process. For this thesis research, in order to assess CYP isoform 
specific effect of therapeutic hypothermia, a cocktail was designed that contains multiple probe 
drugs together and bioanalytical assays were established for measuring multiple probe drug 
concentrations simultaneously. The application and feasibility of cocktail cytochrome P450 
(CYP450) probes was reported first by Breimer and Schelllens around twenty years ago 
(Breimer et al., 1990). Since then many interests has been drawn to the CYP probes cocktail 
applications for in vitro drug screening and clinical assessment for CYP activity, drug-drug 
interaction, genotyping in different patients populations, new chemical screening, drug-therapy 
interaction, and disease metabolism interaction (Breimer and Schellens 1990; Tucker et al., 
2001). The advantages of cocktail approach include less inter-subject and inter-occasion 
variability, and relatively less amount of work and costs compared to analyzing single drug 
separately. Despite the advantages, some of the drawbacks  of the cocktail approach may include 
potential drug-drug interactions among probes, demand for a higher sensitivity analytical 
equipment, the discrepancy between in vitro and in vivo due to the factors such as absorption, 
protein binding, transporter effect and lack of preclinical pharmacokinetics data for the evidence 
of safety and validation of cocktail combination (Paolini, et al., 1993;  Zhou et al., 2004; Davit et 
al., 1999 ).  
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In this thesis study, we have established two set of cocktail assays and they both involved in new 
probe drugs combination. In this chapter, I am discussing the establishment of the first 
bioanalytical assay, which will be used later used in a preclinical animal study. Compared to 
previous reported cocktail studies, we have made three additional advances as: 1) a strategy of 
low dosages of all probes has been applied, since lower dose can potentially minimize the drug-
drug interaction, toxicity and improve the probe specificity for the metabolic pathway; 2) a 
sensitive, rapid and reliable analytical method by advanced ultraperformance liquid 
chromatography-triple quadrupole mass spectrometry (UPLC/MS/MS) has been used for 
simultaneously measuring all probe drugs and metabolites in one run; and 3) an intravenous (IV) 
approach is used for all probe drugs rather than given orally to avoid the possible absorption, 
possible extra-hepatic metabolism, and active transport effect from oral route.  
 
The purpose of this assay establishment is to be able to measure the plasma concentration of 
probe substrates for four different CYP isoforms simultaneously and be able to evaluate these 
specific CYP isoforms activities from one set of experiment. Since no previous method has been 
set up in the lab or in literature, this study has first reported of this assay development. Bio-
analytical assays should be selective and sensitive and it involves multiple steps to get to the 
assay validation. I summarized the method development and validation into multiple steps, 
which has been shown in Figure 2-1.  
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Figure 2-1: Method development and method validation multi-steps 
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2.2 EXPERIMENT AND METHOD VALIDATION 
 
2.2.1 Chemicals and reagents 
Dextromethorphan (DEX), dextrorphan (DOR), chlorzoxazone (CHL), 6-hydroxychlorzoxazone 
(6OHCHL), diclofenac (DIC), 4-hydroxydiclofenac (4OHDIC), β-glucuronidase (from Helix 
Pomatia) were obtained from Sigma-Aldrich (St. Louis, MO, USA). 1-Hydroxymidazolam 
(1OHMDZ) and midazolam-d4 standards were purchased from Cerilliant Corp (Round rock, TX, 
USA). Dextrorphan-d3, chlorzoxazone-d3, and 4-hydroxydiclofenac-d4 were purchased from 
Medical Isotopes, Inc (Pelham, NH, USA). Midazolam (MDZ, 5mg/mL) injection (Versed, 
Roche, USA) was used. Blank rat plasma (pooled, heparized) was purchased from Innovative 
Research, Inc (Novi, MI, USA). High purity solvent acetonitrile and water were purchased from 
Honeywell B&J brand (Muskegon, MI, USA). Formic acid (~98%) was bought form Fluka 
(Germany). Oasis 1cc HLB (hydrophilic-lipophilic balance) solid phase extraction cartridges 
were purchased from Waters (Milford, MA, USA).  
 
2.2.2 Instrumentation and conditions 
Waters UPLC systems with ACQUITY BEH C18 1.7μm×2.1mm×50mm column plus UPLC 
guard column (1.7μm×2.1mm×5mm) were used to separate the analytes. Column temperature 
was maintained at 50°C. The mobile phase consists of 0.1% formic acid in water (A) and pure 
acetonitrile (B), gradient from 90:10 (A:B) to 70:30 (A:B) within 3 minutes and come back to 
90:10 at 6.0mins. Flow rate was used at 0.25mL/min. Strong needle wash: pure acetonitrile, 
weak needle wash: 10% acetonitrile in water. All injection volumes were 7.5 µL. (1.0ng/mL= 7.5 
pg/column)  
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Thermo triple-quadrupole mass spectrometer, equipped with electrospray ionization (ESI) source 
was used for mass analysis and detection (Thermo Fisher Scientific, San Jose, CA). ESI operated 
at six positive (spray voltage 4.0kV) and six negative ionization (spray voltage 4.0kV) modes, 
with argon as the collision gas at 1.2mTorr. Other working parameters set as follows: capillary 
temperature 300°C, sheath gas pressure 60 psi, auxiliary gas pressure 55psi. The mass peak 
widths were 0.7 Da for both Q1 and Q3. MS/MS condition and tuning were performed by a T-
connection with analyte and mobile phase (running at 0.25mL/min) entering the cone together. 
The intensities of fragment ion was monitored and optimized to the maximum by using the 
Quantum Tune master software. Selected reaction monitoring was used for quantification using 
the product ion with the highest sensitivity. Scan rate was set at 0.01s/scan. Xcalibur version 
2.0.6 software was used for data acquisition and analysis (ThermoFinnigan, San Jose, CA) 
(Figure 2-2). 
 
2.2.3 UPLC/MS/MS assay development  
2.2.3.1 Calibration standard and quality control sample                        
All standard stock solution of probes and metabolites and internal standards are 1.0mg/ml or 
100ug/ml (for midazolam-D4) in methanol and stored at -20°C for 2 months. All glassware used 
for preparation of calibrations and samples were silanized tubes. The four probe parents drug 
were combine together in one cocktail stock with concentrations at midazolam 1.0μg/ml, 
dextromethorphan 2.5μg/ml, chlorzoxazone 2.5μg/ml and diclofenac 2.5μg/ml. The four 
metabolites were combined together in one cocktail metabolite stock with concentrations at 1-
hydroxymidazolam 1.0μg/ml, dextororphan 2.5μg/ml, 4-OH-diclofenac 2.5μg/ml and 6-
hydroxychlorzoxazone 2.5μg/mL. The four duterated internal standards were combined together 
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in one cocktail IS stock with concentrations at midazolam-d4 0.1μg/ml, dextrorphan-d3 
0.1μg/ml, chlorzoxazone-d3 0.5μg/ml and 4-hydroxydiclofenac-d4 1.0μg/ml. Further dilution of 
lower concentration of the analytes used 80:20 acetonitrile: water. Quality control (QC) samples 
were prepared at three different concentrations designated within the low, medium and high 
concentration ranges of the curve. 
 
2.2.3.2 Sample extraction method 
Solid phase extraction (SPE) is newly developed method for sample concentrate and sample 
cleaning. Solid phase cartridges simply can be considered as a small short HPLC column, the 
analyte will be separated from mobile phase and stationary phase. Normally the desired analytes 
of interest or undesired impurities in the sample are retained on the stationary phase then elute 
with the appropriate solution which can dissolve or have better affinity to the analytes than the 
stationary column. The reason for us to choose solid phase extraction is because SPE can 
increase sensitivity compared to other traditional extraction methods, reduce matrix effects, 
maximize selectivity, optimize recovery efficiency and provide consistent results. In this study, 
solid phase extraction method using Waters 1cc Oasis HLB reverse phase cartridge has been 
used. HLB column provides relatively large range of pKa and working pH range and therefore is 
suitable for extraction of variety of acids, bases and neutrals compounds.  
 
During the experiment, the cartridges were first activated and equilibrated with 1mL methanol 
and 1mL of water. After the samples have been loaded, the cartridges were washed with 1mL 
water and 1mL 5% methanol, discarded the elute. Cartridges were then washed with 2×1mL 
methanol and the elute was collected. The elute was dried down under constant a gentle stream 
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of nitrogen at 37°C, the residue was reconstituted with 100μL mobile phase (80:20 acetonitrile: 
water with 0.1% formic acid) and transferred to a clean autosampler vial. 
 
                                      
Figure 2-2: Ultra performance liquid chromatography equipped with triple-quadrupole mass 
spectrometer (UPLC-MS/MS)   
 
2.2.4 Method validation  
Method validation is a dynamic process intended to make sure as well as satisfy different 
complementary objectives (especially technical and regulatory). Food and drug administration 
(FDA), International Conference on Harmonization (ICH) and the US pharmacopeia and 
National Formulary (USP/NF) consistently define validation of an analytical method as “the 
process by which a method is tested by the user or developer for reliability, accuracy and 
preciseness of its intended purpose” (FDA 1994; Winslow et al., 2003). Method validation with 
respect to the selectivity, linearity, precision, accuracy, limit of detection, limit of quantitation, 
stability as well as extraction efficiency, the matrix effect, the simultaneous analysis methods for 
the eight analytes were tested.  
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Every calibration curve consisted of eight concentrations. Calibration curves were constructed 
using the analytes/IS peak area ratio vs the analyte concentration. The curves were fitted by 
linear least squares regression, analysis with weighting factor of 1/y. The sensitivity was 
described from limit of detection (LOD) and limit of quantitation (LOQ). The LOD is the lowest 
concentration at which the analytes can be detected. The LOD was determined based on the peak 
area of lower than 5-digit. The LOQ was determined based on the peak area at this level can be 
determined with variability less than ± 20% (accuracy of 80-120%) when repeated six times in 
extracted samples. QC samples at low, medium and high in six replicates were analyzed on the 
same day to determine the intra-day precision. The process was repeated in three separate days to 
determine the inter-day precision. Precision was calculated as the coefficient of variation (CV%) 
of the replicate analysis, whereas accuracy is the percent difference between nominal and 
observed values (% bias). The acceptable inter-day and intra-day precision and bias were set as 
<20 % deviations of nominal concentrations.   
 
The recovery efficiency and evaluation of matrix effect were determined by three different 
process of QC samples: 1) “neat sample”, which was prepared by spiking the calibration stock 
directly into reconstitute solution; 2) “post extraction”, which was prepared by adding the matrix 
(50μL blank plasma) through the extraction cartridges without the analyte, the analytes was then 
added into the elute, dried down, then reconstituted; 3) normal extraction procedure, prepared 
QC samples, extracted with solid phase cartridges.  The matrix effect was calculated as (Apost-
extraction/ANeat-1)×100. Negative value represents the ion suppression effect. The recovery 
efficiency of every analyte was calculated as Aextraction/Apost-extraction×100.   
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QCs in five replicates of each concentration have been prepared to test the stability. The analytes 
were evaluated for autosampler (72 hr, 4°C), short term (24 hr, room temperature), and long term 
(2 months, -70°C) stability. The analyte was considered stable when the percent difference 
between nominal and observed concentrations was within 20% of relative error.  
 
2.2.5 Animals treatment and sampling procedures  
Male Sprague-Dawley rats (body weight, 300-350g, 2 months old) were purchased from Hilltop 
Laboratories (Scottdale, PA). The animals were maintained on a 12-h light/dark cycle and were 
allowed free access to food and water. The University of Pittsburgh Animal Care and Use 
Committee approved the study and animal procedures.  
 
Rats were anesthetized with 0.5-1.0% isoflorane via a nose cone, endotracheally intubated, and 
mechanically ventilated to maintain PaCO2 between 35 and 45 mm Hg. Body temperature was 
maintained with appropriate heating pad (38.0±0.5°C). Rat left femoral artery was cannulated for 
measurement of mean arterial pressure and arterial blood gases, and the left femoral veins were 
cannulated bilaterally for drug administration and blood sampling.  The cocktail drugs were 
given as an intravenously bolus of 0.2mg/kg midazolam, 0.5mg/kg dextromethorphan, 0.5mg/kg 
diclofenac, and 0.5mg/kg chlorzoxazone. The IV formulation was made in saline with ethanol 
(<20% v/v).  The injection volume given to rats was 1.0mL/kg body weight.  Saline was injected 
to flush the line after the drug administration. Blood samples (0.3 mL) were obtained via the 
femoral venous with a heparinized syringe at baseline, 5, 15, 30, 60, 120, 180, 240, 300, 360 and 
480 minutes. Blood samples were immediately centrifuged at 2000g for 7 minutes and the 
plasma was transferred to a labeled eppendorf tube. Rats were sacrificed via decapitation after 8 
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hours blood sampling. All samples were kept in freezer during the study and then transferred to -
80⁰C until analysis.  
 
2.2.6 Sample analysis  
All plasma samples were thawed on ice, an 20-100μL of rat plasma (20μL for 5 minutes sample, 
100 μL for 8 hr sample, 50μL for all others) per sample was added to 900 μL water, a 10μL IS 
cocktail solution was spiked in, vortex. The samples were extracted using solid phase extraction 
as previous described. Probe substrates concentrations were calculated based on the validated 
standard curves and the sample volume difference from final reconstitute volume has been 
adjusted.   
 
2.2.7 Pharmacokinetic estimate and comparison 
Non-compartmental (AUC0-inf, Cls T1/2, and Vss) pharmacokinetic analysis by WinNonlin 
(Pharsight, CA) 5.2 was used. Estimated pharmacokinetic parameters (Cls T1/2, Vss) were 
compared with the previous literature values when these drugs were given in healthy rat at 
different doses.  
 
2.2.8 Data analysis  
All figures (except chromatograms) and data expressed as mean ±SD. The figures were 
generated from Prism 5.0 (GraphPad Software, San Diego, CA.). One-way ANOVA with 
Bonferroni post hoc was used for all comparison (all pharmacokinetic parameters), a p<0.05 was 
considered significant.  
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2.3 RESULTS 
 
2.3.1 Probe drugs and dosage selection 
In this study, midazolam, diclofenac, dextromethorphan and chlorzoxazone were chosen based 
on the specificity for the CYP3A, CYP2C, CYP2D and CYP2E1, respectively. In addition, a less 
possibility of drug-drug interaction, relatively shorter half-life and clinical relevance (Frye et al., 
1997; Streetman et al., 2000) are also considered. Previous research showed that chlorzoxazone 
significantly inhibits the CYP3A-mediated first pass metabolism of midazolam in the gut, in 
contrast, the intravenous injection of midazolam did not shown any interaction with 
chlorzoxazone (Palmer et al., 2001; Blakey et al., 2004). Relatively shorter or similar half-lives 
of four probes helped us design better sampling duration and time points. Dextromethorphan is 
often used as a CYP2D probe because of its wide safety margin and availability compared with 
other possible probes such as debrisoquine, and sparteine. In addition, all probe substrates were 
listed by FDA as preferred probes/reactions for CYP enzymes in vivo and in vitro.  
 
The IV dosage for probe drugs were chosen based on the sensitivity of the developed analysis 
method and allowing the 8-hr concentration can be detected well above the limit. The dosage 
used in the study was the lowest dosages compared to previous pharmacokinetic studies in rats. 
The dosages for each drug was at least five-fold lower than the typical dosage used in rats 
pharmacokinetics study.  
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2.3.2 UPLC/MS/MS instrument condition  
Every analytes was tested both in positive mode and negative mode, then the polarity as well as 
the collision energy, UPLC conditions related to the highest fragment was chosen. The ion 
transitions for all 12 compounds, collision energy (20-37ev), polarity (six positive, six negative 
modes), and retention time (RT) were shown in Table 2-1. Under the experimental condition, the 
representative chromatograms of a standard extracted calibrate at 0.2ng/mL (for MDZ, 1-
OHMDZ, MDZ-d4, DIC, DEX, DOR, DOR-d3, CHL, CHL-d3) and 2.0ng/mL (for 4-OHDIC, 4-
OHDIC-d4, 6-OHCHL) were depicted in Figure 2-3.  
 
The total run was 6.0 minutes with no peak interference with others. The retention times for 12 
analytes were distributed between 2.64 to 4.16 minutes. The established methods allow a 
sufficient time to: divert the first 2 minutes into the waste if necessary; to add in more 
hydrophilic analyte into the cocktail combination; or to push the 12 analytes together for an 
earlier or later retention time if necessary. In addition, the mass spectrometry scanned positive 
and negative mode alternatively with 0.01s/scan speed faster than machine default (1.0s/scan), 
which provided at least 10 points across each peak and therefore better captured the peak shape 
and improved the sensitivity. 
 
Four duterated compounds midazolam-d4, 4-hydroxydiclofenac-d4, dextrorphan-d3 and 
chlorzoxazone-d3 have been used for internal standards. In most cases, the duterated compounds 
ranged from 3-8 mass units heavier than the parent compounds are suitable for using as internal 
standard. However, diclofenac (MW 294) can be detected at both 294 and 298 mass weight 
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because of the two natural 35Cl and 37Cl isotopes in the structure, therefore diclofenac-d4 (MW: 
298) has to be avoided.   
 
2.3.3 Method validation 
2.3.3.1 Linearity and sensitivity  
Calibration curves were prepared in three individual days with the precision and accuracy 
testing. All probe substrates and metabolite curves have a R2>0.99. All calibration ranges were 
listed in Table 1. The LLOQ for eight analytes were between 0.2-5.0ng/mL (1.5-75pg/column). 
UPLC/MS/MS method significantly decreased the background noise, therefore improved the 
sensitivity and provided wider range of linearity. Our study and other studies have shown that 
500-1000 fold of analysis linearity range are accessible with triple tandem mass spectrometry 
(Ghassabian et al., 2009, Beaudry et al., 1998).  
 
2.3.3.2 Precision and accuracy   
The intra-day and inter-day precision were < 20% for all QCs. The accuracy (% bias) of all 
analytes QCs were < 13.6 %. The good precision and accuracy indicate that the analytical 
methods are reproducible and reliable (Table 2-2).  
 
2.3.3.3 Matrix effect and recovery  
The areas of neat samples, post extraction samples and normal extraction samples have been 
used for calculation of matrix effect and recovery. The matrix effect for every analyte was 
different and ranged between -42.7% to + 20.2%. There was a matrix ion suppression effect for 
most analytes (post extraction response was lower than the neat sample response) while there 
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was matrix improvement effect for midazolam and chloraxazone at medium and high QC levels. 
For all eight analytes, the recovery (normal extraction/post extraction ×100%) ranged between 
72.5-112.6%. Recovery efficiency indicated that the solid phase extraction method was sufficient 
to recover > 72.5% of compound from standard solution without significant loss in the extraction 
procedure. In addition, four internal standards, midazolam-d4, 4-hydroxydiclofenac-d4, 
dextrorphan-d3 and chlorzoxazone-d3 have also been evaluated individually for matrix effect by 
comparing the area of neat samples and post extraction samples. The results showed the internal 
standards were well correlated with the characteristics of the parent drugs. These results showed 
the methods were robust and specific (Table 2-3).  
 
2.3.3.4 Stability   
High, medium and low QC concentrations in five replicates have been utilized to evaluate the 
stability. Since all calculated relative error was less then± 15%, no significant loss/gain or 
interaction in solution of the analytes was observed at any of the investigated conditions. The 
samples were considered stable within 72 hours at 4°C, 24 hours at room temperature, and 2 
months at -70°C freezer. Therefore, the method can be used to analyze samples under the tested 
conditions, and considered stable without significant degradation or condensation (Table 2-4).  
 
2.3.4 Time-plasma concentration profiles and pharmacokinetic estimates 
Time-plasma concentration profiles of midazolam, diclofenac, dextromethorphan and 
chlorazoxazone were shown in Figure 2-4. Pharmacokinetic estimates from non-compartment 
model were shown in Table 2-5. Multiple previous literature reported CLs T1/2 and Vss values for 
midazolam, diclofenac, dextromethorphan and chlorazoxazone from rats were listed in Table 2-6 
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for comparison. Compared with other literature preclinical PK parameters for these four drugs, 
our preclinical rat data from healthy rats are consistent with previous literature reported value.  
 
 
Figure 2-3: UPLC/MS/MS chromatograms of both positive and negative ion analytes resulting 
from a 7.5μL injection of a low concentration calibration standard (0.2ng/mL for all analytes 
except for 2.0ng/mL for diclofenac, chloraxazone and 5.0ng/mL for 4-OH-diclofenac, 4-OH-
diclofenac-d4 and 6-OH-chlorzoxazone) at the LOQ in plasma.  
RT: 3.39 
SN: 13074 
 
RT: 3.39 
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Table 2-1: SRM transition method for MS/MS (precursor to product) for four parent drugs, four 
major metabolites and their respective internal standards 
CYP450 Compound SRM 
transition 
Collision 
energy (ev) 
Polarity RT 
(min) 
CYP3A1/2 
 
 
 
CYP2C11 
 
 
 
CYP2D1 
 
 
 
CYP2E1 
 
 
Midazolam 
1-OH-midazolam 
Midazolam-d4 
 
Diclofenac 
4-OH-diclofenac 
4-OH-diclofenac-d4 
 
Dextromethorphan 
Dextorphan 
Dextorphan-d3 
 
Chlorzoxazone 
6-OH-Chlorzoxazone 
Chlorzoxazone-d3 
325.7>291 
342>324 
330>295 
 
294>250 
310>230 
314>234 
 
272>171 
258>157 
261>157 
 
168.6>132 
186>120 
171>134 
27 
25 
27 
 
25 
20 
20 
 
37 
33 
30 
 
22 
25 
25 
+ve 
+ve 
+ve 
 
-ve 
-ve 
-ve 
 
+ve 
+ve 
+ve 
 
-ve 
-ve 
-ve 
3.39 
3.39 
3.39 
 
4.16 
3.77 
3.77 
 
3.39 
3.18 
3.18 
 
3.60 
2.64 
3.60 
 
 
 
Table 2-2: Calibration curve ranges, precision and accuracy evaluation of eight analytes (n=6) 
 QC 
 
 Day1               Day2             Day 3 %bias Precision (CV%) 
Day1  Day2  Day3 
LOQ 
ng/mL  
Standard Curves  
MDZ 
 
 
1-OHMDZ 
 
 
DIC 
 
 
4-OHDIC 
 
 
DEX 
 
 
DOR 
 
 
CHL 
 
 
6-OHCHL 
5 
40 
200 
5 
40 
200 
12.5 
100 
500 
12.5 
100 
500 
12.5 
100 
500 
12.5 
100 
500 
12.5 
100 
500 
12.5 
100 
500 
4.96±0.37     4.88±0.44      4.98±0.17 
36.2±3.0       39.0±3.9        37.5±3.9 
204±13         212±8.3         198±19.0 
5.12±0.87     5.09±0.36      5.14±0.60 
40.4±3.5       41.0±1.9        39.5±4.1 
197±8.1        198±16.4       204±17.4 
 11.9±2.4      10.4±1.9        10.7±1.8 
105±16.8      108±12.3       110±12.5 
482±55.9       491±86.4      498±43.6 
10.8±2.0        10.2±1.6       9.40±1.4 
105±13.5       109±17.2      113±4.3 
469±73.2       486±60.3      462±43.6 
11.5±1.9        10.9±1.5       11.2±1.6 
96.1±10.5      105.6±10.7   110±10.3 
480±33.1       489±60.1      509±62.6 
11.5±0.03      11.0±0.5       11.9±0.05 
99.1±10.7      105±14.7      105±12.3 
489±41.6       469±53.9      492±24.2 
11.2±1.5        11.4±2.1       10.9±1.9 
101±8.79       95.7±17.8     91.3±10.9 
527±59.0       539±51.7      505±48.5 
10.5±2.0        11.0±2.1       10.9±1.4 
82.0±15.3      93.4±9.06     84.9±9.3 
464±64.0       458±62.3      444±63.0 
- 1.2 
- 6.1 
  2.3 
  2.3 
0.75 
- 0.17 
- 12.0 
10.2 
- 0.33 
- 13.4 
 13.0 
 - 3.1 
 - 8.0 
3.9 
 - 1.5 
 - 8.3 
 3.0 
 - 3.3 
-10.7 
 - 4.0 
4.7 
 - 13.6 
- 13.2 
 - 8.9 
7.5     9.1       3.4 
8.3     10.0    10.4 
6.4      3.9      9.6  
16.9    7.0      11.7 
8.7      4.8      10.4 
4.1      8.3      8.5 
20.0    17.8   16.6 
16.0    11.4    11.4 
11.6    17.6    17.6 
18.7    15.7    14.8 
12.9    15.8    3.8 
15.6    12.4    9.4 
17.1    14.0    13.9 
10.9    10.1     9.3 
6.9      12.3    12.3 
8.5       8.0     9.6 
10.8    14.0    11.7 
8.5      11.5     4.9 
13.6    18.3    17.2 
8.7      18.6    12.0 
11.2     9.6      9.6 
19.1    19.5    12.5 
18.7     9.7     11.0 
13.8    13.6    14.2 
0.2 
 
 
0.2 
 
 
2.0 
 
 
5.0 
 
 
0.2 
 
 
0.2 
 
 
2.0 
 
 
5.0 
 
 
0.2-200ng/mL (plasma) 
 
 
0.2-200ng/mL (plasma) 
 
 
2.5-500ng/mL (plasma) 
 
 
5.0-500ng/mL (plasma) 
 
 
2.0-500ng/mL (plasma) 
 
 
1.0-200ng/mL (plasma) 
 
 
2.5-500ng/mL (plasma) 
 
 
10-500ng/mL (plasma) 
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Table 2-3: Evaluation of recovery efficiency and matrix effect of probes, metabolites and internal 
standard (n=6) 
Compound  QCs 
(ng/mL) 
Recovery (%) 
Value   SD  
Matrix effect (%) 
Value   SD  
Midazolam 
 
 
1-OH-midazolam 
 
 
Diclofenac 
 
 
4-OH-diclofenac 
 
 
Dextromethorphan  
 
 
Dextrophan 
 
 
Chlorzoxazone 
 
 
6-OH-chlorzoxazone 
 
 
Dextorphan-d3 
Midazolam-d4 
Chlorzoxazone-d3 
4-OH-diclofenac-d4 
5 
40 
200 
5 
40 
200 
12.5 
100 
500 
12.5 
100 
500 
12.5 
100 
500 
12.5 
100 
500 
12.5 
100 
500 
12.5 
100 
500 
10 
10 
50 
100 
89.2      13.1 
73.5      10.9 
81.7      12.1 
94.6      2.6 
92.4      1.6 
82.9      5.9 
113.0    19.6 
95.7      10.2 
106.0    5.2 
106.3    12.1 
101.0    5.6 
93.5      7.0 
86.4      12.5 
87.2      16.1 
93.9      7.7 
92.6      6.7 
101.7    7.5 
87.5      5.9 
112.6    17.8 
103.1    11.2 
101.9    10.2 
72.5      11.5 
77.5      15.9 
79.2      17.5 
 
 10.6      5.4 
 19.8      5.6 
 20.2      7.1 
-5.1        3.5 
-17.9      9.9 
-25.4      10.1 
-8.8        2.8 
-27.5      3.7 
-32.0      14.9 
-29.8      11.2 
-25.9      13.0 
-17.7      5.9 
-1.7        1.0 
 12.5      0.8 
 0.6        0.3 
-37.5      10.1 
-25.6      12.5 
-27.8      14.9 
-10.4      6.9 
 3.7         0.8 
-6.7        3.5 
-35.2      10.6 
-12.5      14.2 
-42.7      11.9 
-34.3      7.9 
 17.8      3.6 
-19.8      10.4 
-13.1      5.1 
Table 2-4: Stability assessment, high, medium and low QCs were evaluated (n=5) 
Mean(SD) QCs 
 (ng/mL) 
72-hrs at 4°C  
RE% (SD) 
24-hrs room 
temp RE% (SD) 
2 months -70°C 
RE% (SD) 
MDZ 
 
 
1-OHMDZ 
 
 
DEX 
 
 
DOR 
 
 
DIC 
 
 
4-OHDIC 
 
 
CHL 
 
 
6-OHCHL 
5 
40 
200 
5 
40 
200 
12.5 
100 
500 
12.5 
100 
500 
12.5 
100 
500 
12.5 
100 
500 
12.5 
100 
500 
12.5 
100 
500 
5.1(1.2) 
6.6( 1.1) 
3.5(0.55) 
-0.7(0.17) 
14.9(1.7) 
11.0(78) 
11.2(1.0) 
5.1(2.1) 
-8.9(2.2) 
-3.6(0.41) 
9.3(1.9) 
6.6(1.2) 
-5.9(1.0) 
6.9(1.3) 
7.9(1.2) 
-11.0(2.6) 
14.1(3.2) 
3.0(1.6) 
-5.2(2.0) 
9.8(1.3) 
8.7(0.45) 
-10.9 (2.8) 
8.9 (1.6) 
5.4 (0.39) 
8.4(4.1) 
4.9(1.3) 
3.3(0.9) 
11.9(1.1) 
7.4(0.68) 
4.7(0.52) 
13.6(1.5) 
10.6(1.9) 
4.3 (0.22) 
-10.1(0.41) 
-0.7(0.23) 
2.1(0.38) 
-10.8(0.95) 
5.3(1.1) 
14.8(3.2)   
-1.6(0.18) 
2.0(0.13) 
-8.4(1.3) 
-14.8(1.3) 
-8.2(0.71) 
3.3(0.94) 
-12.8(3.4) 
-8.5(2.2) 
-6.9(2.6) 
7.3 (1.5) 
8.8(3.9) 
6.5(0.31) 
3.2(1.2) 
10.2(5.8) 
4.9(2.1) 
-4.5(1.7) 
-9.2(3.1) 
-11.9(2.4) 
2.5(1.0) 
8.4(2.0) 
-3.4(0.23) 
9.4(1.0) 
8.4(1.9) 
-5.8(17.0) 
6.6(2.6) 
11.0(8.5) 
4.2(12) 
2.5(0.5) 
-8.4(3.5) 
3.6(2.0) 
3.5(1.3) 
10.9(5.8) 
8.7(0.55) 
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Figure 2-4: Time-plasma concentration profiles of probes after IV bolus of 0.2mg/kg midazolam, 
0.5mg/kg diclofenac, 0.5mg/kg dextromethorphan, and 0.5mg/kg chlorzoxazone from six healthy 
Sprague-Dawley rats.  
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Table 2-5: Pharmacokinetics parameters estimates from non-compartmental model analysis 
(Mean ±SD) 
Pharmacokinetic estimates 0.2mg/kg  
Midazolam 
0.5mg/kg  
Diclofenac 
0.5mg/kg 
Dextromethorphan 
0.5mg/kg 
Chlorazoxazone       
 
AUC0-T (ug×min/mL) 
AUC0-inf (ug×min/mL) 
Cmax (ng/mL) 
Vss (L/kg) 
T1/2 (minutes) 
CLs (mL/min/kg) 
9.95 ±1.31 
10.0 ±1.36 
388.6 ±95.3 
1.18 ±0.30 
74.0±10.5 
20.9±5.94 
49.3±16.7 
51.7±16.7 
1806±1028 
1.29±0.61 
108.9±36.7 
10.3±2.60 
53.0±20.2 
58.6±21.7 
1324±553 
1.49±0.73 
112.8±34.2 
8.63±2.42 
81.2±16.8 
83.7±17.0 
1434±624 
0.65±0.13 
77.3±12.0 
6.16±1.15 
 
 
 
Table 2-6: Pharmacokinetics parameters of midazolam, diclofenac, detromethorphan and 
chlorazoxazone estimated from our study and from previous literature when the probe drugs 
were given in IV/infusion in control rats.   
 
(Mean ±SD) Author (Reference) Dose 
(mg/kg) 
CLs (ml/min/kg) Vss/Vd (L/kg)       
 
T1/2 (miuntes) 
Midazolam 
 
THIS STUDY 
(Xia, 2010) 
(Strelevitz, 2006) 
(Umathe, 2008) 
(Kurosawa, 2009) 
(Tuk, 2002) 
0.2 
1.0 
1.0 
5.0 
5.0 
5.0 
20.9 ±5.9 
23.9±5.1 
22.8 
NA 
36.6±1.4 
70±15 
1.18 ±0.30 
NA 
NA 
NA 
1.21±0.07 
3.0±1.0 
74 .0±10.5 
81.1±18.4 
NA 
58.8±3.6 
43.1±3.9 
21.1 
Diclofenac 
 
THIS STUDY 
(Xia, 2010) 
(Kim, 2006) 
(Reyes-Gordillo, 2007) 
(Dostalek, 2005) 
(Cui, 2010) 
0.5 
0.5 
5.0 
3.2 
5.0 
6.75 
10.3±2.6 
43.5±4.1 
13.6±1.62 
129.21±9.2 
NA 
4.02±0.82 
1.29±0.61 
NA 
1.58±0.497 
0.37±0.04 
0.253±0.081 
NA 
108.9±36.7 
110.2±25.8 
175±55.6 
43.8±4.95 
177±5.0 
NA 
Dextromethorphan THIS STUDY 0.5 8.63±2.42 1.49±0.73 112.8±34.2 
Chlorazoxazone THIS STUDY 
(Xia, 2010) 
(Muzeeb, 2005) 
(Wan, 2006) 
(Rockich, 1999) 
(Moon, 2003) 
(Ahn, 2008) 
0.5 
0.5 
20 
25 
15 
20 
20 
6.16±1.15 
29.5±5.0 
3.17±0.67 
12.6±1.9 
9.23±0.63 
8.96±3.14 
12.3±3.21 
0.65±0.13 
NA 
0.37±0.13 
0.403±0.071 
0.39±0.04 
0.373±0.091 
0.391±0.061 
77.3±12.0 
53.2±4.61 
80.4±15.0 
22.2±2.6 
30.5±1.78 
32.0±12.6 
28.9±2.97 
NA: Data not available. To match the same unit, certain units from original literature have been converted 
(such as hour to minutes, ml/min to ml/min/kg, etc). 
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2.3.5 Conclusion 
In this study, a method for the simultaneous evaluation of the activities of four major drug-
metabolizing cytochrome P450s (CYP3A, CYP2D, CYP2C, and CYP2E) was developed using 
ultraperformance liquid chromatography-triple quadrupole mass spectrometry (UPLC/MS/MS). 
UPLC/MS/MS method for analysis all parent drugs and metabolites simultaneously from one 
injection has been validated with inter-day and intra-day variance less than 20% with extraction 
recovery greater than 72.5%. The lowest limits of detection ranged from 0.2-5.0ng/mL (1.5-
75pg/column). Probe drugs were given to six control rats intravenously at a bolus of 0.2mg/kg 
midazolam, 0.5 mg/kg diclofenac, 0.5mg/kg dextromethorphan, and 0.5mg/kg chlorzoxazone in 
a cocktail formulation. The pharmacokinetic estimates obtained from the healthy rats were 
consistent with previous literature in a different dose range.  
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2.3 DISCUSSION 
 
The UPLC systems takes advantages of sub-2-micron porous particle manufacturing and high 
pressure hardware, significantly improves the sensitivity and provide high resolution for analysis 
multiple analytes. In addition, compared to traditional LC column, UPLC column is capable of 
produce a rapid analysis since it creates wider linear range with high flow rate and high numbers 
of theoretical plates. Our UPLC/MS/MS method provided the specificity and sensitivity for 
measuring the concentrations of multiple CYP probes administered via a low-dosed strategy. The 
method allows us to measure drug and metabolite concentrations in the low picogram range.  
 
Compared with previous cocktails, this study is the only study done using UPLC/MS/MS and 
provided the in vivo preclinical pharmacokinetic parameters for the probe drugs with a low dose 
cocktail IV strategy (Zhu et al., 2001; Streetman et al., 2000; Frye et al., 1997). A recent study 
by Xia et al. has used the very similar dosages as ours (Xia et al., 2010). A previous study by Liu 
et al., developed a simplified HPLC method and provided the time concentrations profile of five 
CYP probes in rats, however did not estimate the pharmacokinetic parameters of each probe (Liu 
et al., 2009). The pharmacokinetic estimates obtained from the healthy rats were consistent with 
previous literature. This study demonstrated that the ability of using four probe drugs to measure 
the activity of their respective enzymes was not affected by their coadministration in the current 
dosage. Therefore, the CYP 3A, CYP2E1, CYP2C and CYP2D activities can be estimated by the 
cocktail approach in a single experimental session. Future study can be designed upon modifying 
current bio-analytical method and preclinical animal study protocol such as using alternate probe 
drug, the dosage, sampling duration, and injection volume. This method is likely to be 
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particularly useful as a screening, drug drug interaction or phenotyping method for preclinical 
pharmacological and toxicological research in the future.  
 
In addition, the listed previous pharmacokinetic studies covered different dosages for each probe 
drug. Therefore, it is possible to extrapolate the pharmacokinetic profiles from a therapeutic dose 
to a lower dose for a compound characterized by linear PK (Benedetti et al., 2009). Previous 
study has used LC/MS/MS for microdosing in rats for fluconazole and tolbutamide, which are 
known to have similar pharmacokinetic properties in humans and rats (Balani et al., 2006). With 
the analytical method development, the microdosing strategy might be promising for future 
pharmacokinetic study, especially for early assessment of human pharmacokinetics of new 
chemical entities (Balani et al., 2006).  
 
Furthermore, it is possible to link and predict preclinical in vivo results from the in vitro animal 
data with the knowledge of Km, Vmax, protein content, liver weight and extraction ratio. It is 
also possible to extrapolate animal data to pharmacokinetic parameters in humans, with the 
knowledge of the allometric scaling, the specific equation Y = aWb (where the bodyweight (W) 
of the species is plotted against the pharmacokinetic parameter of interest on a log-log scale, a is 
compound specific parameter) and molecular properties (Boxenbaum et al, 1995; Mahmood et 
al., 1999; Jolivette et al., 2005; Mager et al., 2009; Sinha et al., 2011). Therefore, every piece of 
preclinical data might provide the evidence needed for preclinical to clinical translation.   
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3.0 THE EFFECTS OF THEAPEUTIC HYPOTHERMIA AND CARDIAC 
ARREST ON SPECIFIC CYTOCHROME P450 ISOFORM ACTIVITY IN RATS 
 
Zhou J, Empey PE, Bies RR, Kochanek PM and Poloyac SM Cardiac arrest and therapeutic 
hypothermia interaction with isoform-specific Cytochrome P450 drug metabolism  
Drug Metabolism and Disposition 2011 (in press) 
 
3.1 INTRODUCTION 
 
As previously discussed, brain injury is a common cause of morbidity and mortality after 
resuscitation from cardiac arrest (CA) (Geocadin et al., 2008, Manole et al., 2009). 
Therapeutically reducing body temperature to 32-35°C over 12 to 24 hours after out-of-hospital 
CA is the proven neuroprotective strategy in these highly susceptible patients (Bernard et al., 
2002; Hypothermia after cardiac arrest study group, 2002; Holzer, 2010;  Peberdy et al., 2010). 
Despite the benefit of therapeutic hypothermia, whole body cooling after resuscitation 
complicates drug therapy due to its potential effects on both drug disposition and response. 
Previous studies have found significant elevated drug levels and prolonged drug response during 
hypothermia for drugs such as phenytoin, neostigmine, vecoronium, morphine, propofol, and 
fentanyl (see detail in Chapter 1).  Given the large number of medications used in critically ill 
patients after CA and possible adverse drug effects, a close pharmacokinetic (PK) and 
pharmacodynamic (PD) monitoring is required by critical care practitioners (Cullen et al., 1997; 
Lazarou et al., 1998; Vargas et al., 1998). Currently, the specific changes in drug metabolism and 
disposition during hypothermia after CA are largely unknown. 
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Many of the drugs used in CA patients do not have readily measurable pharmacodynamic (PD) 
endpoints and have narrow therapeutic indices. This fact necessitates the evaluation of a systemic 
drug metabolism and PK as a tool to ensure drug safety and efficacy. Cytochrome P450 (CYP) 
enzymes play an essential role in metabolizing medications commonly used in critical care 
medicine including benzodiazepines, calcium channel blockers, anesthetics, and opioids 
(Tortorici et al., 2007). The magnitude of altered activity of specific CYP isoforms in CA with 
changes in body temperature is poorly understood. In addition, as we discussed before, during 
hypothermia post CA, the alterations in normal drug metabolism, can be quite complex due to 
suppressed effects from heart failure, multiple organ dysfunction and temperature. Therefore, 
changes in drug metabolism and drug response may also be a disease state and with interactions 
of temperature process. Therefore a thorough understanding of both the temperature and cardiac 
arrest pathophysiologic effects on individual CYP isoform activity is necessary to delineate the 
alterations in drug disposition.  
 
In this study, we estimated the activities of four major CYP isoforms CYP3A, CYP2C, CYP2D 
and CYP2E. A probe cocktail of midazolam, diclofenac, dextromethorphan, and chlorzoxazone 
was utilized for the phenotypic assessment of CYP3A, CYP2C, CYP2D, and CYP2E1 activity, 
respectively.  In vivo validation of all these probe drugs or in combination in cocktail has been 
previously tested (Scott et al., 1999; Xia, et al., 2010; Yu et al., 2007; Ghassabian et al., 2009; 
Krösser et al., 2006; Blakey et al., 2004). Midazolam, diclofenac, dextromethorphan and 
chlorzoxazone were also chosen based on their relative specificity, their relatively short half-life, 
and their prior clinical use as probe drugs (Frye 2004; Streetman et al., 2000).  In addition, these 
drugs were selected based on the fact that mass spectrometric detection limits allowed for lower 
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doses of these drugs in rats to decrease the likelihood of probe drug interactions upon co-
administration.  We hypothesized that the metabolisms of CYP probe substrates decrease during 
cooling due to the acute effect of hypothermia on the enzyme activity and that these alterations 
would be isoform specific. The first endpoint of the study is to evaluate systemic clearance of 
probe drugs within different groups by noncompartmental PK analysis. The secondary endpoint 
is to determine the specific correlation between hypothermia and CA with probe drug 
pharmacokinetics by nonlinear mixed effect PK modeling. The objective of this study can be 
described in Figure 3-1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-1: The study objectives 
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3.2 EXPERIMENT METHODS AND PROCEDURE  
 
3.2.1 Animals 
Animal care and all experimental protocols were approved by The University of Pittsburgh 
Animal Care and Use Committee. Male Sprague-Dawley rats (300-350g) were purchased from 
Hilltop Laboratories (Scottdale, PA). The animals were maintained on a 12-h light/dark cycle 
and were allowed free access to food and water. All animals were acclimated for one week prior 
to the experiment.  
 
All proposed animal studies were approved by the IACUC and met the standards for humane 
animal care and used as set by the Animal Welfare Act and the NIH Guide for the Care and & 
Use of Laboratory Animals.  All animals were under isoflurane anesthesia with vecuronium 
since isoflurane is thought to be less hepatotoxic than halothane or enflurane. Intensive care 
including saline infusion and necessary bicarbonate adjustment will help decreasing the 
possibility of distress. In the event that an animal demonstrates undue distress, the animal will be 
humanely euthanized. 
 
3.2.2 Surgery and cardiac arrest procedure 
The animals were randomly divided into four groups: (a) sham normothermia, (b) CA 
normothermia, (c) sham hypothermia, and (d) CA hypothermia (n=6). Rats were anesthetized 
with 1-1.5% isoflurane via a nose cone, tracheally intubated, and mechanically ventilated to 
maintain eucapnia (PaCO2 between 35 and 45 mm Hg) to start surgery and cannulation. 
Anesthesia was maintained throughout the experiment with isoflurane and oxygen.  The left 
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femoral artery was cannulated for measurement of mean arterial pressure, and the femoral vein 
was cannulated bilaterally for drug administration and blood sampling. Neuromuscular blockade 
was induced and maintained with vecuronium 2 mg/kg intravenously before the cannulation. 
After preparative surgery, isoflurane was washed out with 100% oxygen for 3 minutes and room 
air for 2 minutes. CA was initiated by asphyxiation via disconnection of the mechanical 
ventilation. Asphyxial CA was continued for 8 minutes, with approximately 6 minutes of 
asystole, confirmed by electrocardiogram. Resuscitation was initiated by reconnecting the rat to 
the ventilator, administering intravenous epinephrine (0.005 mg/kg) and sodium bicarbonate 
(1mEq/kg), and performing manual chest compressions for about 40-60 seconds until restoration 
of spontaneous circulation. Sham animals received all of the above surgeries for blood sample 
collection but were not made hypothermic or subjected to cardiac arrest. Figure 3-2 has shown 
the cannulation into the blood vein under ScreenLens magnifier. The incision is on the left thigh 
of the rat. There are two cannulation tubes, one is placed inside of the femoral artery (on the 
back, already secured on two ends) and the other is placed inside of the femoral vein (on the 
front, just put in, have not secured the two ends yet). Figure 3-3 has shown that blood pressure 
change at the time around CA insult (close to zero after disconnection of the intubated tubing) 
and resuscitation.  
 
3.2.3 Hypothermia and temperature measurement 
Hypothermia was induced starting 60 minutes after resuscitation. Systemic hypothermia with a 
target temperature of 32.5-33°C was initiated by surface cooling for 30 minutes, followed by 15 
minutes stabilization. The animals were maintained in a hypothermic state for 8-hr after 
temperature stabilization. Rectal temperature of the normothermic group was maintained at 37.5-
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38°C. Body temperature was continuously measured using a rectal temperature probe. A heating 
pad, heating light, cooling fan and ice bags were used to adjust and maintain the target 
temperature.  
 
3.2.4 Microdosed formulation  
Microdosed IV cocktail dosage designed at 0.2mg/kg midazolam, 0.5mg/kg dextromethorphan, 
0.5mg/kg diclofenac and 0.5 mg/kg chloraxazone. Except midazolam available in injection 
solution, the other three dextromethorphan, diclofenac and chloraxazone are originally powder. 
They were dissolved in the saline solution with the minimal ethanol concentration. The final 
cocktail formulation contains less than 20% (v/v) ethanol in saline. Drug was given to rats 
intravenously 1.0mL/kg, (e.g. 400g rats, give 0.4mL). 
 
3.2.5 Drug administration and pharmacokinetics sampling 
Once rectal temperature was stabilized, the four probe drugs were given intravenously at doses 
of 0.2mg/kg midazolam, 0.5mg/kg dextromethorphan, 0.5mg/kg diclofenac, and 0.5mg/kg 
chlorzoxazone simultaneously. The probe substrate cocktail formulation was prepared in saline 
with ethanol (<20% v/v).  Normal saline solution (1.0mL) was injected to flush the catheter after 
the drug administration. Baseline and blood samples (0.3 mL) at 5, 15, 30, 60, 120, 180, 240, 
300, 360 and 480 minutes were obtained via a heparinized syringe. The blood sample volume 
was replaced with an equal volume of normal saline. The blood samples were centrifuged and 
the supernatant plasma was transferred to a labeled microcentrifuge tube and immediately placed 
into a -20°C freezer. Probe drug plasma concentrations or urine metabolites were measured 
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simultaneously by ultraperformance liquid chromatography- triple quadrupole mass spectrometry 
(UPLC/MS/MS) which has been described in Chapter 2.  
 
3.2.6 Arterial blood gas sampling and physiological parameter 
Multiple arterial blood gas samples (100μL) were collected (at baseline before CA, 10, 30, 60 
minutes after return of spontaneous circulation, at the end of hypothermia induction, and every 
hour during the blood sampling) for the purpose of monitoring the status of the animals over the 
time. Physiological parameters including pH, MAP, PaCO2, pH, lactate, hematocrit, K+, Mg2+, 
glucose, and blood urea nitrogen (BUN) were measured at each time point. A maintenance 
infusion of saline (3mL/hr/kg) was started beginning at 20 minutes after drug administration and 
continued for 8 hours. Doses of bicarbonate were given as needed to correct acidosis. The 
complete study procedure has been described in Figure 3-4. 
 
3.2.7 Statistical analysis   
Physiological variables were compared by repeated measure ANOVA (among groups and across 
time) with Bonferroni post hoc correction. Systemic clearances (from the non-compartmental 
analysis or the population analysis) of each probe drug from different treatments were compared 
by one-way ANOVA with Bonferroni post hoc. All figures and data expressed as mean ± SD as 
determined from Prism 5 (GraphPad Software, San Diego, CA) or Microsoft Excel. Significance 
was denoted by a p value <0.05. 
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Figure 3-2: Cannulation into the blood vein under ScreenLens magnifier. The incision is on the 
left thigh of the rat. There are two cannulation tubes, one is placed inside of the femoral artery 
(on the back, already secured on two ends) and the other is placed inside of the femoral vein (on 
the front, just put in, have not secured the two ends yet). 
 
 
 
 
Figure 3-3: Blood pressure curve at the time around CA insult and resuscitation 
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Figure 3-4:  Experiment design 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
82 
 
3.3 PK ANALYSIS 
 
3.3.1 Non-compartmental model analysis and systemic clearances 
Non-compartmental pharmacokinetic analysis was used for calculating area under curve (AUC0-
inf) and systemic clearance (CL) from each individual time concentration curve of midazolam, 
diclofenac, dextromethorphan and chlorzoxazone by Winnonlin 5.2. AUC was calculated from 
drug plasma concentration data based on trapezoidal rule. The clearance then has been calculated 
from the total dose and AUC0-inf.  
 
Non-compartmental pharmacokinetics describes the PK characteristics of a drug without 
assuming any kinetic compartments. Non-compartmental pharmacokinetics with the method of 
statstistical moments does not describe the concentration-time course of a drug in different body 
fluids by means different equations. Instead, it calculates PK parameters independently without 
making assumptions with drug distribution compartments (Gillespie 1991; Cobelli et al., 1984; 
Rowland et al., 1995). The following parameters that has been calculated by the non-
compartmental approach used for evaluation purposes in this thesis:  
1) Area under the concentration-time curve (AUC): The AUC can be calculated by means of the 
linear trapezoidal rule. 
                               AUC=1/2  ∫ 0-t (Ck-1+Ck) × (tk-tk-1)] 
where tk-1 and tk correspond to two successive measurement time points with the concentrations 
Ck-1 and Ck during the time period t0- tk. Average concentrations can be obtained by dividing the 
AUC of one dosing interval by the dosing interval τ. 
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2) Systemic clearance :  CL=Dose/AUC 
 
Clearance by definition represents the volume of the blood cleared through an organ at a unit of 
time. Clearance is one the most useful pharmacokinetics parameters. Clearance of a drug from 
the body depends on the intrinsic ability such as liver and kidney to metabolism or to excrete. 
For certain drugs that get metabolized primarily, the total clearance is equal to hepatic clearance.  
In addition, clearance is the function of the blood flow to these organs.  For drugs that belong to 
capacity limited elimination (Q>>CL’int), their clearance highly depend on the hepatic intrinsic 
clearance. Clearance cannot be estimated from an oral dose because not all the dose gets into the 
circulation.  
1) CLTotal=CLH+CLR, when CLH>>CLR, CLTotal=CLH 
2) CLH=Q× CL’int/(Q+CL’int), when Q>>CL’int, CLtotal=CLH=CL’int 
 
3.3.2 Population pharmacokinetic (PK) modelling     
3.3.2.1 Background and importance of population PK 
The subspecialty of population PK was introduced into clinical pharmacology from 1970s as a 
method to develop model based sparse sampling analysis. Later the population PK has been 
developed into the discipline of pharmacometrics, pioneered by Sheiner and Beal (Sheiner et al., 
1977; Sheiner et al., 1979; Bonate 2005). It describes the typical relations between physiology 
and pharmacokinetics, the inter-individual, inter-occasion variability in these relations and their 
residual variability. Population pharmacokinetics seeks to identify the measurable 
pathophysiologic factors that cause changes in the dose-concentration relationship and the extent 
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of these changes so that, if such changes are associated with clinically significant shifts in the 
therapeutic index, dosage can be appropriately modified. The population pharmacokinetic 
approach has been recommended by guidelines issued by the Food and Drug Administration 
(FDA) in 1999 and the International Conference on Harmonisation (ICH) as a tool for the 
identification of the sources and correlates of variability in drug concentrations between 
individuals representative of those in whom a drug when relevant dosage regimens are 
administered (Williams and Ette, 2000; Gobburu et al., 2001; Powell et al., 2001). For this thesis 
research, the major goal of using population PK is to determine whether and to what extent that 
the factors such as temperature, and disease, leading to the changes in PK and PD response of 
CYP probe drugs and those clinical relevant drugs.  
 
3.3.2.2 Model estimation method-Maximum likelihood test   
The aim of the PK estimation is to obtain parameters that result in an optimal description of the 
modeled data given a model function. A likelihood function is a function of the parameters of a 
statistical model, defined as follows: the likelihood of a set of parameter values given some 
observed outcomes is equal to the probability of those observed outcomes given those parameter 
values. The notions of probability and likelihood can be connected together by Bayes’ Theorem: 
P(A|B)=[P(B|A)P(A)]/P(B), we can also write: P(A)P(B|A)=P(B)P(A|B). If we assign B to be the 
model and A to be the data, then it will be P(data)P(model|data)=P(model)P(data|model). After 
we have the data, and the P(data) will not change, considering a constant, therefore 
P(model|data)= P(model)P(data|model).  
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The aim of maximum likelihood estimation is to find the parameter value that makes the 
observed data most likely. When applied to an obtained time concentration data set and given a 
statically PK model, maximum-likelihood estimation (MLE) provides the estimates for the 
model’s parameters in their maximum likelihood. For example: I am interested in the clearance 
of a drug from normal healthy human being, but unable to measure the clearance of every single 
human being in a population. Then I am assuming that the clearances are normally distributed 
(Gaussian) with some unknown mean and variance, the mean and variance then can be estimated 
with the MLE approach while only knowing the clearance of some people from the overall 
population. MLE would accomplish this task by taking the mean and variance as parameters and 
finding particular parametric values that make the observed results the most possible (given the 
model). MLE is a method of estimating the parameters of a statistical model used in NONMEM 
program. In NONMEM, this is done by minimizing the extended least squares objective function 
value (OFV): 
                         OFV (xj, θ, σ2) = ∑i-n [ln σ2 + (yi-f(xj,θ)) 2 / σ2] 
 
where x is the independent variable, θ is the model parameter, σ2 is the variability, and y is the 
vector of data.  OFV is equal to -2 of the log likelihood of the fit. Therefore, a minimum OFV 
reflects the maximum likelihood of parameters that maximize the probability of observing the 
data given a specific model. 
 
 
3.3.2.3 Population PK model components  
Nonlinear mixed effect modeling (NONMEM) program is one of the most commonly used 
programs for population PK modeling and simulation.  It was first introduced by Sheiner and 
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Beal in late 1970 in UCSF. Nonlinear mixed effect modeling approach can be applied to more 
sparse sampling schedules, allowing a less restrictive and also unbalanced study design. It 
enables study pooling and the simultaneous investigation of different drug administration routes. 
In this approach, all parameters are estimated simultaneously, and individual parameters can be 
determined based on the estimated variances. In addition, mixed effect model allow some or all 
the parameters to vary with experimental unit through the inclusion of random effects which can 
flexibly account for the within-unit correlation often observed with repeated measures and 
provide proper inference (Ette and Williams, 2004). In our study, temperature change correlated 
to the continuous changing parameters, and therefore it is the best PK estimation approach to 
calculate the effect of hypothermia on drug metabolism.  NONMEM program was used for 
population PK parameter estimates in this thesis.  
 
3.3.2.4 Model selection- Statistical comparison 
After model construction, decision on model improvement or deterioration can be based on 
serveral criteria. First, the difference in the OFV of two nested models (e.g. between different 
base models, or between a covariate model and the base model) difference in OFV is 
approximately χ-square distributed. Hence, a difference in OFV of 3.84 and 6.64 points to 
significant level of 0.05 and 0.01, respectively, given 1 degree of freedom (df). Moreover, 
precision of parameter estimates can be obtained based on their standard errors. Furthermore, 
goodness of fit diagnostic plot and visual predictive check are often used to test the robustness 
and accuracy of the final model (Ette 1997).  
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3.3.3 Population PK model construction in the study 
As discussed above, population model components include structure model, pharamcostatistics 
model (inter-individual, inter-occasion and residual error) and covariate model, which has been 
shown in Figure 3-5.  
 
3.3.3.1 Structural model and pharmacostatistics model 
The population pharmacokinetic model was constructed using a nonlinear mixed-effects 
approach as implemented in the NONMEM VI program (Icon, Hanover, Maryland). The first 
order conditional estimation method (FOCE) with interaction was used to estimate all 
parameters. The population pharmacokinetic model consisted of a pharmacokinetic structural 
model and a statistical model in which between subject and within subject variability were 
described. One and two-compartment structural pharmacokinetics models were investigated as 
base model structures.  The one-compartment model structure was evaluated using the ADVAN 
1 TRANS 2 subroutine (estimate CL and V) and the two-compartment model structure was 
implemented as the ADVAN3 TRANS4 subroutine (estimate CL, V1, V2 and Q). The inter-
individual variability in the pharmacokinetic parameters was assumed to be log-normally 
distributed for all population parameters. Inter-individual variability in model parameters are 
modeled using an exponential term. θi=θ×℮η with ηi~N(0, ω2), θ is the population value and ηi is 
the variable accounting for inter-individual variability with mean zero and variance ω2. Residual 
variability (σ2), the discrepancy between the individual observed (Cobs,ij) and the individual 
model-predicted (Cpred,ij) plasma concentrations, was evaluated using additive, proportional or 
a combined additive and proportional model Cobs,ij = Cpred,ij ×(1+εij1+ εij2), Where Cobs, ij is 
the jth measured observation in individual i, Cpred ij, is the jth model predicted value in 
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individual i, εij is the residual error. Further refinement of the error model was performed as 
needed. 
 
The model building process was guided by analyzing the goodness of fit plots, plausibility of 
parameter estimates, precision of parameters estimates, and the lowest objective function value 
provided by NONMEM. Goodness of fits plots including population predicted concentrations 
(PRED) vs observed concentration (OBS), individual predicted concentrations (IPRE) vs 
observed concentration, population predicted concentrations (PRED) vs weighted residuals 
(WRES) and time vs weighted residuals (WRES) were used for internal validation. Final model 
parameters were reported with estimates mean with standard error (se%).  
 
3.3.3.2 Covariate model 
After a base model was chosen for each drug, covariate effects on the parameters of that model 
were evaluated in the following way. Factors treated as categorical covariates were temperature 
(TEMG, 0= normothermia, 1=hypothermia), and CA injury (CAG, 0= sham, 1=CA). They have 
been tested in forward addition in either of the following ways: PTV = θ1+ θ2 ×(Cov) or PTV = θ1× 
θ2 (Cov) , where θ1  and θ2 are estimated fixed effect parameters and Cov is the subject specific 
value of the categorical covariate. Three physiological parameters (Glucose, BUN and K) were 
tested in forward fashion as continuous covariates, which has been tested in the following: PTV =  
θ1 × θ2 (Cov/Medcov) , where θ1  and θ2 are estimated fixed effect parameters, Cov is the subject 
specific value of the continuous covariate, and MedCov is the median value of the Cov. To 
assess whether the model with covariates statistically improved the fit to the data from base 
model, the difference between their objective function values, referred to as the log likelihood 
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ratio, was calculated. This ratio is approximately be chi-square (χ2) distributed. A decrease in the 
OFV of 3.84 and 6.63 are significant at the p=0.05 and p=0.01 respectively, with 1 degree of 
freedom. For the final model, stepwise forward addition and then backward elimination process 
was used. The final covariate models were also evaluated using diagnostic plots, successful 
minimization, precision for all parameters (standard error %) and visual predictive check. The 
individual clearances generated for each time point of four groups have been graphed.  Full 
covariate model building process has been depicted in Figure 3-6. 
 
3.3.3.3 Visual predictive check  
Monte Carlo simulations for 1000 times have been performed for each model as predictive 
check. Monte Carlo simulation performs probability analysis by building models of possible 
results by substituting a range of values, a probability distribution, for any possible factor that 
has inherent uncertainty. It then calculates results over and over, each time using a different set 
of random values from the probability functions. Monte Carlo simulation produces distributions 
of possible outcome values. Depending upon the number of uncertainties and the ranges 
specified for them, a Monte Carlo simulation could involve thousands or tens of thousands of 
recalculations before it is complete (Ette et al., 2007, Nestorov 2001). Therefore, in an internal 
evaluation procedure 1000 new individual concentration-time profiles were simulated based on 
the parameter estimates from the final base model. After fitting the final covariate model to each 
of the resulting datasets, the model parameters were compared with the estimates and the 
confidence intervals of the original dataset. The predict check of a good final model using 
simulation should be able to demonstrate that the simulated distribution of median and 95% CI 
values are in agreement with the observed values. The simulation as well as the goodness of fit 
90 
 
graphs revealed that the final models provided a reliable description of the data with good 
precision of the structure model estimates and covariate effect.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-5: Schematic structure of the population PK model 
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Figure 3-6: Covariate model building process  
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3.4 RESULTS 
 
3.4.1 Temperature  
The body temperatures at sham normothermia, sham hypothermia, CA normothermia, and CA 
hypothermic groups were 37.9±0.4°C, 32.5±0.4°C, 37.8±0.5°C, and 32.8±0.3°C, respectively 
(n=6). Time temperature curves of four treatment groups have been depicted in Figure 3-7.  
 
3.4.2 Arterial blood gas sampling and physiological parameter 
Physiological parameters of MAP, PaCO2, pH, glucose, lactate, BUN, hematocrit, Mg2+ and K+ 
from each treatment group  at each time point (baseline, 1-hr after resuscitation, end of cooling 
induction, 4-hr cooling, 8-hr cooling) are shown in Table 3-1. Glucose level decreased over the 
time in all four groups (p<0.01). BUN increased over the time in all four groups, especially in 
CA groups. Hematocrit decreased over the time, likely due to multiple blood sampling. Mg2+ and 
K+ both increased at 8-hr in CA groups (p<0.01). At 1-hr after resuscitation, MAP in both CA 
groups was lower than in the sham control groups. At 1-hr after resuscitation, the glucose level in 
the CA hypothermia was the lowest among groups, and then recovered. pH in the CA 
hypothermia group was lower than in the other groups from 1-hr after resuscitation. There was 
no significant correlation between temperature and multiple physiological parameters (PaCO2, 
glucose, lactate, Hct, BUN and K+).  
 
3.4.3 Time-concentration curves 
Time-concentration curves from 0-8 hrs for midazolam, diclofenac, dextromethorphan and 
chlorzoxazone were shown in Figure 3-10. Non-compartmental pharmacokinetic analysis was 
93 
 
used for calculating systemic clearance (CL) from each individual time concentration curve of 
midazolam, diclofenac, dextromethorphan and chlorzoxazone by Winnonlin 5.2 (PharSight, CA). 
Systemic clearances of each probe drug from different treatments were compared by one-way 
ANOVA with Bonferroni post hoc test. Significance was denoted by a p value <0.05. All figures 
and data expressed as mean ±SD as determined from Prism 5 (GraphPad Software, San Diego, 
CA) or Microsoft Excel.  
 
3.4.4 Systemic clearance and non-compartmental analysis 
Systematic clearances calculated from non-compartmental analysis of all four drugs were shown 
in Figure 3-11.  The clearances of midazolam in sham hypothermia, CA normothermia and CA 
hypothermia groups were 83.2%, 62.4% and 52.5%, respectively, compared to those in sham 
normothermia group. Significant reduction in the clearance of midazolam in hypothermic CA 
was found compared with the sham normothermic control (681.6±190.0 mL/hr/kg vs 
1268.8±348.9 mL/hr/kg, p<0.05). In addition, the systemic clearances of midazolam in combined 
hypothermia groups were 67.8% of those in combined normothermia groups. The clearances of 
diclofenac in sham hypothermia, CA normothermia and CA hypothermia groups were 89.6%, 
102.8% and 75.5% compared to those in sham normothermia group. There was no significant 
difference found in clearances of diclofenac when compared within four groups.  
 
The clearances of dextromethorphan in sham hypothermia, CA normothermia and CA 
hypothermia groups were 106.9%, 111.5% and 79.9%, respectively, compared to those in sham 
normothermia group. There was no significant difference found in clearances of 
dextromethorphan within four groups. The clearances of chlorzoxazone in sham hypothermia, 
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CA normothermia and CA hypothermia groups were 63.1%, 45.3% and 40.9%, respectively, 
compared to those in sham normothermia group. The systemic clearances of chlorzoxazone in 
combined hypothermia groups were 71.6% of those in combined normothermia groups. 
Significant reductions in clearances of chlorzoxazone for CA normothermia and CA 
hypothermia were observed when compared with sham normothermia (254.7±55.5 mL/hr/kg, 
229.6±75.6 mL/hr/kg, vs 561.8±215.9 mL/hr/kg, p<0.05).  
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Figure 3-7: Temperature curves of four treatment groups (Mean±SD). Dashed lines are 
hypothermia groups and solid lines are normothermia groups. (● sham normothermia, ■ sham 
hypothermia,  ○ CA normothermia, □ CA hypothermia). 
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Table 3-1: Physiological parameters at different time points in four groups 
  Baseline 
before CA 
1-hr after 
ROSC 
End of cooling 
induction, PK 
baseline 
4-hour after 
cooling 
8-hour after 
cooling 
MAP Sham normo 
Sham hypo 
CA normo 
CA hypo 
101.7±7.5 
110.6±29.5 
109±27.9 
88±11.5 
92.7±8.8 
100.3±11.5 
59.3±14.4† 
69.2±16.8#† 
102.8±13.8 
119.5±17.4 
86.3±21.3 
138.6±12.9#† 
125.8±16.4 
131.7±21.9 
110±5.8 
130.5±20.5# 
115±15.2  
129.2±14.5 
136.5±11.9# 
126.3±9.9# 
pCO2 Sham normo 
Sham hypo 
CA normo 
CA hypo 
37.9±5.9 
37.1±4.5 
39.3±3.2 
36.5±2.6 
36.4±4.4 
37.2±2.4 
32.4±5.4# 
29.1±2.3 # † 
35.8±4.2 
40.1±5.1 
36.7±4.1 
49.7±5.9#† 
35.2±3.4 
36.8±7.1 
39.6±8.0 
42.9±5.5#† 
34.8±4.4 
30.8±3.7# 
35.4±5.3 
36.9±8.3 
Glucose Sham normo 
Sham hypo 
CA normo 
CA hypo 
86.8±20.2 
113.5±30.7 
112±39.9 
92.6±17.0 
65.7±8.07# 
76.8±16.6# 
63.6±11.8# 
53±13.4#† 
69.7±10.9# 
87.8±19.1# 
56±5.5#† 
72.8±29.6# 
78.2±18.6 
83.8±18.2# 
85.2±28.2# 
80.7±16.7# 
75.3±23.5 
89.2±17.4# 
71±30.3# 
73.3±38.1# 
Lactate Sham normo 
Sham hypo 
CA normo 
CA hypo 
0.78±0.23 
0.96±0.24 
0.82±0.18 
0.96±0.31 
0.78±0.29 
0.9±0.35 
1.40±0.7† 
0.88±0.48 
0.82±0.36 
0.56±0.23# 
0.7±0.4 
0.25±0.13#† 
0.32±0.30# 
0.62±0.23#† 
0.8±0.23† 
0.47±0.25#† 
0.5±0.25# 
0.4±0.34# 
1.32±1.5#† 
0.38±0.11#† 
BUN Sham normo 
Sham hypo 
CA normo 
CA hypo 
24.7±7.3 
23.2±5.6 
26.5±8.3 
26.8±7.9 
22.5±4.5 
24±3.8 
30.1±6.2† 
32.2±9.0#† 
23.5±6.0 
23.2±4.6 
32.3±7.5#† 
31.7±5.7#† 
38±12.7# 
37.2±10.3# 
45±9.8#† 
46.2±10.2#† 
57.8±19.7# 
49.2±16.7# 
66.8±18.0#† 
60.6±16.8# 
Hemato
crit% 
Sham normo 
Sham hypo 
CA normo 
CA hypo 
36.7±2.9 
35.8±1.6 
37±2.8 
37±4.3 
35.3±1.2 
35.4±2.4 
35.5±1.5 
36.8±2.1 
34.2±1.6 
35±1.0 
33.3±3.2# 
37.5±1.6† 
32.3±2.7# 
31.6±1.0# 
30±1.9# 
31±1.3# 
35±1.0 
30.8±1.7#† 
30.8±1.6#† 
32.8±3.7#† 
pH Sham normo 
Sham hypo 
CA normo 
CA hypo 
7.38±0.03 
7.38±0.02 
7.37±0.03 
7.39±0.03 
7.38±0.03 
7.45±0.16 
7.44±0.03 
7.43±0.03 
7.39±0.03 
7.36±0.01 
7.39±0.01 
7.29±0.04#† 
7.36±0.06 
7.37±0.03 
7.38±0.02 
7.32±0.05#† 
7.36±0.04 
7.39±0.03 
7.35±0.06 
7.33±0.03# 
Mg2+ Sham normo 
Sham hypo 
CA normo 
CA hypo 
0.36±0.03 
0.39±0.03 
0.36±0.04 
0.34±0.05 
0.37±0.03 
0.39±0.04 
0.39±0.04 
0.43±0.05#† 
0.37±0.04 
0.40±0.03 
0.41±0.02 
0.42±0.02#† 
0.41±0.05 
0.41±0.05 
0.43±0.04# 
0.41±0.05# 
0.41±0.06 
0.43±0.05 
0.46±0.06#† 
0.46±0.09#† 
K+ Sham normo 
Sham hypo 
CA normo 
CA hypo 
4.75±0.53 
4.91±0.30 
4.78±0.35 
4.6±0.48 
4.74±0.40 
4.79±0.24 
4.84±0.31 
4.73±0.45 
4.61±0.37 
4.12±0.35 
4.84±0.37 
3.89±0.36#† 
5.25±0.66# 
3.75±0.34#† 
5.43±0.47 
4.83±0.18 
5.62±0.98# 
4.83±0.28 
5.97±0.42# 
5.67±0.9# 
#: p<0.01 compared with the baseline time point within the same treatment group (compare 
within row), by one way repeated ANOVA. †: p<0.01 compared with the sham normothermia 
within the same time point (compare within column) by one way repeated ANOVA with 
Bonferroni post hoc test. 
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Figure 3-8: Time-plasma concentrations (ng/mL) obtained for midazolam, diclofenac, 
dextromethorphan and chlorzoxazone from 0-8 hours after IV bolus 0.2 mg/kg midazolam, 0.5 
mg/kg diclofenac, 0.5mg/kg dextromethorphan, and 0.5mg/kg chlorzoxazone.  Dashed lines are 
hypothermia groups and solid lines are normothermia groups. (● sham normothermia, ■ sham 
hypothermia, ○ CA normothermia,  □ CA hypothermia). 
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Figure 3-9: Systemic clearances of midazolam, diclofenac, dextromethorphan and chlorzoxazone 
in four groups by non-compartment model analysis. Significant difference among four groups 
was tested from one-way ANOVA with Bonferroni post hoc test. *p<0.05 
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3.4.6 Midazolam population PK model  
3.4.6.1 Base Model  
The two-compartment model structure was significantly better than a one compartment model 
for the disposition of midazolam (OFV difference at least 16.0 points, 2df, p<0.001). Normally, 
in a two-compartment model two different phases can be distinguished in the semi-logarithmic 
concentration-time plot: a rapid distribution phase and a slower elimination phase whereas the 
semi-logarithmic concentration-time plot is a linear curve.  The plasma concentrations obtained 
are associated with the central compartment (Figure 3-12). From our time concentration curves 
for all probe drugs, the two compartment model fits better. The population pharmacokinetic 
model consisted of a structural model and a pharmaco-statistical model in which between subject 
and within subject variability were described. Inter-individual variability (ω2) was chosen for all 
four CL, V1, Q, and V2 parameters. Residual error model used was described as: 
Y=F+F×ERR(1). Parameter estimates of midazolam base model have been listed in Table 4-2.  
 
 
 
Figure 3-10: Typical two compartment model, in which we chose to estimate CL, V1, V2 and Q. 
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3.4.6.2 Covariate model  
Two significant covariates were identified reducing the OFV 10.4 points (p<0.01) compared to 
base model of midazolam. The final pharmacokinetic model for midazolam included a CAG 
covariate (0=healthy, 1=CA) in systemic clearance (CL), and a TEMG (0=normothermia, 
1=hypothermia) covariant in central volume of distribution (V1). CA groups decreased the 
clearance of midazolam, which can be described as CL=0.990+CAG×(-0.318). Systemic 
clearance of midazolam in CA groups was estimated to be 67.9% of those in healthy groups. In 
addition, hypothermia decreased the V1 of midazolam, which can be described as 
V1=0.258+TEMG×(-0.0786). The central volume of distribution of midazolam in hypothermia 
group was estimated to be 69.5% of those in normothermia.  Inter-individual variability of CL, 
V1, Q and V2 were 11.9%, 1.8%, 46% and 21.4%, respectively.  
 
3.4.6.3 Final model evaluation  
The final covariate model was evaluated using diagnostic plots, successful minimization, 
precision for all parameters (se%) and a predictive check. Diagnostic plots include individual 
predicted concentration-observed concentration (IPRED-OBS) and time-weighted residual 
(TIME-WRERS) of final models of midazolam has been shown in Figure 3-11.  
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Table 3-2: Population pharmacokinetic parameter estimates (with se%) from NONMEM for 
midazolam of base model and covariate model. 
 
 
Parameters 
Estimate (se%.) 
Midazolam 
Base model 
Midazolam Final model 
CL=θ1+CAG×θ5; 
V1= θ2+TEMG×θ6 
CL(θ1) 
V1(θ2) 
Q(θ3) 
V2(θ4) 
Covariate θ5 
Covariate θ6 
ω2 (CL) 
ω2 (V1) 
ω2 (Q) 
ω2 (V2) 
σ2 
Final OFV 
OFV change 
Covariates p value  
0.801 
0.206  
0.639 
0.991  
— 
— 
0.146  
0.0075 
0.385 
0.212  
0.112  
1279.06 
 
0.990 (12.7) 
0.258 (2.42) 
0.644(10.6) 
1.0 (11.9) 
-0.318(11.5) 
-0.0786 (16.4) 
0.119 (6.21) 
0.018(14.6) 
0.460(12.4) 
0.214 (14.7) 
0.107 (12.5%) 
1268.8 
10.4 
p<0.01 (2d.f.) 
 
CL: clearance, L/hr/kg; V1: central compartment of distribution, L/kg; Q: inter-compartmental 
clearance, L/hr/kg, V2: peripheral compartment of distribution, L/kg. CAG: 0=healthy, 1=CA; 
TEMG: 0=normothermia, 1=hypothermia; ω2: inter-individual variability; σ2: residual error 
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Figure 3-11: Goodness-of-fit diagnostic plots: Individual predicted concentration-Observed 
concentration (IPRED-OBS) and Time-Weighted Residual (TIME-WRERS) of final models of 
midazolam. The solid line in the top panel is the line of unity. 
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3.4.6.4 Predictive check  
Simulation curves with median curve and 95% CI distribution generated from 1000 times Monte 
Carlo simulation has been shown below in Figure 3-12.  The simulated data and the observed 
data are in great agreement with each other, suggesting the robust and accuracy of the final 
model.  
 
0 2 4 6 8
0
20
0
40
0
60
0
80
0
10
00
TIME (hr)
ng
/m
l
 
Figure 3-12: Predictive check from 1000 simulations using the final model estimated parameter 
for midazolam. Solid line is the median of all simulated concentration. Dashed lines are 5th and 
95th percentiles of all simulated values. All dots are observed values from the study.  
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3.4.6.5 Discussion of final midazolam model  
Total body clearance for midazolam (CYP3A) during hypothermia after CA was reduced from 
the clearance of the sham normothermia group as assessed by either the non-compartmental or 
population model analysis. CA is more likely correlated with the decreased activity of CYP3A 
observed in the hypothermic CA group. CA and associated sequelae can cause severe metabolic 
disturbances. Surprisingly, these effects on hepatic drug metabolism are currently also poorly 
understood.  
 
Previous studies have shown that the metabolism and elimination of drugs are often altered in 
critically ill patients. Shelly et al demonstrated the failure of critically ill patients to metabolize 
midazolam. The clearance of midazolam was reduced and plasma concentration of its metabolite 
1’-hydroxymidazolam was decreased in septic shock patients (Shelly et al., 1987). Spina et al 
has shown that therapeutic monitoring of midazolam in the ICU is warranted (Spina and Ensom, 
2007). Kirwan et al showed that midazolam can be used to monitor changes in hepatic drug 
metabolism in critically ill patients. The concentration of midazolam at 4 hours after 
administration was significantly greater in critically ill patients as compared to normal renal 
function subjects (Kirwan et al., 2009).  A previous study by Vree et al has reported the 
decreased elimination rate of midazolam in the intensive care patients, which may due to the 
decreased albumin and altered tissue binding (Vree et al., 1989). The CA effect as well as 
possible CA-temperature interactions observed in our study thus maybe related to hepatic 
ischemia, liver dysfunction, compromised renal function, or decreased albumin. The use of 
hypothermia in patients with CA could thus results in an unrecognized interaction if it is 
translated to the clinical conditions for predicting metabolism of CYP3A in critical illness. 
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Previous study by Patal et al. has studied the midazolam PK in patients with congestive heart 
failure (CHF). In the CHF patients, the elimination half-life of midazolam was prolonged around 
25-50% (4-4.5 vs 3 hours), and the systemic clearance of midazolam was reduced to 68% (376 
vs 551 ml/min) (Patal, et al. 1990).  
 
The reduced metabolism of midazolam from CA as well as possible CA-temperature interactions 
observed in our study thus maybe related to hepatic ischemia, liver dysfunction, compromised 
renal function, or decreased albumin. The use of hypothermia in patients with CA could thus 
results in an unrecognized interaction if it is translated to the clinical conditions for predicting 
metabolism of CYP3A in critical illness. 
 
Hypothermia decreased the central compartment volume of midazolam in this study, and 
therefore also explained the observed higher plasma concentration during hypothermia. Altered 
pharmacokinetic parameters during hypothermia including the changes of both clearance and 
volume of distribution have been reported previous. Previous studies demonstrated reduced 
metabolism of CYP3A substrates during hypothermia (Caldwell et al., 2000; Fritz et al., 2005; 
Fukuoka et al., 2004; Hostler et al., 2010). In the next chapter, we will discuss one of our clinical 
studies, in which we have found mild hypothermia reduced midazolam clearance and around 
11.1% midazolam clearance decrease per degree Celsius change below 36.5°C in healthy 
volunteers. Our current understanding is that the combination of hypothermia and CA may both 
affect the activity of CYP3A and the metabolism and distribution of CYP3A substrates. 
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3.4.7 Diclofenac model  
3.4.7.1 Base Model 
The two-compartment model structure was chosen. The population pharmacokinetic model 
consisted of a pharmacokinetic structural model and a statistical model in which between subject 
and within subject variability were described. Four inter-individual variability (ω2) were chosen 
for CL, V1, Q, V2. Residual error model used was Y=F+F×ERR(1). Parameter estimates of 
diclofenac base model have been listed in Table 3-3.  
 
3.4.7.2 Covariate Model 
Final pharmacokinetic model for diclofenac included a TEMG covariate in systemic clearance 
(CL) (p<0.05), which can be described as CL=0.587+TEMG×(-0.184). The systemic clearance 
of diclofenac in the combined hypothermic groups was estimated to be 68.7% of those in 
normothermia groups. Inter–individual variability of CL, V1, Q and V2 were 14.9%, 8.25%, 
31.2%, 40.6%, respectively. Final model decreased OFV 6.0 points (p<0.05) from the base 
model of diclofenac.  This effect is considered marginal.  
 
3.4.7.3 Model Validation  
The final covariate model was evaluated using diagnostic plots, successful minimization, 
precision for all parameters (se%) and a predictive check. Diagnostic plots for diclofenac has 
been shown in Figure 3-13.  
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Table 3-3: Population pharmacokinetic parameter estimates (with se%) from NONMEM for 
diclofenac. 
 
Parameters 
Estimate(se%.) 
Base model Final model 
CL= θ1+TEMG×θ5 
CL(θ1) 
V1(θ2) 
Q(θ3) 
V2(θ4) 
Covariate θ5 
ω2 (CL) 
ω2 (V1) 
ω2 (Q) 
ω2 (V2) 
σ2 
Final OFV 
OFV change 
Covariates p value 
0.494(5.28) 
0.139 (2.06) 
0.513 (8.28) 
0.868 (14.0) 
― 
0.175 (7.34) 
0.089(9.02) 
0.294(11.0) 
0.401(12.0) 
0.119 (1.65) 
1945.54 
 
0.587(6.55) 
0.138 (2.31) 
0.507 (8.22) 
0.854 (15.1) 
-0.184 (9.06) 
0.149 (5.48) 
0.082(12.4) 
0.312(12.6) 
0.406(11.8) 
0.119 (1.87) 
1939.5 
6.0 
p<0.05  
 
CL: clearance, L/hr/kg; V1: central compartment of distribution, L/kg; Q: inter-compartmental 
clearance, L/hr/kg, V2: peripheral compartment of distribution, L/kg. TEMG: 0=normothermia, 
1=hypothermia; ω2: inter-individual variability; σ2: residual error 
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Figure 3-13: Goodness-of-fit plots for diclofenac final model (IPRED-OBS, TIME-WRES). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
108 
 
3.4.7.4 Predictive check  
Simulation curves with median curve and 95% CI distribution generated from 1000 times Monte 
Carlo simulation has been shown below in Figure 3-14.  The simulated data and the observed 
data are in great agreement with each other, suggesting the robust and accuracy of the final 
diclofenac model.  
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Figure 3-14: Predictive check from 1000 simulations using the final model estimated parameter 
for diclofenac. Solid line is the median of all simulated concentration. Dashed lines are 5th and 
95th percentiles of all simulated values. All dots are observed values from the study.  
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3.4.7.5 Discussion of final diclofenac model 
There was no significant difference found for diclofenac (CYP2C) clearance by non-
compartmental model analysis among four groups. However, in the population PK model, two 
hypothermia groups combined vs two normothermia groups combined, there was a weak 
association between hypothermia and reduced clearance of diclofenac. Previous studies have 
shown that hypothermia reduced metabolism of several CYP2C substrates including phenytoin, 
acenocoumarol and phenobarbital (see details in Chapter 1). Hypothermia increased phenytoin 
AUC and decreased its clearance in TBI patients (Iida et al., 2001). Clearance of S-
acenocoumarol was decreased by 34% at 32.5°C (Daemen et al., 1986). Moderate hypothermia 
(30-31°C) decreased the metabolism of phenobarbital in critically injured children (Kadar et al., 
1982).  
 
In addition, in this population analysis, omega block structure on CL, Q and V2 was used. This 
indicated a correlation between estimated clearance and estimated volume of distribution. 
Therefore, this analysis indicated possibilities effects of hypothermia on both diclofenac 
clearance and on volume of distribution. Therefore, the result from this rat study also referred a 
differential effect from mathematic calculation and the reduced CYP2C activity, although it may 
not be clinically significant for comparing temperature effect on CA patients. Based on different 
patient population and their physiological status, further studies are still needed to confirm the 
effects of hypothermia in critical ill patients. 
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3.4.8 Dextromethorphan model  
3.4.8.1 Base Model 
The two-compartment model structure was chosen. NONMEM subroutine ADVAN3 TRANS4 
was used which was the same as midazolam and diclofenac models. The population 
pharmacokinetic model consisted of a pharmacokinetic structural model and a statistical model 
in which between subject and within subject variability were described. Four inter-individual 
variability (ω2) were chosen for CL, V1, Q, V2. Residue error model used for dextromethorphan 
models was Y=F+F×ERR(1). Parameter estimates of dextromethorphan base model have been 
listed in Table 4-4.  
 
3.4.8.2 Covariate Model 
Final pharmacokinetic model for dextromethorphan included a TEMG covariate in central 
volume of distribution (V1), which can be described as V1=0.204+TEMG×(-0.0685). The 
central volume of distribution of dextromethorphan in hypothermia group was estimated to be 
66.4% of those in normothermia. Inter–individual variability of CL, V1, Q and V2 were 26.9%, 
17%, 3.85%, and 23.4%, respectively. Final model reduced OFV of 4.7 points (p<0.05) from the 
base model. 
 
3.4.8.3 Model evaluation  
The final covariate model was evaluated using diagnostic plots, successful minimization, 
precision for all parameters (se%) and a predictive check. Diagnostic plots for dextromethorphan 
has been shown in Figure 3-15.  
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Table 3-4: Population pharmacokinetic parameter estimates (with se%) from NONMEM for  
dextromethorphan.   
 
 
Parameters 
Estimate(se%.) 
Base model Final 
V1= θ2+TEMG×θ5 
CL(θ1) 
V1(θ2) 
Q(θ3) 
V2(θ4) 
Covariate θ5 
ω2 (CL) 
ω2 (V1) 
ω2 (Q) 
ω2 (V2) 
σ2 
Final OFV 
OFV change 
p value 
0.506(5.67) 
0.171 (2.02) 
1.01 (12.7) 
1.43 (15.2) 
― 
0.269(11.2) 
0.174 (6.09) 
0.0609 (5.1) 
0.237(9.0) 
0.0827 (1.49) 
1885.56 
 
0.504 (5.33) 
0.204 (2.63) 
1.01 (12.5) 
1.42 (15.5) 
-0.0685 (3.2) 
0.269 (11.3) 
0.170 (5.73) 
0.0385 (2.86) 
0.234 (8.99) 
0.0838 (1.47) 
1880.9 
4.7 
p<0.05 
 
CL: clearance, L/hr/kg; V1: central compartment of distribution, L/kg; Q: inter-compartmental 
clearance, L/hr/kg, V2: peripheral compartment of distribution, L/kg. TEMG: 0=normothermia, 
1=hypothermia; ω2: inter-individual variability; σ2: residual error 
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Figure 3-15: Goodness-of-fit plots for dextromethorphan final model (IPRED-OBS, TIME-
WRES). 
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3.4.8.4 Predictive check 
Simulation curves with median curve and 95% CI distribution generated from 1000 times Monte 
Carlo simulation has been shown below in Figure 3-16.  The simulated data and the observed 
data are in great agreement with each other, suggesting the robust and accuracy of the final 
model.  
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Figure 3-16: Predictive check from 1000 simulations using the final model estimated parameter 
for dextromethorphan. Solid line is the median of all simulated concentration. Dashed lines are 
5th and 95th percentiles of all simulated values. All dots are observed values from the study.   
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3.4.8.5 Discussion of final dextromethorphan model 
There was no significant difference found for clearance of dextromethorphan (CYP2D) among 
the four groups in the study. Hypothermia was correlated with the reduced central volume of 
distribution of dextromethorphan. Simulation results showed the concentration at serveral points 
at a later time has a large inter-individual varibity among all individuals.  
 
Compared with other CYP isoforms, CYP2D as well as CYP2C can interact with specific 
functional groups in the substrate (e.g., a basic nitrogen for CYP2D6 and an acid for CYP2C9) 
and help orient them and possibility maintain the metabolic rate and the clearance of the 
substrates better than other CYP isoforms (Redlich et al., 2008). Therefore, CYP2D maybe more 
stable in the setting of hypothermia and CA injury compared with other CYP isoforms.  
 
During hypothermia, the volume of distribution of many drugs is affected, among which 
pentobarbital and rocuronium are CYP2D substrates (Kalser et al., 1968; Beaufort et al., 1995; 
Schaible et al., 1982), which are consistent with this study. In addition, dextromethorphan has 
been suggested as a medium to high extraction high extraction drug, thus its metabolism is 
majorly related to the blood flow (Miles et al., 2009; Kukanich et al., 2004). Therefore, an 
alternative CYP2D substrate is needed for futher confirmation.  Potential mechanisms for altered 
volume of distribution during hypothermia include global blood perfusion changes, blood pH 
alterations, altered lipid solubility, and potential alterations in drug tissue binding.  Currently no 
studies have explored the exact mechanisms of these alterations. However, the reduction in 
volume of distribution has been consistent across studies and warrants future mechanistic 
evaluation.  
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3.4.9 Chlorzoxazone model  
3.4.9.1 Base model 
The two-compartment model structure was chosen. The population pharmacokinetic model 
consisted of a pharmacokinetic structural model and a statistical model in which between subject 
and within subject variability were described. Inter-individual variabilities (ω2) were included 
for CL, Q, and V2 parameters. Residual error model used was Y=F+F×ERR(1). Parameter 
estimates of chlorzoxazone base model have been listed in Table 3-5.  
 
3.4.9.2 Covariate model 
Final pharmacokinetic model for chlorzoxazone included a CAG covariate in systemic clearance 
(CL), and TEMG covariant in peripheral volume of distribution (V2). CA groups decreased the 
clearance of chlorzoxazone, which can be described as CL=0.433+CAG×(-0.204). Therefore,  
systemic clearance of chlorzoxazone in CA groups was estimated to be 52.9% of those in healthy 
groups. In addition, hypothermia decreased the V2 of chlorzoxazone, which can be described as 
V2=0.970+TEMG×(-0.478). Therefore, the peripheral compartment volume of chlorzoxazone in 
hypothermia group was estimated to be 50.7% of those in normothermia. Inter–individual 
variability of CL, Q and V2 were 12.6%, 21.8%, and 17%, respectively (Table 3-5). Final model 
reduced OFV of 23.6 points (p<0.01) from base model. 
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Table 3-5: Population pharmacokinetic parameter estimates (with se%) from NONMEM for 
chlorzoxazone.   
 
 
Parameters 
Estimate(se%.) 
Base model Final model 
CL= θ1+CAG*θ5;  
V2= θ4 +TEMG *θ6 
CL(θ1) 
V1(θ2) 
Q(θ3) 
V2(θ4) 
Covariate θ5 
Covariate θ6 
 ω2 (CL) 
ω2 (Q) 
ω2 (V2) 
σ2 
Final OFV 
OFV change 
p value 
0.311(3.13) 
0.141 (1.62) 
0.894(10.7) 
0.697 (8.37) 
― 
― 
0.224(6.05) 
0.212(9.39) 
0.282 (9.41) 
0.0664(0.894) 
2118.12 
0.433(5.64) 
0.142 (1.68) 
0.889(10.6) 
0.970 (15.1) 
-0.204 (6) 
-0.478 (15.8) 
0.126 (3.54) 
0.218 (9.44) 
0.170 (5.91) 
0.0662 (0.877) 
2094.5 
23.6 
p<0.01 
 
CL: clearance, L/hr/kg; V1: central compartment of distribution, L/kg; Q: inter-compartmental 
clearance, L/hr/kg, V2: peripheral compartment of distribution, L/kg. CAG: 0=healthy, 1=CA; 
TEMG: 0=normothermia, 1=hypothermia; ω2: inter-individual variability; σ2: residual error 
 
 
 
3.4.9.3 Model evaluation  
The final covariate model was evaluated using diagnostic plots, successful minimization, 
precision for all parameters (se%) and a predictive check. Diagnostic plots for chlorzoxazone has 
been shown in Figure 3-17.  
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Figure 3-17: Goodness-of-fit plots for chlorzoxazone final model (IPRED-OBS, TIME-WRES). 
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3.4.9.4 Predictive check 
Simulation curves with median curve and 95% CI distribution generated from 1000 times Monte 
Carlo simulation has been shown below Figure 3-18.  The simulated data and the observed data 
are in great agreement with each other, suggesting the robust and accuracy of the final model.  
0 2 4 6 8
0
50
0
10
00
15
00
20
00
25
00
30
00
TIME (hr)
ng
/m
l
 
 
Figure 3-18: Predictive check from 1000 simulations using the final estimated parameter of 
chlorzoxazone. Solid line is the median of all simulated concentration. Dashed lines are 5th and 
95th percentiles of all simulated values. All dots are observed values from the study.  
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3.4.9.5 Discussion of final chlorzoxazone model 
Our results suggest that CYP2E1 activity is affected by both hypothermia and CA injury. There 
was a hypothermia-CA interaction effect on the clearance of chlorzoxazone (see details in 
below). In addition, hypothermia reduced the peripheral volume of distribution.  Based on our 
limited numbers of subjects in each group, all population models include midazolam, diclofenac, 
dextromethorphan and chlorzoxazone should continue test for ETA shrinkage to make sure the 
estimates described the true distribution.  
 
A previous study by Harbrecht et al. showed that the metabolisms of chlorzoxazone and 
mephenytoin were correlated with the multiple organ dysfunction score and the multiple organ 
failure score, when they studied CYP2C9, CYP2C19 and CYP2E1 activity in critically ill trauma 
patients (Harbrecht et al., 2005). Compared with other CYPs, the CYP2E isoform exhibited a 
relatively constrained heme environment which could be affected easily by a change in 
physiological conditions. Our previous study showed that hypothermia reduced binding affinity 
(Km) rather than capacity (Vmax) for chlorzoxazone at 30°C in vitro, therefore reduced intrinsic 
clearance of chlorzxazone (Tortorici et al., 2006).  
 
3.4.10 Possible CA-hypothermia Interaction  
The individual clearances of midazolam, diclofenac, dextromethorphan and chlorzoxazone from 
their final models were generated by NONMEM. Temperature-clearance relationship graphs for 
each drug were shown in Figure 3-19. Temperature-clearance trend lines within sham control 
and CA groups were added. Possible temperature-CA interaction existed for dextromethorphan 
and chlorzoxazone when the two trend lines were not parallel with each other (not in the same 
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trend). The interaction indicated that when both CA and hypothermia exist, the metabolism for 
dextromethorphan and chlorzoxazone would be different than if either occurred alone.   
(A)                                                                      (B) 
     
(C)                                                                                   (D) 
            
 
Figure 3-19: Temperature-individual generated clearance from final pharmacokinetic model for 
midazolam, diclofenac, dextromethorphan and chlorzoxazone. Filled dots (▲) with solid trend 
line are healthy rats. Blank dots (○) with dashed trend line are CA rats.  
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3.4.11 Possible mechanisms for isoform specific effect  
Although the the potential mechanisms for hypothermia CYP isoform specific effect are 
currently unknown, some of our proposed potential mechanisms including:  1) Specific protein 
structure and substrate binding affinity: each CYP isoform has its specific quantitative structure 
activity relationships (QSAR). For example, CYP2E1 is believed to has a very small binding 
pocket compared with other isoforms, this protein structure can be easily disturbed when 
environment or physiological changes, therefore leads to the changes of substrate binding 
affinity and leads to the reduced elimination. CYP2D6 isoform can interact with specific 
functional groups in the substrate (e.g. a basic nitrogen for CYP2D6) and help orient them and 
possibility maintain the metabolic rate of the substrates. Our previous experiment in lab showed 
at lower temperature, Km increase for chlorzoxazone. Based on this information and our results, 
one potential explanation for isoforms specific changes is the affinity change between substrate 
and the active enzyme binding pocket. 2) Different reaction: different Phase I/CYP reaction may 
require different level of energy in the stage of product formation and product release from the 
P450 reaction, and they include: N-dealkylation, aliphatic and aromatic hydroxylation, N-
demethylation, O-demethylation, epoxidation, N-oxidation, S-oxidation, etc. Therefore, 
hypothermia effect could be pathway specific and substrate specific.  3) Reaction cofactors 
cytochrome b5 and electron transfer: cytochrome b5 is an electron-transport protein, and it is 
involved in the transfer of the second electron to P450. In vitro system has shown that human 
CYP3A and CYP2E1, and possibility CYP2C9 and CYP2C19 isoforms require cytochrome b5 
for the demonstration of maximal catalytic activities, (but not required for other isoforms) 
(Shimada et al, 1998). Therefore, a possible change in cytochrome b5 activity would affect the 
electron transfer in a specific CYP isoform reaction and this matches our observation in this 
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study. 4) Molecule energy: The rate of CYP mediated metabolism (or clearance) can be 
correlated with expressions involving either the orbital energies or its equivalent ionisation 
energy of the substrate molecule. This energy calculated from the substrate molecule itself. The 
higher the energy of the molecule, the more likely it is a CYP3A4 substrate (Ioannides et al., 
2004; Lewis 2003). This orbital energy of the molecule might change under a lower temperature, 
and therefore, the rate of metabolism will be reduced accordingly and represented in a CYP 
specific manner. 5) Enzyme-substrate complex and pH environment: Hypothermia leads to a 
lower pH environment clinically (also showed in my data in the CA hypothermia group, 
although this may be related to the cardiac arrest acidosis). pH change will re-adjust the original 
availability of the ionization and un-ionization drugs, and affects the solubility and permeability 
of the drug. In our study, we observed the clearance reduction in midazolam (CYP3A) and 
chlorzoxazone (CYP2E1) in the CA hypothermia group from the control, but not for diclofenac 
(CYP2C) and dextromethorphan (CYP2D). This theory seems to work for diclofenac (pKa 4.0, 
not affected by small pH change around 7.4) and chlorzoxazone (pKa 8.3, lower pH lowers the 
un-ionization portion). Therefore, if pH change is an explanation of CYP isoform specific effect, 
this maybe only a participate mechanism which works along with a combination of other 
mechanisms.  
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3.5 DISCUSSION 
 
Due to the complex relationship between disease state, temperature alteration, and regulation of 
CYP functional activity, development of specific dosage guidelines after hypothermic CA has 
been difficult. This study evaluated the effects of systemic hypothermia mediated alterations on 
the activity of multiple CYP isoforms in vivo after cardiac arrest. Our results have revealed that 
the magnitude of the CA and temperature effects are CYP isoform-specific with the greatest 
alterations in the metabolism observed for CYP3A and CYP2E1 isoforms. Hypothermia reduced 
volume of distribution of CYP3A, CYP2E and CYP2D probe drugs. This study suggested that 
the combination of hypothermia with CA was more likely to be associated with decreased 
enzyme activities. Compared with previous studies focused on single hypothermia effect, the 
current results have shown the hypothermia isoform specific effect as well as CA injury effect on 
CYP isoforms. We believe that CA and temperature-CA interaction findings may have clinical 
implications for patients with CA in whom therapeutic hypothermia is used.  
 
Currently, the population based pharmacokinetic modeling (nonlinear mixed effect modeling) 
has been used to better describe the complex relationship between multiple covariates (such as 
diseases, treatment, temperature, drug combination) and drug elimination rate from various 
clinical and animal studies. This approach provides for the preservation of data structure so that 
each individual condition contributes to the population description. In addition, fixed effect and 
random effect are calculated at the same time, therefore, the approach can better capture the 
mechanism structure while allowing the inter-individual and inter-occasion variability. A 
previous study by Caldwell et al. reported that hypothermia has a significant association with 
124 
 
inter-compartmental clearances of vecuronium using population pharmacokinetic modeling.  A 
11.3% clearance decrease per degrees Celsius was predicted for vecuronium (Caldwell et al., 
2000). The study by Michelsen et al. demonstrated that the clearance of remifentanil decreased 
by 6.37% for each degree Celsius below 37°C in patients who undergoing coronary artery bypass 
surgery using population pharmacokinetic modeling from NONMEM software (Michelsen et al., 
2001).  It is one of our goals to develop pharmacokinetic models for each probe drug that can be 
used to describe the relationship between the changes of temperature and CA injury and 
metabolism. Understanding biological process and disease progression is essential for further 
mathematic model estimation and prediction (Bies et al., 2008). 
 
In general, the clearance of hepatically metabolized drugs is either dependent on hepatic blood 
flow or are dependent on liver enzyme activity / plasma protein binding based on the classic 
Pang et al. paper describing the well-stirred model (Pang and Rowland, 1977). Since the goal of 
this study was to evaluate the CYP isoform specific metabolism via the use of probe drugs, all of 
the selected drugs have low hepatic extraction ratios, therefore, their clearance is highly 
dependent on enzyme intrinsic activity rather than hepatic blood flow. In addition, the most 
severe changes in hepatic blood flow would be expected to occur during the acute period of 
cardiac arrest. Since our drug compounds were not administered until 90 minutes after 
resuscitation, it is also highly unlikely that hepatic blood flow changes at this later time point 
would have a significant effect of the hepatic clearance of low hepatic extraction probe drugs.  
However, the effects of cardiac arrest and hypothermia on hepatic elimination of high and low 
extraction drugs is important given the significant number of high extraction ratio drugs, such as 
propofol and fentanyl, that are administered to this patient population. Future studies to elucidate 
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clearance changes and alterations in hepatic blood flow in these models represent an important 
area of study.   
 
One limitation of this study is the use of probe drugs as indices of given CYP phenotypic 
activities. Although the best possible probes were selected for this analysis, it is important to 
note the significant limitations of the use of these probes as phenotypic measures of CYP 
isoform specific activity.  In particular, diclofenac has been shown in both rats and humans to 
undergo significant glucuronication as a major route of elimination.  Indeed, several papers have 
demonstrated that acyl glucuronidation of diclofenac is the predominant route of elimination in 
non human primates and human liver microsomes (Kumar et al., 2002; Prueksaritanont et al., 
2006). In the rat, diclofenac elimination is more dependent on CYP2C, however, glucuronidation 
is a significant contributor to the overall elimination, therefore, our results with diclofenac are 
likely due to alterations in CYP2C metabolism and/or acyl glucuronidation. Similarly, other 
probes have demonstrated involvement of other CYP isoforms and are likely not solely due to 
changes in a single isoform (Kuo et al., 2003; Wang and Unadkat, 1999). Although these 
limitations of probe drug specificity exist, the selected drugs do represent different pathways of 
elimination and therefore, changes in clearance are likely reflective of differing changes in their 
individual elimination routes. The translational relevance of these alterations to humans will 
require further investigation with the important consideration that several of these probe drugs 
are even less selective in humans.  It is clear from this study that differential effects are seen with 
drugs that predominantly rely on differing routes of hepatic metabolism during cardiac arrest and 
hypothermia. 
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Collectively, using a rat model, our study reveals important and therefore unrecognized 
interactions between hypothermia and CA that may magnify the impact seen in CYP drug 
metabolism caused by either conductor alone. Give the prominent role that the use of mild 
hypothermia in the management of patients with CA, further translational studies on clinically 
relevant drugs and pharmacokinetics-pharmacodynamics models are vital to further explain and 
confirm the isoform specific effect in different disease and temperature states.  
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4.0 MILD HYPOTHERMIA ALTERED THE PHARMACOKINETICS OF 
MIDAZOLAM IN HEALTHY HYMAN VOLUTEERS  
 
Hostler D, Zhou J (First two authors contribute equally), Tortorici MA, Bies RR, Rittenberger 
JC, Empey PE, Kochanek PM, Callaway CW, and Poloyac SM.  Mild hypothermia alters the 
pharmacokinetics of midazolam in normal healthy subjects. Drug Metabolism and Disposition, 
2010: 38; 5: 781-8 
 
4.1 INTRODUCTION  
 
As discussed before, medications commonly used in critical ill patients (antiarrythmics, β-
blockers, calcium channel blockers, benzodiazepines, anesthetics, opioids, anticonvulsants, and 
proton pump inhibitors, etc) are largely metabolized through CYP450 system. One of the most 
important CYP isoforms is CYP3A4. Studies to identify the effects of mild hypothermia on 
CYP450 metabolism in humans are limited and the translational significance of the observations 
in the rat model remains to be identified. The primary objective of our study was to evaluate the 
effect of temperature reduction on CYP3A4 activity in healthy human subjects by determining 
the alterations in the metabolism of midazolam, a well-known CYP3A4 probe in human.  
 
In addition, hypothermia is currently achieved through methods that force core temperature 
below the internal homeostatic set point. Forced cooling induces compensatory responses such as 
shivering and vasoconstriction which are an obstacle to reaching target clinical hypothermic 
temperatures prior to hospital admission (Nagao et al., 2000; Hayashi et al., 2000; Kim et al., 
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2009; Polderman and Herold, 2009). Magnesium sulfate (MgSO4) has been shown to facilitate 
cooling and blunt the shivering response associated with cold saline infusion (Zweifler et al., 
2004; Wadhwa et al., 2005). The secondary objective of our study was to determine if 
benzodiazepine administration with magnesium would facilitate the induction of therapeutic 
hypothermia in conscious patients. In the current study, we chose a factorial design to examine 
the effects of administration of cold saline in conjunction with benzodiazepine sedation and 
magnesium sulfate induced vasodilation as a method to induce hypothermia in concise subjects.  
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4.2 EXPERIMENT METHODS 
 
4.2.1 Human subjects 
This study was approved by the University of Pittsburgh Institutional Review Board. Six healthy 
male subjects between the ages 19-39 years provided informed consent and completed all phases 
of the study. Each subject received a standard history, physical examination, laboratory studies 
(serum electrolytes, renal and liver function, thyroid stimulating hormone, hemoglobin, and 
hematocrit) and a twelve-lead ECG to screen for the presence of cardiac or any other underlying 
disease. Subjects were excluded if they had an abnormal laboratory value, any known medical 
problems, or if they were taking any medications with the exception of seasonal allergy 
medication, over the counter non-steroidal anti-inflammatory drugs, or acetaminophen. Other 
exclusion criteria included a history of cardiac disease in a family member under the age of 40, 
allergy to midazolam or other benzodiazepine/narcotic medication, current smoker or 
recreational drug user, and a body mass index > 35. Body fat percentage was measured by three 
site skinfold analysis prior to the first protocol visit (Pollack et al., 1980). The subjects were 
asked not to consume grapefruit juice and herbal dietary supplements including St. John’s wort 
from two days before each study day. Alcoholic drinks and caffeine-containing food and 
beverages were also not allowed 24 hours before or during the study.  
 
4.2.1.1 General characteristics  
Subjects were male aged 18 – 39 years. All races and ethnic groups were eligible for enrollment. 
Eight subjects were screened to ensure six subjects can enter the protocol. 
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4.2.1.2 Inclusion of children  
The target group for this intervention is adults with cardiovascular and cerebrovascular disease.  
These diseases may be qualitatively different in children.  Therefore, we did not enroll subjects 
less than 18 years old. 
 
4.2.1.3 Inclusion criteria 
Subjects must be male between the ages of 18 and 39 years have no known medical problems.  
 
4.2.1.4 Exclusion criteria 
— Abnormal laboratory values or ECGs 
— Those individuals who have any known history of current or previous medical problems, 
including but not limited to:  cardiac disease, history of arrhythmia or heart murmur, 
hypotension or hypertension, pulmonary disease including asthma, diabetes mellitus, 
thyroid disease, renal disease, liver disease, neurologic disease or seizures, connective 
tissue disorder or Raynaud’s disease, sickle cell disease, anemia, or hematologic 
disorders 
— HIV status will not be evaluated specifically for the purpose of this study; however, those 
individuals who are known to be HIV positive or are otherwise immunocompromised for 
any reason will be excluded 
— Subjects taking any medications (including herbal preparations) with the exception of 
allergy medication, ibuprofen or tylenol.  Subjects will be specifically questioned about 
MAO inhibitor, antidepressant, Cimetidine, and St John’s Wort use 
— Individuals with a history of cardiac disease in family members below the age of forty 
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— Individuals with a known allergy to benzodiazepines  
— Individuals with a history of long-term benzodiazepine use 
— Individuals who are currently ill with a viral or other infection 
— Individuals with renal insufficiency 
— Individuals who have abnormal vital signs as follows:  systolic blood pressure less than 
90mmHg or greater than 140mmHg, heart rate less than 40 or greater than 100, 
respiratory rate less than 10 or greater than 24   
— Individuals who currently smoke or use any other recreational drugs 
— Individuals who are morbidly obese (BMI > 36) 
— The CorTemp system is contraindicated in subjects with any history of gastrointestinal 
disorder, including inflammatory bowel disease, esophageal disease, hypomotility 
disorders, history of GI surgery, impaired gag reflex, or who weighs less than 80 pounds 
or is morbidly obese.  Any subjects who met any of these criteria would be excluded 
from the study 
 
4.2.1.5 Recruitment procedures  
An announcement has been made in Center for Emergency Medicine, Department of Emergency 
Medicine, and School of Pharmacy courses and grand rounds.  A recruitment flyer has been 
placed in common areas of the University.  
Volunteers have been given a phone number to call to arrange for an appointment with an 
investigator.  Informed consent and screening took place at that meeting.  Subjects were fully 
informed of the nature of the research, including the risks and benefits of the study and their 
rights as a research subject prior to obtaining their signatures on the informed consent document. 
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4.2.1.6 Screening 
A study physician performed a history and physical exam on each subject to assess for the 
presence of medical conditions.  The screening took place in the department of emergency 
medicine offices on a visit separate from the experimental protocol and normally took 
approximately 60 minutes.  Special focus was placed on a history of early cardiac death in family 
members or any other signs that an underlying cardiac anomaly may be present. Body 
composition was assessed by measuring skinfolds at three sites.  Blood samples were collected 
for sodium, potassium, TSH (thyroid-stimulating hormone), aspartate aminotransferase (AST or 
SGOT) and alanine aminotransferase (ALT or SGPT), alkaline phosphatase, bilirubin, BUN, 
creatinine, and a complete blood count to exclude undiagnosed liver, hematologic, and metabolic 
disease.  Finally, a standard 12-lead EKG was obtained and interpreted by a study physician to 
assess for any other apparent cardiac pathology.  Normal lab values used by the University of 
Pittsburgh Medical Center Presbyterian Hospital lab were accepted as the normal range.  In the 
event a lab value was outside the normal range, but not clinically significant in the study 
physician’s opinion, the subject was allowed to repeat the lab test once.  Two lab tests outside 
the normal range excluded the subject. Any subject excluded from the study was provided the 
information concerning their exclusion and they are referred to their primary care physician. 
 
4.2.1.7 Treatment groups and randomization  
After screening, subjects completed all arms of the study in a randomly generated order. Subjects 
were entered sequentially into the randomization scheme as they are enrolled. The four treatment 
groups were 1) 37ºC saline infusion (Warm), 2) 37ºC saline infusion with magnesium sulfate 
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infusion (Warm+Mg), 3)  saline infusion (Cold), and 4) 4ºC saline infusion with magnesium 
sulfate infusion (Cold+Mg). The four visits were separated by at least one week. 
 
4.2.2 Testing protocol 
We conducted a prospective, randomized, single center, four-way crossover laboratory study. 
Testing was performed in the Emergency Responder Human Performance Lab under the 
supervision of a study physician. Subjects were asked to refrain from caffeine and alcohol for 24 
hours prior to the protocol and from grapefruit juice for 48 hours.  Grapefruit juice is known to 
alter cytochrome P450 metabolism while caffeine and alcohol may alter hydration status. Upon 
arriving for a protocol, subjects voided their bladder and were weighed.  
 
4.2.2.1 Induction period 
During this 30-minute period, the subject received a weight based infusion of normal saline and, 
depending on randomization, a magnesium infusion. Subjects received 30mL/kg of cold (4°C) or 
(37°C) saline administered by peripheral IV.  The total saline dose was delivered over 30 
minutes. Subjects received midazolam 2 mg administered intravenously just prior to initiating 
the infusion. Additional 2 mg doses were administered 10 and 20 minutes into the infusion (total 
of 6 mg). When randomized to the appropriate arms, 4 g of magnesium sulfate were 
administered during the 30-minute induction.  Other studies of induced hypothermia have 
demonstrated that the vasodilatory effect of magnesium sulfate enhances cooling and increases 
subject comfort. Normothermia group control was given the warm saline infusion at same speed 
with or without magnesium. When provided, magnesium was administered with the cold or 
warm saline infusion. 
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4.2.2.2 Maintenance period 
 Following the 30-minute saline infusion, an infusion of lorazepam (1 mg/hr) was initiated to 
maintain mild sedation for three hours.  This infusion was titrated to maintain the subject’s 
sedation so that they respond to questions appropriately. Blood samples were drawn and 
physiological monitoring were continued during this period. 
 
4.2.2.3 Follow up period 
 Following the three-hour maintenance period, the lorazepam infusion was discontinued and the 
subject was monitored for a minimum of 60 minutes.  Physiological monitoring was continued 
during this period and one final blood sample was obtained. 
 
4.2.2.4 Monitoring 
Subjects received standard three-lead electrocardiogram, blood pressure monitoring, pulse 
oximetry, and end-tidal carbon dioxide monitoring throughout each study visit. Blood pressure 
and subject thermal sensation were measured at five-minute intervals throughout the infusion and 
every ten minutes thereafter. Our study involved a minimal sedation from given midazolam, a 
universal Ramsay sedation scale has been used to evaluate the sedation state. Pertaining to this 
study, ERHPL and has the following equipment available 1) ECG monitor with non-invasive 
blood pressure, 2) ETCO2 (end-tidal CO2), SPO2 monitor, 3) ACLS medications and reversal 
agents, 4) suction, oxygen, BLS and ALS airway equipment, 5) defibrillator, and 6) a full range 
of temperature monitoring equipment.  Both study physicians and a paramedic are present at all 
procedures.  In the event a patient needs to be transferred to Presbyterian Hospital, Pittsburgh 
EMS will be contacted. The study procedure has been shown in Figure 4-1. 
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Figure 4-1: The study procedure. Midazolam was given 3 times bolus at zero, ten, twenty 
minutes, cold saline infusion from the zero minutes at 30ml/kg until 30 minutes. Mild 
hypothermia was then maintained by lorazepam infusion and magnesium (when applied). 
Recovery started from 210 minute and subjects were discharged at 270 minutes. There are 10 
time points of blood draws (BD) indicated above.  
 
4.2.3 Temperature measurements 
Core body temperature was monitored using a pre-calibrated ingestible thermometer pill that 
continuously measures temperatures in the range of 0 to 50°C (HQ Technologies, Palmetto, 
Florida) (Figure 4-2). This pill continuously reads the body temperature while it slowly drifts 
from esophagus to colon, transmitting the readings to an accompanying handheld. Temperature 
values recorded by this device are intermediate to esophageal and rectal temperature (O'Brien et 
al., 1998). The capsule was administered to the subject 60 minutes prior to the beginning of the 
protocol with approximately 30 mL of water. The protocol was initiated after three consecutive 
measurements indicated a stable core temperature reading. Skin-surface thermistors were placed 
over 1) the clavicular head of pectoralis major, 2) supraspinatus, 3) triceps brachii, and 4) 
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quadriceps femoris muscles. Core and skin surface temperatures were documented every two 
minutes during the infusion and every ten minutes thereafter. Mean skin temperature (Tsk) was 
calculated by using the formula Tsk = chest (0.25) + back (0.25) + thigh (0.3) + arm (0.2) 
(Ayling, 1986). To mathematically describe the temperature reduction on these subjects, we 
estimated the area of temperature change as a reflection of cooling burden. Every cooling burden 
was calculated from individual time-temperature curves. (Trapezoid area from 0-210 minutes 
minus the area under temperature curve calculated from Prism).  
 
 
 
Figure 4-2: Ingestible thermometer pill (copied from HQ.Inc web) 
 
4.2.4 Drug administration and sampling 
Total 6mg midazolam was given intravenously by in 3 separate doses (2mg per dose). The three 
doses were given at zero, ten, and twenty minutes from starting saline infusion. Blood samples 
were collected at baseline and at 5, 15, 25, 30, 50, 80, 140, and 200 minutes. The 5, 15, 25, 30, 
50, 80, 140 and 200 minutes sample were referring to the time after the first midazolam IV 
administration. Specifically, the 5 minutes sample and 15 minutes samples were prior to the 2nd 
and 3rd midazolam doses, respectively. The blood samples were centrifuged at 2000×g for 10 
minutes. Total urine volume was measured at the end of rewarming and a urine aliquot was 
collected from the final volume for calculating formation clearance of the major metabolite 1’-
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hydroxymidazolam. All plasma and urine samples were frozen at −70°C until the time of 
analysis.  
 
4.2.5 Drug assay  
Plasma concentrations of midazolam and urine concentration of 1’-hydroxymidazolam were 
determined by using liquid chromatography-single quadrupole mass spectrometry (LC/MS, 
ThermoFinnigan single quad MS). A total of 150μL of plasma was added to 0.5M 
Na2CO3/NaHCO3 (pH=9.6) buffer solution. Samples were then spiked with 20μL of midazolam- 
duterated d4 (0.1μg/mL) (Cerilliant Corp, TX) as internal standard. After vortexing, 5mL 
methyl-terbutyl-ether was added to the sample, centrifuged at 3000×g, 4 °C for 10 minutes. The 
extracted supernatant was collected in a glass tube and evaporated to dryness under gentle 
nitrogen, followed by reconstitution in 200 μL of mobile phase which consisted of 0.1% formic  
acid in water and acetonitrile. A volume of 20μL of each sample was injected onto a Thermo 
RP18 5μm, 2.1 ×150mm HPLC column. The mass spectrometer was operated in the positive ion 
mode for detection of the protonated-molecular ions [M + l] + with a cone temperature of 350°C 
and a capillary voltage of 2200V. Positive ions at m/z for midazolam, 1’-hydroxymidazolam and 
midazolam-d4 were 325.9, 341.9 and 330.7, respectively. To measure 1’-hydroxymidazolam 
concentration in the urine, urine samples were incubated with 2000UI glucuronidase (Sigma, MI) 
with 0.2M acetate buffer (pH 4.9) at 37°C for 24 hrs. The extraction and LC/MS analytical 
procedure was similar to the midazolam method described above. Calibration curves (r2 ≥0.99) 
for midazolam (3-300ng/mL) and 1’-hydroxymidazolam (100-2000ng/mL) were linear. 
Midazolam and 1’-hydroxymidazolam analytical LC/MS methods have been validated with < 
9.5% and <8.3% inter-day precision, and < 7.2% and < 7.3% intra-day precision over all 
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concentrations, respectively. Recoveries of the midazolam and 1’-hydroxymidazolam from 
liquid-liquid extraction were > 89.2% and > 91.7% over all concentrations, respectively.  
 
4.2.6 Physiological data analyses 
 Repeated temperature measurements (core and skin temperatures), heart rate, respiratory rate 
and end-tidal CO2 were compared by generalized estimating equations using the factors of time, 
cold saline infusion, magnesium infusion, and the interaction of cold and magnesium. Estimated 
effect for each factor is presented as the coefficient estimate (B) with 95% confidence interval 
(95% CI). Analyses were performed with Prism release 4.0c.  
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4.3 PK ANALYSIS 
 
4.3.1 Non-compartmental pharmacokinetic analysis  
Non-compartmental analysis (WinNonlin professional Version 4.01, Pharsight, Mountain View, 
CA) was used to fit the time-concentration data and obtain the estimation for the area under the 
curve from time zero to infinity (AUC0-inf), area under the curve from time zero to the last 
sample time (AUC0-T), systemic clearance (CLs), estimated half-life (T1/2), elimination rate (Ke) 
and volume of distribution (Vz). Formation clearance (CLf) of 1’-hydroxymidazolam was 
calculated by dividing the amount in the urine (1’-hydroxymidazolam concentration in the urine 
times total urine volume) by the plasma midazolam AUC0-T. One way repeated ANOVA with 
Bonferroni post hoc analysis was used to compare formation clearance in the four treatments. 
Significance was denoted by a p value <0.05.  
 
4.3.2 Population pharmacokinetic modeling 
4.3.2.1 Model construction 
The population pharmacokinetic model describing midazolam disposition under the conditions 
outlined in this study was constructed using a nonlinear mixed-effects approach as implemented 
in the NONMEM V1.1 program (Icon, Hanover MD). The population pharmacokinetics model 
consists of a pharmacokinetics structural model and a statistical model in which between subject 
and within subject variability are described. One and two-compartment structural 
pharmacokinetics models were investigated as base model structures. The one-compartment 
model structure was evaluated using the ADVAN 1 TRANS 2 routine and the two-compartment 
model structure was implemented as the ADVAN3 TRANS4 subroutine. The first order 
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conditional estimation method (FOCE) with interaction was used to estimate all parameters. The 
inter-individual variability in the pharmacokinetic parameters was assumed to be log normally 
distributed. The residual variability was evaluated using three candidate model structures, 
additive, proportional and a combined additive and proportional model 
Yij=Fij×(1+Err(1))+Err(2)).  
 
The model building process was guided by analyzing the goodness of fit plots, precision of 
parameters estimates, and the objective function value (OFV) provided by NONMEM. After the 
base model was selected, we evaluated the effect of core temperature (TEM), heart rate (HR) and 
magnesium (MG) effect (Y/N) on the pharmacokinetic parameters (CL, V, or CL, V1, V2, Q). 
Covariate effects were evaluated using a forward stepwise addition and reverse deletion 
approach. The impact of the covariates were evaluated using the change in the −2 × log 
likelihood (-2LL), visual diagnostics, successful minimization, parsimony and physiologic 
reasonableness of the covariate effects. Improvements in the model were accepted as significant 
(p < 0.01, 1d.f.) when a decrease of > 6.64 points in the OFV per added model parameter was 
observed. Diagnostic plots included population predicted concentrations (PRED) vs observed 
concentration, individual predicted concentrations (IPRED) vs observed concentration, 
population predicted concentrations (PRED) vs weighted residuals (WRES) and time vs 
weighted residuals. Empirical Bayes estimates for individual patient PK parameters clearances 
were generated and compared with the results from the non-compartmental analysis.  
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4.3.2.2 Bootstrap evaluation 
 A nonparametric bootstrap approach using sampling with replacement was used to assess the 
robustness of the model estimates (Parke et al., 1999). Sampling with replacement involved 
creating a series of datasets of equal size to original data set that are generated by repeatedly 
sampling individuals from the original dataset, removing these individuals and replacing them at 
random. The model was refitted to each new data set and this process was repeated 1000 times. 
The stability of the final model was evaluated by examining the 95% confidence intervals (95% 
CI) of model parameter estimates. The Wings for NONMEM (G77 Fortran with WFN 408b) 
implementation for bootstrapping was utilized (Hayes et al.,1989).  Bootstrap is considered an 
important validation tool and model validation is defined as the process of substantiating that the 
model within its domain of application provides the required functionality, including input and 
output variable, and that the values it computes are sufficiently accurate for the intended use.   
 
4.3.2.3 Simulation 
One goal of a PK model is its predictive performance, especially if clinical decision-making will 
be based upon the model. Simulation has been promoted as a powerful method for predicting the 
outcome of various drug development scenarios and hence, for designing more cost effective 
development programs is very useful. The population parameter estimates obtained from the 
final model were used to simulate the population average concentration-time profiles at three 
fixed core temperatures, 36.5°C, 34°C and 32°C, over a duration of 400 minutes. Midazolam two 
mg was administered in the simulation as iv three doses (as used in this study). The simulations 
were implemented in WinNonlin 4.01 use the population estimated parameters from the 
NONMEM.  
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4.4 RESULTS 
 
4.4.1 Subjects and physiologic variables 
Eight subjects provided informed consent and were screened for this study. Two subjects were 
excluded during screening due to laboratory values that were outside the normal range. The 
demographics and morphometrics of six subjects were: age 28.5 ± 7.6 (yr), height: 175.7± 4.7 
(cm), mass: 78.8 ± 8.6 (kg), and body fat: 17.3 ± 3.2 (%). The procedure was well tolerated in all 
subjects. In our study, we observed relatively minimal sedation with ventilatory and 
cardiovascular functions unaffected by midazolam. No subject exceeded a value of ‘3’ (Patient 
awake, responds to commands only) on the Ramsey sedation scale. Patient responds quickly to a 
voice command and no deeper sedation found. There was an effect of magnesium [B = 8.18 
(1.66, 14.7), p = 0.014] and on heart rate. There was no effect of cold saline, magnesium, or time 
on respiratory rate and end-tidal CO2.  
 
Since this study is a cross-over design, the intra-individual varibilty, which is normally smaller 
than the inter-individally varibilty was used to estimate a preliminary sample size. Assuming the 
intra-individual variability is 15%, when |μ0-μ1|=25%, based on the power=80% and α=0.05, per 
group N=6 has been used in the study.  
 
4.4.2 Temperature 
 Rapid infusion of 37ºC saline resulted in a small 0.4 ± 0.2ºC decrease from baseline. Infusion of 
37ºC saline with magnesium resulted in a temperature reduction of 0.9 ± 0.3ºC. Infusion of cold 
saline reduced core temperature 1.4 ± 0.3ºC from baseline with a mean nadir temperature of 
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35.8°C ± 0.3°C. Addition of magnesium to the infusion reduced core temperature 1.8 ± 0.3ºC 
from baseline with the mean nadir at 35.4°C ± 0.4°C. In Cold and Cold+Mg groups, the duration 
(time below the 36.3°C which is the lowest value in the warm saline infusion groups) of the mild 
hypothermia is 47.0 ± 24.5min and 101.3 ± 26.6min, respectively. Statistically, there was an 
effect of cold saline [B = -0.48 (-0.87, -0.92) p = 0.015] and magnesium [B = -0.40 (-0.77, -0.02) 
p = 0.035] on core temperature. There was neither a time nor a cold saline/magnesium 
interaction on core temperature. Mean skin temperature changed over time [B = -0.007 (-0.01, 
0.0) p = 0.004] but did not differ by the temperature infusion or the addition of magnesium. 
Cooling burden was calculated and a significant difference was found between Warm and 
Cold+Mg groups (p=0.01). The core temperature curve and the cooling burden were shown in 
Figure 4-3 and Figure 4-4.  
 
4.4.3 Midazolam time-concentration profile and non-compartmental analysis 
Six individual time-plasma concentration profiles of midazolam of all four treatments were 
shown in Figure 4-5. The estimated Cmax, AUC0-inf, CLs, CLf , T1/2, Ke and Vz of the four 
treatments from noncompartmetnal analysis was shown in Table 4-1. A significant decrease in 
the 1’-hydroxymidazolam formation clearance was observed during Cold+Mg compared with 
Warm group (2.43 ± 0.782 mL/min/kg vs 3.41 ± 0.735 mL/min/kg, p=0.0168). Systemic 
clearance during Cold+Mg compared with Warm saline group demonstrated a trend towards a 
significant reduction during hypothermia vs normothermia (3.76 ± 0.386 mL/min/kg vs 4.49 ± 
0.560 mL/min/kg, p=0.0568). No significant difference in Cmax, T1/2, AUC0-inf, and Vz among the 
four treatments. Individual 1’-hydroxymidazolam formation clearance and midazolam systemic 
clearance of four treatments were plotted in Figure 4-6. 
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Figure 4-3: Core body temperature (Mean ±SD) over time in four treatment groups. The 
temperatures were recorded every 2 minutes during the first 30 minutes and every 10 minutes 
thereafter. 
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Figure 4-4: Cold burden area was calculated from every individual temperature time curve. 
There was significant difference found between warm-Cold+Mg groups (p<0.05) of cold burden 
area.  
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Figure 4-5: Individual time (minute)-concentration (ng/ml) midazolam profile of four treatments.  
In most subjects, the highest Cmax were found in the hypothermia groups (Cold or Cold+Mg 
group). The concentrations became stably higher after Tmax (around 25 or 30 minutes) in 
hypothermia groups.  
 
147 
 
4.4.4 Population based nonlinear-mixed effect pharmacokinetic modeling 
The data set comprised 258 plasma concentrations from 24 visits. A two-compartment base 
model structure was significantly better at describing the disposition of midazolam than the one       
compartment model (OFV difference 16.0 points, 2df, p<0.001). The final two-compartment 
model including covariate relationships is shown below: CLs (L/hr) =18.5×(TEM/36.5)4.24, V1 
(L)=9.11, Q (L/hr) =230×(TEM/36.5) (-17.9), V2 (L) =37.3+(HR/68) (-5.08) +MG×(-3.75). The final 
model had an objective function value (OFV) of 1152.0, 28.9U lower than the best base model 
OFV of 1180.9. Graphical model performance is depicted in Figure 4-7. Both systemic clearance 
and intercompartment clearance of midazolam were affected by core temperature. Temperature 
was not a significant covariate when tested in relation to the V1 and V2 parameters. Heart rate 
and magnesium significantly affected V2. The presence of magnesium reduced the volume of 
distribution by 3.75L (close to 10% volume of V2). The V2 changed 73.13% and 75.06% from 
the maximum to the minimum observed heart rate with or without magnesium, respectively. The 
pharmacokinetic parameters estimated from the NONMEM analysis were consistent with the 
non-compartmental analysis. Based on this model, the lowest core temperature 34.8°C in this 
study would result in a CLs of 16.0 L/hr which was 29.6% lower than the clearance from the 
highest core temperature 37.8°C 22.7L/hr. As temperature decreases, midazolam elimination 
from the central compartment declines. The model describes an estimated 11.1% reduction in 
midazolam clearance for every one degree reduction in core temperature from 36.5°C. The 
individual level model predicted relationships (based on the empirical Bayes estimates) between 
specific temperature and midazolam clearance are shown in Figure 4-8.  
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4.4.5 Bootstrapping and simulation 
 The final model has been assessed further by nonparametric bootstrapping method, the results of 
bootstrap estimates were consistent with NONMEM estimates which means the final model was 
relatively stable and robust. NONMEM estimates and the 95% CI from bootstrapping are shown 
in Table 4-2. A concentration-time profile of midazolam simulated from the population level 
NONMEM parameters is shown in Figure 4-9. The simulation curve for a core temperature 32 
°C has the highest AUC and Cmax followed by 34 °C and 36.5 °C. The simulations reflect the 
model predicted reductions in midazolam clearance at 32°C (a 42.8% reduction compared to 
36.5°C) and 34°C (a 26.0% reduction compared to 36.5°C).  
 
 
Table 4-1: Pharmacokinetic variables of four treatments from non-compartmental analysis  
 Warm Warm/Mg Cold Cold/Mg P value 
Cmax (ng/mL) 123 (23.1) 120 (6.88) 116 (23.0) 132 (16.2) 0.360 
T1/2 (min) 107 (20.8) 107 ( 20.2) 119 (29.4) 96.3 (9.50) 0.212 
AUC0-T (µg×min/mL)  13.8 (1.64) 15.1 (1.16) 16.0 (2.90) 17.1 (2.27) 0.0364* 
AUC0-inf (µg×min/mL) 17.1 (1.63) 18.7 (0.788) 20.8 (4.33) 20.6 (2.33) 0.0649 
Vz (L)  54.5 (11.7) 49.8 (9.59) 50.3 (10.6) 41.4 (7.11) 0.0908 
Cls (mL/min/kg) 4.49 (0.560) 4.12 (0.492) 3.83 (0.881) 3.76 (0.386) 0.0568 
Clf (mL/min/kg) 3.41 (0.735) 2.65 (0.923) 2.56 (0.917) 2.43 (0.782) 0.0168* 
One way repeated ANOVA with Bonferroni post-hoc has been used to detect the difference among the 
four treatment groups.   Data presented as mean (SD). *p < 0.05 
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Figure 4-6: The systemic clearance of midazolam and 1-hydroxymidazolam formation clearance 
from four groups. 
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Figure 4-7:  Final model diagnosis.  Goodness-of-fit plots for the population pharmacokinetic 
model from NONMEM analysis. Individual predicted concentrations vs observed concentrations, 
and the population predicted concentrations vs observed concentrations. The straight lines are the 
lines of unity (A-B). Population predicted concentrations vs weighted residue and Time vs 
weighted residue (C-D).  
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Figure 4-8: The relationship between core body temperature and individual systematic clearance 
(L/hr) from NONMEM estimation. With temperature decreases, the midazolam systematic 
clearance decreases.   
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Figure 4-9: Time-concentration simulation curves of midazolam (three dose iv bolus) at 36.5°C 
(square symbols), 34°C (circle symbols) and 32°C (triangle symbols) using NONMEM 
estimated parameters.  The 32°C profile has the highest AUC and Cmax followed by 34°C and 
36.5°C curves. The predicted midazolam clearance at 34°C decreased to 74.0% compared to the 
clearance of core temperature baseline 36.5°C, the predicated midazolam clearance of 32°C 
decreased to 57.2% compared to the clearance in 36.5°C.  
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Table 4-2: NONMEM and bootstrap estimates with bootstrap estimated 95% confidence interval 
 NONMEM 
Estimates 
Bootstrap 
Estimates (95% CI) 
THETA(1) 
THETA(2) 
THETA(3) 
THETA(4) 
THETA(5) 
THETA(6) 
THETA(7) 
THETA(8) 
ETA(1) 
ETA(2) 
ETA(3) 
ERR(1) 
ERR(2) 
18.5 
9.11 
230 
37.3 
4.24 
-17.9 
-5.08 
-3.75 
0.0762 
0.0543 
0.135 
0.166 
0.0992 
18.4  ( 17.2~19.6) 
9.65 ( 0.610~18.7) 
226  (19.3~433) 
36.8  ( 28.4~45.2) 
4.10  ( -4.06~12.3) 
-21.3 (-52.2~9.57) 
-4.68  ( -8.90~ -0.410) 
-4.12 ( -7.01~ -1.20) 
0.0618 ( -0.167~0.290) 
0.487 (-1.66~2.64) 
0.100 (-0.199, 0.399) 
0.169 (0.0605, 0.278) 
1.638 (-9.44, 12.7) 
 
CL=θ1×(TEM/36.5) θ5, V1=θ2, TVV1=V1×EXP(ETA(1)), Q=θ3×(TEM/36.5) θ6, TVQ=Q×EXP(ETA(2)), 
V2=θ4+(HR/68) θ7+MG×θ8, TVV2=V2×EXP(ETA(3)),  Y=F+F×ERR(1)+ERR(2). 
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4.5 DISCUSSION  
 
This study demonstrated that midazolam metabolism is reduced by mild hypothermia in normal 
healthy volunteers. The results provided the basis for predicting alterations in midazolam 
clearance and possible drug therapy interaction involved of other CYP3A substrates under mild 
hypothermic conditions. There are two major observations from this study. First, the cold saline 
30mL/kg infusion with midazolam and magnesium reduced the core temperature in normal 
healthy volunteers in the absence of anesthesia, however, the shivering was minimally 
suppressed in healthy subjects. Second, the clearance of midazolam was significantly affected by 
body temperature change in human from both non-compartmental pharmacokinetic analysis and 
population pharmacokinetic modeling. This model predicted that midazolam clearance would 
decrease 11.1% for each degree lower in core temperature from 36.5°C.  
 
The body temperature changes observed in this study from both normothermia and hypothermia 
groups were consistent with previous studies. In our normothermia group, warm saline infusion 
with midazolam resulted in a small 0.4 ± 0.2ºC decrease from baseline. Addition of magnesium 
resulted in a temperature reduction of 0.9 ± 0.3ºC. Kurz et al. used midazolam and surface 
cooling to induce hypothermia and showed that midazolam impairs thermoregulatory control by 
decreasing sweating threshold 0.3 ºC, and decreasing shivering threshold around 0.6ºC (Kurz et 
al., 2005). Our previous study used just rapid warm saline infusion resulted in 0.5 ºC temperature 
reduction (Moore et al., 2008). In our hypothermia group, the lowest core temperature 35.4°C ± 
0.4°C was observed in the cold saline infusion with magnesium group, co-infusion of 4g of 
magnesium during a cold saline infusion resulted in an additional 0.5ºC of cooling compared 
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with cold saline infusion itself. We have previously reported that rapid infusion of cold saline 
can effectively reduce body temperature in normal healthy volunteers compared with surface 
cooling (Moore et al., 2008; Hostler et al., 2009). Magnesium sulfate facilitates cooling through 
its known vasodilatory effects to promote peripheral heat exchange and blunt the shiver response 
upon cold saline infusion. Magnesium sulfate in total given dose of 8.75 to 16.75 g has been 
shown to increase the rate of hypothermia and improve the comfort of healthy subject during 
hypothermia induction (Zweifler et al., 2004). Previous studies have shown magnesium sulfate 
significantly reduce the shivering threshold (36.3 ±0.4 vs 36.6 ±0.3° C, p=0.04) in healthy 
volunteers which was consistent with the observation of this study (Wadhwa et al., 2005). In 
addition, magnesium may provide protection against ischemia in reducing CA1 neuronal death 
combined with modest hypothermia (35°C) in animal model (Zhu et al., 2005). Therefore, 
magnesium use in hypothermia deserves further study. Although the gain of temperature changes 
was small in this study, the infusion was well tolerated in this population and may prove of some 
benefit in achieving a target temperature in conscious patients. These results suggested that it is 
possible to reduce body temperature in conscious subjects. However, cold saline infusion with 
midazolam and magnesium combination used in this study can only create a mild and short 
duration of hypothermia and did not sufficiently maintain hypothermia to a clinical desired level.  
 
In this study, we evaluated the model compound midazolam as an index of CYP3A4 metabolism. 
Midazolam is a well-known CYP3A probe mostly because it exclusively metabolized by human 
CYP3A4 isoforms, and midazolam is not a P-glycoprotein transporter substrate. The primary 
midazolam metabolite produced through CYP3A in human is 1’-hydroxymidazolam (~70%). 
Minor metabolites formed by CYP3A4 are 4’-hydroxymidazolam and 1’,4’-
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dihydroxymidazolam (Galetin et al., 2005). Our results demonstrated that even in mild and short 
duration of hypothermia, the 1’-hydroxymidazolam formation clearance in the Cold+Mg group 
was significant lower compared to normothermia. These results were consistent with previous 
preclinical and clinical studies. CYP3A activity during cooling was previously determined by 
ethylmorphine-N- demethylation in vitro in piglet liver microsomes. This study demonstrated a 
temperature dependence with CYP3A activity (p<0.01). Furthermore, this study indicated that 
the plasma concentration of fentanyl, another CYP3A substrate (liver blood flow dependent), 
significantly increased during hypothermia (31.6 ± 0.2 °C) for 6 hours and after rewarming 
(p<0.001 and p<0.05 respectively) (Fritz et al., 2005). The study by Fukuoka et al. reported 
significant changes of midazolam clearance during moderate (32-34°C) hypothermia in eight 
brain injured patients who were given a continuous infusion of midazolam (Fukuoka et al., 
2004). Collectively, previous preclinical or clinical studies have indicated the possible changes 
of CYP3A activity in cooling, however, the relationship of body temperature and CYP3A 
activity in human was still not fully elucidated.  
 
Our data analysis comprehensively estimated the pharmacokinetic parameters of midazolam 
during mild hypothermia in human and predicted the relationship between core temperature and 
CYP3A activity by using both non-compartmental pharmacokinetic analysis and population 
based nonlinear mixed effect pharmacokinetic modeling. The non-compartmental 
pharmacokinetic analysis assumed that the clearance was constant over time within group which 
may not be a sufficient and sensitive estimate for the changes of systemic clearance with 
changing temperature. Our study was designed to record core temperature and midazolam 
concentration continuously over time, therefore, allowing the time varying covariate of 
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temperature to be modeled using a nonlinear mixed-effects population pharmacokinetic 
approach. The approach provides for the preservation of data structure so that each individual 
condition contributes to the population description. The model estimate of clearance of 
midazolam was 18.5 L/hr at 36.5 °C which was consistent with previous studies (de Wildt et al., 
2003; Shimizu et al., 2007; Bolon et al., 2003). The relationship between core body temperature 
and the midazolam systemic clearance was described using the following function: CL 
(L/hr)=18.5×(TEM/36.5)4.24, which provided the basis for predicting the temperature relationship 
with clearance of midazolam. This population model predicts that a 1°C reduction in core 
temperature from 36.5°C produces an 11.1% reduction in midazolam clearance. This 11.1% 
percentage reduction per degree change in core temperature is consistent with the results of Leon 
et al. who reported that for each 1°C decrease in temperature, a 10% reduction in tissue 
metabolic requirements and free radical production (Leon 2004). In addition, the study by 
Caldwell et al. reported that 11.3% clearance of vecuronium decreased with per degree (Celsius) 
temperature change in healthy human volunteers (Caldwell et al., 2000). A study by Michelsen et 
al. also demonstrated that the clearance of remifentanil decreased by 6.37% for each degree 
(Celsius) below 37°C in patients who undergoing coronary artery bypass surgery (Michelsen et 
al., 2001). Our pharmacokinetic model predicted a midazolam disposition changed under mild 
hypothermia condition was consistent with previous studies.  
 
The model suggested a predictive decrease in drug metabolism per degree change in body 
temperature from simulations at temperature 34°C and 32°C, and the predictive utility of these 
estimates in a prospective validation cohort remains to be determined. However, this study has 
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been done in healthy volunteers and there are maybe difficulties to conduct these lower 
temperature experiments. 
 
Due to the shivering response and discomfort of healthy human subjects, the cooling period of 
this study was designed for duration of 200 minutes followed by rewarming. Due to the 
likelihood of alterations in clearance upon rewarming, blood samples were only drawn during the 
period of time when subjects were actively on the cooling protocol, which was from time zero to 
200 minutes. This duration may not be long enough to capture a better midazolam disposition 
curve, however it was not possible to collect samples at a later time point while accurately 
estimating the cooling effect on the metabolism of midazolam in the hypothermia healthy human  
study. In addition, the estimated half-life of midazolam in healthy normothermia control group of 
this study was consistent with literature as previously mentioned.  
 
In addition, compared to previous animal disease model study results in Chapter 3, in which 
midazolam clearance has been found to be decreased between hypothermic CA and control 
group. This effect was believed to be majorly mediated by the CA disease state which is not 
presented in the current experiment. Hypothermia was associated with reduced the volume of 
distribution. Future studies to determine specific dosing guidelines for commonly used 
medications in critically ill patients during cooling are needed to prevent the unrecognized 
therapy-drug interactions in this highly susceptible patient population. The magnitude of 
pathway specific alterations in drug elimination continue needed to be elucidated in order to 
begin to develop for specific dosing recommendations. Until such guidelines are developed, 
vigilance with drug response monitoring is a clinical necessity.  
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To further understand the underlying mechanisms of the facts that the metabolism rate decrease 
with lower body temperature might need to refer to Arrhenius equation: K=Ae -Ea/KT, where 
metabolism rate decrease with lower body temperature and it has been explained from the  
collision theory, transition state theory, and Q10 (temperature coefficient): Q10=R2/R1 10/(T2-T1) 
theory. 
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5.0 ASSESSMENT OF FOUR MAJOR DRUG METABOLISM ENZYMES AND 
RENAL EXCRETION IN HEALTHY HUMAN SUBJECTS VIA THE 
ADMINISTRATION OF A FIVE-DRUG MICRODOSED COCKTAIL  
 
Zhou J (IRB author and study coordinator), Callaway CW, Hostler D, Rittenberger J and 
Poloyac SM, IRB approved, the study is on going 
 
5.1 INTRODUCTION 
 
A central premise that underlies the importance of this thesis research is the overall incidence 
and importance of adverse drug reactions in critically ill patients. Lazarou and colleagues 
reported a serious adverse drug reaction incidence rate of 6.7% in US hospitalized patients with 
0.32% being fatal (Lazarou et al., 1998). This projected to two million patients and greater than 
100,000 deaths annually; making these events between the fourth and sixth leading cause of 
death.  Adverse drug events cause or contribute to 6-7% of hospital admissions and increase 
length of stay by approximately 2 days (Bates et al., 1997; Classen et al., 1997; Ingelman-
Sundberg et al., 2008). Adverse drug events in critically ill patients are particularly problematic 
because they are more common and often life-threatening (Cullen et al., 1997). The Adverse 
Drug Event Prevention Study Group found an approximately 2-fold increased risk in intensive 
care unit (ICU) patients versus non-ICU comparators. In particular, adverse drug reactions with 
nitrates, opiates, and benzodiazepines are common in ICU patients and are related to increased 
length of stay (Vargas et al., 1998). Furthermore, prolonged sedation can complicate ventilator 
weaning, which also increases length of stay and the rate of complications in these patients. 
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Some adverse drug events, such as propofol infusion syndrome, have fatal consequences in 
critically ill patients and the potential pharmacokinetic origin of this syndrome remains largely 
unexplored (Iyer et al., 2009). Studies have stratified adverse drug events based on drug class 
and determined that significant differences in adverse drug events between ICU and non-ICU 
patients were observed for cardiovascular, antiarrhythmic, muscle relaxant, and anticoagulant 
medications. Realizing that combined with the new hypothermia intervention, the understanding 
for the already complicated pharmacotherapy, disease effects and therapeutic hypothermia on 
drug metabolism and elimination become an urgent research question.   
 
Although clinical outcome data demonstrates an increased incidence of adverse events, the 
alterations in drug disposition are understudied due to an inability to assess metabolic changes in 
the critically ill patient population.  The reason for this lack of information is primarily due to an 
inability to safely assess alterations in drug metabolism in critically ill patients. One potential 
method presented in this study for phenotypically assessing drug metabolism in critically ill 
patients is to use very low doses (microdoses) of probe drugs to evaluate drug metabolism. This 
microdosing strategy typically uses over 10-fold lower than normal pharmacologic doses, 
thereby, improving the safety profile in critically ill patients and minimizes drug-drug 
interaction.  It is the long term goal of our research to evaluate the utility of microdosing of 
probe drugs in cardiac arrest patients as a method to determine optimal dosing strategies in these 
patients, and/or during hypothermia treatment. 
 
In order to further assess the effect of hypothermia on CA patients, the goal of this study is to 
provide a feasibility experiment to determine if microdoses of probe drugs can be used to 
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phenotypically assess individual drug metabolizing enzymes as well as renal function in healthy 
human volunteers. This feasibility experiment will provide essential pharmacokinetic parameter 
estimates to demonstrate the utility of this approach for subsequent use in patient populations.   
 
Four major enzyme isoforms (CYP1A2, CYP3A4, CYP2C19, and CYP2D6) and renal function 
will be evaluated. The microdosed probe drugs used in these studies are theophylline (CYP1A2), 
midazolam (CYP3A4), esomeprazole (CYP2C19), metoprolol (CYP2D6) and famotidine (renal 
secretion). These drugs were selected based on their use as phenotypic probes availability of an 
IV formulation for subsequent use in human studies, and based on their biopharmaceutical 
characteristics (Bates et al., 1997; Frye 2004; Derkenne et al., 2005; Obase et al., 2003; Turpault 
et al., 2009). The use of an IV formulation is important because CA patients rarely receive oral 
administration of drugs, therefore, alterations in absorption are an unnecessary confounder to 
assessment of drug exposure in this population. In addition, esomeprazole, midazolam, and 
metoprolol were recently validated as a high dose probe cocktail in normal healthy volunteers by 
Turpault et al (Turpault et al., 2009) and showed no drug-drug interations. 
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5.2 MULTIPLE PROBE DRUG BIOANALYTICAL ASSAY BY UPLC/MS/MS-FIVE DRUG 
COCKTAIL  
 
The purpose of this UPLC/MS/MS assay establishment is to provide the analytical tool to ensure 
the microdosed cocktail probe drug administration feasible due to the sensitivity provided by the 
UPLC/MS/MS. In addition, the purpose of this assay is also to provide the reproducible 
quantitative assessment of plasma concentrations of five probe substrates for four different CYP 
isoforms and renal elimination simultaneously. This simultaneous assessment will allow for the 
evaluation of these isoform activities from a single study. All probe drugs that are administered 
as a microdose require a high degree of analytical sensitivity and specificity. Since no previous 
method has been established in the literature, we set out to establish this assay as an essential 
step needed for future PK analysis.  
 
5.2.1 Probe drugs selection 
As we have discussed in the previous section (see detail in Chapter 2), basic requirements of a 
probe drug include specificity, no drug-drug interaction, and reasonable half-life. In this cocktail 
combination, all probe drugs are FDA approved drugs. In addition, all of the drugs in this 
cocktail are available as an IV formulation. The five probe drugs (theophylline, midazolam, 
esomeprazole, metoprolol, and famotidine) have been chosen and their metabolism profiles were 
used to represent the enzyme activities of CYP1A2, CYP3A4, CYP3C19, CYP2D6 and renal 
secretion in humans. Their specific metabolites (1-hydroxymidazolam, 5-hydroxyomperazole, 1, 
3-dimethyluric acid, and 1-hydroxymetoprolol) have also been included in the cocktail method 
development. 
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5.2.2 Instrumentation and conditions 
As dusicussed in previous chapters, UPLC/MS/MS assays have been developed. The highest 
intensity daughter ion fraction with its corresponding collision energy has been used for the 
selective MS transition for each probe drug.  The MS/MS conditions for all analytes have been 
listed in Table 5-1. Instrument condition establishment is also similar to the previous chapter.  
 
5.2.3 Analytical assay development  
5.2.3.1 Calibration standard  
All standard compounds have been ordered from Toronto Chemical Company (Toronto, Canada) 
and Cerilliant (Round Rock, TX). Blank human plasma (pooled, heparized) was purchased from 
Central Blood Bank of Pittsburgh (Pittsburgh, PA). Oasis 1cc HLB (hydrophilic-lipophilic 
balance) and 1cc MAX (mixed mode anion exchanges) solid phase extraction cartridges were 
purchased from Waters (Milford, MA, USA). All stock solution of probes, metabolites and 
internal standards are 1.0mg/mL in methanol and stored at -20°C. All glassware used for 
preparation of calibrations and samples were silanized tubes. Two different reconstitute 
solutions/further dilution were: A) 80:20 acetonitrile: water for midazolam, metoprolol, 
esomeprazole and 1-hydroxymidazolam, 5-hydroxyomeprazole; B) 10:90 acetonitrile: water for 
1-hydroxymetoprolol, famotidine, theophylline and 1,3-dimethyluric acid.  
 
5.2.3.2 Sample preparation and extraction 
Solid phase extraction (SPE) with HLB and MAX cartridges has been used. HLB column has 
been used in the previous section for four drug cocktail assay development. MAX column utilize 
a mixed-mode strong anion exchange and reversed-phase mechanisms to separate both polar and 
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non-polar, neutral and anionic compounds simultaneously from aqueous media. Typical 
applications include acidic drugs and their metabolites. In this set of assay development, MAX 
column has been used to extract theophylline (weak acid) and its metabolite 1,3-dimethyluric 
acid from plasma and urine samples. The specific procedures for using HLB and MAX 
extraction have been described in Figure 5-1. SPE choice and reconstitute solution choices refer 
to Table 5-2.  
 
 
 
  
Figure 5-1: Solid phase extraction procedure for using HLB and MAX cartridges 
 
Table 5-1: SRM transition method for MS/MS (precursor to product) for four parent drugs, four 
major metabolites and their respective internal standards (IS) 
CYP450 Compound SRM 
transition 
Collision 
energy (ev) 
Polarity RT 
(min) 
LOD/LOQ 
 (ng/mL) 
CYP3A4 
 
 
 
CYP2C19 
 
 
 
CYP2D6 
 
 
 
CYP1A2 
 
 
 
Renal  
 
 
Midazolam 
1-Hydroxymidazolam 
Midazolam-d4 (IS) 
 
Esomperazole 
5-Hydroxyomperazole 
Omperazole-d3 (IS) 
 
Metoprolol 
1-Hydoxymetoprolol 
Metoprolol-d7 (IS) 
 
Theophylline 
1,3-dimethyluric acid 
Theophylline-d6 (IS) 
 
Famotidine 
Ranidine (IS) 
325.7>291 
342>324 
330>295 
 
346>179.9 
362>151.9 
349>135.9 
 
268>191 
284>91 
275.1>191 
 
181>124 
196.9>169 
187>127 
 
338.1>188.9 
315>175.9 
 
27 
25 
27 
 
34 
31 
34 
 
18 
41 
17 
 
23 
17 
23 
 
20 
21 
 
+ve 
+ve 
+ve 
 
+ve 
+ve 
+ve 
 
+ve 
+ve 
+ve 
 
+ve 
+ve 
+ve 
 
+ve 
+ve 
 
3.57 
3.55 
3.57 
 
3.43 
3.57 
3.43 
 
3.32 
1.46 
3.32 
 
1.18 
0.9 
1.18 
 
0.87 
0.99 
0.05/0.1 
0.05/0.1 
 
 
0.2/0.5 
0.1/0.2 
 
 
0.2/0.5 
0.1/0.2 
 
 
0.5/2.0 
0.5/2.0 
 
 
0.2/0.5 
 
HLB                                                                              
Equilibrate column with 1mL MeOH, 1mL H20   
Load sample (diluted in water)  
Wash with 1mL pure H20                                           
Wash with 1mL 5% Formic acid in H20   
Change to clean tube 
Elute with 2mL pure MeOH  
 MAX 
Equilibrate column with 1mL MeOH, 1mL H20 
Pretreatment sample with 5% NH4OH 
Load sample on column 
Wash with 1mL 5% NH4OH in H2O                            
Change to clean tube 
Elute with 2mL 2% FA in MeOH 
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Table 5-2: The extraction and reconstitute solution for different compounds 
    Reconstitute solution 
Extraction 
method  St curve range 
CocktailA  Metoprolol  80:20 Acetonitrile:H20  SPE/HLB  0.2‐500ng/mL 
  5‐hydroxyomeprazole  80:20 Acetonitrile:H20  SPE/HLB  0.2‐500ng/mL 
  esomeprazole  80:20 Acetonitrile:H20  SPE/HLB  0.2‐500ng/mL 
  1‐hydroxymidazolam  80:20 Acetonitrile:H20  SPE/HLB  0.2‐500ng/mL 
  Midazolam  80:20 Acetonitrile:H20  SPE/HLB  0.2‐500ng/mL 
CocktailB‐1  1‐hydroxymetoprolol  10:90 Acetonitrile:H20  SPE/HLB  1.0‐500ng/mL 
  Famotidine  10:90 Acetonitrile:H20  SPE/HLB  1.0‐500ng/mL 
Cocktail B‐2  Theophylline  10:90 Acetonitrile:H20  SPE/MAX  2.0‐500ng/mL 
  1,3‐dimethyluric acid  10:90 Acetonitrile:H20  SPE/MAX  2.0‐500ng/mL 
 
 
5.2.4 Method validation  
Analytical method validation has been described in aspects of linearity, sensitivity, precision and 
accuracy, matrix effect and recovery efficiency. A typical chromatography window from 
UPLC/MS/MS from one of the validation days has been shown in Figure 5-2. 
 
5.2.4.1 Linearity and sensitivity  
Every calibration curves consisted of ten concentrations. Calibration curves were constructed 
using the analytes/IS peak area ratio vs the analyte concentration. Calibration curves were 
prepared in three individual days with the precision and accuracy testing. Cocktail A analytes 
(midazolam, metoprolol, esomeprazole and 1-hydroxymidazolam, 5-hydroxyomeprazole) 
standard curves were ranged from 0.2-500ng/mL. Standard curve range for 1-
hydroxymetorprolol and famotidine were 1.0-500ng/mL, and the standard curve range for 
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theophylline and it metabolites were 2.0-500ng/mL. QC samples are prepared in the low, 
medium and high range of the curve. 
 
The sensitivity was described from limit of detection (LOD) and limit of quantitation (LOQ). 
The LOD was determined based on the peak area of lower than 5-digit ( when area <10,000). 
The LOQ was determined based on the peak area at this level can be determined with variability 
less than ± 20% (accuracy of 80-120%) when repeated five times in extracted samples. The LOQ 
for eight analytes were between 0.1-2.0ng/mL (0.75-15pg/column). UPLC/MS/MS method 
significantly decreased the background noise, therefore improved the sensitivity and provided 
wider range of linearity. Our study and other studies have shown that 500-2500 fold of analysis 
linearity range are accessible. 
 
5.2.4.2 Precision and accuracy   
Precision and accuracy of the method were determined by preparing and analyzing QC samples. 
QC levels at low, medium and high in five replicates were analyzed on the same day to 
determine the intra-day precision. The process was repeated in three separate days to determine 
the inter-day precision. Precision was calculated as the coefficient of variation (CV%) of the 
replicate analysis, whereas accuracy is the percent difference between nominal and observed 
values (% bias). The acceptable inter-day and intra-day precision and bias were set as <20 % (or 
accuracy between 80-120%) deviations of nominal concentrations.  The intra-day and inter-day 
precision were < 17.9% for all QCs. The accuracy (%) of all analytes QCs ranged from 92.9-
121.6% depends on the analyses.  The good precision and accuracy indicate that the analytical 
methods are reproducible and reliable (Table 5-3).  
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5.2.4.3 Matrix effect and recovery  
 The recovery efficiency and evaluation of matrix effect were determined by preparing and 
analyzing QC samples. There are three sets of QC samples for each compound, they are called 
neat injection, post extraction, and standard extraction (see detail in Chapter 2). The areas of neat 
samples, post extraction samples and normal extraction samples have been used for calculation 
of matrix effect and recovery. The matrix effect was calculated as (A post-extraction/ADI -1) ×100. 
Negative value represents the ion suppression effect. The recovery efficiency of every analyte 
was calculated as A extraction/A post-extraction×100. The matrix effect for every analyte was different 
and ranged from 74.8% to 132.5%. There was a matrix ion suppression effect for most analytes 
(post extraction response was lower than the neat sample response). For all analytes, the recovery 
ranged between 74.5-95.7%. Recovery efficiency indicated that the solid phase extraction 
method was sufficient to recover > 74.5% of compound from standard solution without 
significant loss in the extraction procedure (Table 5-4).  
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Figure 5-2: Typical chromatography window from UPLC/MS/MS in one of the validation days.  
Above showed chromatographies are midazolam, metoprolol, midazolam-d4, metoprolol-d7, 
esomeprazole, 1-hydroxymidazolam, omeprazole-d3 and 5-hydroxyomperazole (from left to 
right, then up to down direction) 
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Table 5-3: Calibration curve ranges, precision and accuracy evaluation of eight analytes. (n=6) 
 
 QC 
ng/mL 
 
                  Observed  
     Day 1          Day 2       Day 3 
Accuracy (%) Precision (CV%) 
Day1  Day2   Day3 
Standard Curves (three days) 
MDZ 
 
 
1-OHMDZ 
 
 
MET 
 
 
1-OHMET 
 
 
ESO 
 
 
5-OHOMP 
 
 
FAM 
 
2.5 
40 
250
2.5 
40 
250
2.5 
40 
250
4 
40 
250
2.5 
40 
250
2.5 
40 
250 
4 
40 
250 
2.34±0.10    2.72±0.19    2.45±0.09  
37.9±0.75    42.9±1.38    41.9±1.91  
256.1±9.59  256.8±7.49  255.7±7.31 
2.69±0.15    2.54±0.24    2.44±0.24 
42.3±4.64    40.7±2.86    38.3±5.25 
266.9±10.6  252.2±15.9  268.1±14.7 
2.39±0.43    2.26±0.17    2.53±0.33 
41.2±4.20    44.8±1.76    43.4 ±1.45 
277.8±18.9  256.8±9.5  248.9±12.2 
3.68±0.67    4.03±0.61    3.47±0.49 
38.8±3.10    40.8±4.96    44.3±3.59 
252.7±35.2  241.3±7.18  268.1±22.4 
2.60±0.18    2.60±0.25    2.39±0.08 
43.4±1.41    45.6±1.16    43.5±1.44 
263.2±6.41  264.4±6.23  273.5±16.4 
2.68±0.35    2.39±0.21   2.27±0.14 
45.5±4.63    46.7±1.09   46.4±1.39 
265.1±13.2  286.1±12.1 277.9±22.2 
3.93±0.39   3.42±0.53   3.69 ±0.45   
33.3±4.36   43.1±2.55   47.3 ±4.39 
235.8±31.7  288.9±8.91 298.6±28.7 
98.4±7.92 
100.4±6.34 
102.5±3.29 
103.4±8.74 
102.1±11.2    
105.4±5.68 
95.8±14.3 
106.4±8.28 
106.1±7.94 
92.9±15.5  
101.3±10.2 
101.5±11.4 
121.6±17.5 
110.3±4.27 
106.4±4.12 
100.1±13.0 
115.0±8.58 
109.4±6.99 
94.5±19.2 
96.3±18.4  
105.7±15.7  
   4.27    7.10    3.62 
   1.99    3.12    4.56 
   3.74    2.92    2.86 
   5.77    9.51    9.76 
   10.9    7.04    13.7 
   3.99    6.33    5.47 
   17.9    7.61   13.0 
   10.2    3.93   3.34 
   6.80    3.71   4.92 
   18.2   15.1    14.2 
   7.99   12.2    8.12 
   13.9    2.97   8.36 
   6.84    9.71   3.48     
   3.25    2.55   3.32 
   2.43    2.35   6.01 
   13.1    9.0     6.08 
   10.1    2.36   2.99 
   4.98    4.23  7.97 
   9.91   15.6   12.3 
  13.2   5.93   9.27 
  13.5   3.08   9.68 
y1=0.01673+0.09159x R2=0.9980 
y2=-0.01762+0.0997x R2=0.9972 
y3=-0.00347+0.09992x R2=0.9981 
y1=0.03407+0.11260x  R2=0.9979 
y2=-0.01647+0.11848x R2=0.9967 
y3=-0.00496+0.11767x R2=0.9934 
y1=0.05533+0.07474x R2=0.9976 
y2=0.02858+0.07506x R2=0.9991 
y3=0.03535+0.07079x  R2=0.9929 
y1=0.02472+0.03545x  R2=0.9912   
y2=0.02651+0.02988x  R2=0.9854   
y3=0.06659+0.04817x  R2=0.9849 
y1=0.02667+0.05885x  R2=0.9979 
y2=0.02781+0.05563x R2=0.9966 
y3=0.07000+0.05489x R2=0.9969 
y1=0.03836+0.07918x R2=0.9963 
y2=0.07035+0.08608x R2=0.9972 
y3=0.03535+0.07079x  R2=0.9929 
y1=0.04112+0.13508x R2=0.9809 
y2=-0.03508+0.08237x R2=0.9091 
y3=0.013002+0.13404x  R2=0.9879 
 
 
 
Table 5-4: Evaluation of recovery efficiency and matrix effect of probes, metabolites and internal 
standard (n=6) 
Compound  QCs 
(ng/mL) 
Recovery (%) 
Value   SD  
Matrix effect (%) 
Value   SD  
Midazolam 
 
 
1-OHMDZ 
 
 
Metoprolol 
 
 
1-OHMET 
 
 
Esomprazole 
 
 
5-OHOMP 
 
 
Famotidine  
 
 
2.5 
40 
250 
2.5 
40 
250 
2.5 
40 
250 
4 
40 
250 
2.5 
40 
250 
2.5 
40 
250 
4        
40 
250 
80.9    13.6 
86.6    8.8 
81.4   16.8 
76.5    5.1 
95.7    3.8 
74.5    13.8  
94.7    6.4 
91.1    16.0 
86.5    9.9 
94.5  18.7 
95.2  9.17 
92.4  3.83 
86.7    10.3 
91.6    4.7 
91.6    15.1 
86.8    4.2 
84.9    6.8 
90.3    14.2 
89.3    15.0 
101.9  15.8 
99.1    10.3     
 74.8     11.0 
 76.9     3.9 
 81.8     7.8 
108.0    13.6 
 81.6     2.9 
 99.0     8.9 
119.2    15.2 
108.4    9.7 
132.5    8.9 
96.4      13.1 
98.5      6.2 
92.3     12.6 
106.0    12.5 
94.5      4.9 
94.6      8.8 
87.5      10.6 
83.9       2.7 
88.1       8.1 
110.1   24.0 
87.0     12.9 
79.8     11.1 
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5.2.5 Conclusion  
The cocktail bioanalytical assays for four probe drugs (midazolam, esomeprazole, metoprolol 
and famotidine) have been established and validated. All assays are selective and reproducible. 
Total running time is 6.0 minutes per sample. The assays are ready to be used for sample 
analysis. Theophylline is still on the way to be validated. 
 
Due to the differences in physicochemical characters (e.g. hydrophilic vs hydrophobic, acid vs 
neutral) of these analytes, this set of cocktail has been divided into two different reconstitute 
groups and used two different extraction methods for the best sensitivity and selectivity. The 
dynamic nature of the validation process requires a constant re-evaluation of the method when 
changes of the research objective or analytical instrumentation.  
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5.3 STUDY PROCEDURE 
 
5.3.1 Human subjects 
This study was approved by the University of Pittsburgh Institutional Review Board.  All race 
and ethnic groups are eligible for enrollment. Based on our experience in the area of Allegheny 
County, the actual enrollment of clinical trial has been 50% female subjects and 11% minority 
subjects.  
 
      5.3.1.1 Inclusion criteria: Subjects between the ages of 18 and 45 years of age who are not 
pregnant (for female subject) and who have no known medical problems are eligible for 
inclusion.  
 
5.3.1.2 Exclusion criteria: 
— Those individuals who have any known history of current or previous medical problems, 
inducing but not limit to: heart disease, history of abnormal heart rhythm or heart murmur, 
low blood pressure, high blood pressure, lung disease including asthma, diabetes mellitus, 
thyroid disease, kidney disease, liver disease, nerve disease or seizures, connective tissue 
disorders, sickle cell disease, anemia or other blood disorders.  
— Subjects who are known to have the human immunodeficiency virus (HIV positive) or are 
otherwise have difficulty fighting infection (weakened immune system).  
— Subjects who take any medications (including herbal preparations) with the exception of 
allergy medications, ibuprofen or Tylenol.  
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— Subjects who take any of the following medications or over-the-counter items: MAO 
inhibitors (such as Parnate or Nardil) or any other antidepressant, St John’s Wort, 
Participating in the study while on these medications may lead to the incorrect estimate of the 
enzyme activities.  
— Individuals with a history of heart disease in family members below the age of forty.  
— Individuals who have a known allergy to midazolam or a history of other narcotic allergy. 
— Individuals who have a known allergy to metoprolol or a history of  β1-receptor blocker ( 
such as propranolol, atenolol, esmolol) allergy. 
— Individuals who have a known allergy to theophylline or other xanthine (such as caffeine, 
aminophylline, paraxanthine, throbromine) allergy. 
— Individuals who have a known allergy to esomeprazole or other proton pump inhibitor (such 
as Lansoprazole, omeprazole, pantoprazole, dexlansoprazole) allergy. 
— Individuals who have a known allergy to famotidine or other H2-receptor antagonist (such as 
cimetidine, ranitidine, and nizatidine) allergy.  
— Subjects who have a history of long term benzodiazepine use.  
— Individuals who are currently ill with a viral or other infection. 
— Individuals who have kidney problems or renal insufficiency.  
— Individuals who have abnormal vital signs including systolic blood pressure (the first number 
given when your blood pressure is taken) less than 90mmHg or greater than 140mmHg. 
Heart rate less than 40 or greater than 100, or a respiratory rate (the number of times you 
breathe in one minute) less than 10 or greater than 24. 
— Individuals who currently smoke or use any other recreational drugs. 
— Individuals who are morbidly obese (very overweight-Body Mass Index>36). 
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— A body weight of less than 80 pounds. Any subject who met any of these criteria would be 
excluded from the study.  
 
5.3.1.3 Recruitment procedures  
An announcement was made in Center for Emergency Medicine, Department of Emergency 
Medicine, and School of pharmacy courses and grand rounds. Recruitment flyers were placed in 
common areas of the University. Volunteers were given a phone number to call to arrange for an 
appointment with an investigator. Informed consent and screening took place at that meeting. 
Subjects are fully informed of the nature of the research, including the risks and benefits of the 
study and their rights as a research subject prior to obtaining their signatures on the informed 
consent document.  
 
5.3.2 Drug dosage and IV formulation 
5.3.2.1 Microdose simulation  
One of the challenges of this study is to define the appropriate “microdosage”. First, all probe 
drugs need to be at doses at 1/100th - 1/10th (one to the hundredth to one to the tenth fold) of the 
doses typically used for treating disease. In addition, the cocktail analytical assays established in 
the laboratory must provide a lowest limit of detection that allows for the assessment of 
concentrations throughout the time-concentration profile. Therefore, the complete time 
concentration profile can be accurately quantified. Thirdly, the study duration has to cover on 3-5 
half-life of all probe drugs. Fourth, we used literature reported clearance (CL) and volume of 
distribution (V) to simulate the elimination and time concentration profile.  
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Combined with above mentioned total study duration, analytical limit of detection, clinical dose, 
available PK parameters, this “microdosage” have been determined by performing PK simulation 
using simple one compartment model (Figure 5-3). The lowest doses that produce the detectable 
concentration for the entire sampling time have been chosen for this study for each probe drug. 
The final dosage chosen for these probe drugs are theophylline 1.0mg, midazolam 0.1mg, 
esomeprazole 0.2 mg, metoprolol 0.5mg and famotidine 1.0mg. Detailed information refers to 
and Table 5-5. 
 
 
 
 
 
Figure 5-3: Microdose simulation rationale.  
 
 
5.3.2.2 Microdosage and formulation 
Microdosage cocktail formulation (theophylline 1.0mg, midazolam 0.1mg, esomeprazole 0.2 mg, 
metoprolol 0.5mg and famotidine 1.0mg) has been prepared by Investigational Drug Services of 
C1, V1 
Dose IV 
CL, V 
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University of Pittsburgh Medical Center. The IV formulation are made of: 1) one aminophylline 
1.25mg/2.5mL syringe (note that 1.25 mg of Aminophylline is equivalent to 1 mg of 
Theophylline), 2) one esomeprazole 1mg/2ml syringe, 3) one 6mL syringe containing three 
medications: famotidine 1mg/2mL, metoprolol 0.5mg/2mL, midazolam 0.1mg/2mL. These IV 
doses have been given to subjects at approximately the same time at the PK time zero. 
 
Table 5-5: Typical IV pharmacological dose and the proposed microdosages for five probe drugs 
Isoform Probe drugs  
Typical IV 
Clinical Dose 
Human  
Micro‐Dose
Dose proposed 
for the study Half Life 
Sample 
Time Expected Conc.
UPLC/MS/MS 
requirement 
CYP1A2 Theophylline  
0.4 mg/kg/hr 
(400 mg) 
0.112 mg 
(1.6µg/kg) 1mg   ( <1/100th) 8.7 (6.1‐12.8) hours 24 hours 0.486ng/mL 0.2ng/mL 
CYP3A4 Midazolam 1.0‐4.0mg 
0.1mg 
(1.43µg/kg) 0.1mg ( <1/10th) 3 (1.8‐6.4) hours 12 hours 0.0687ng/mL 0.2ng/mL 
CYP2C19 Esomeprazole 20‐40 mg 
0.07mg  
(1.0µg/kg) 1mg  ( <1/20th) 1‐2 hours 8 hours 0.109ng/mL 0.4ng/mL 
CYP2D6 Metoprolol 0.2mg/kg 
0.056mg  
(0.8µg/kg) 0.5mg ( <1/20th) 4 (3‐7) hours 20 hours 0.0098ng/mL 0.02ng/mL
Renal 
Secretion Famotidine 10‐20mg 
0.5mg  
(7.14µg/kg) 0.5mg ( <1/20th) 2.5‐3.5 hours 16 hours 0.1365 ng/mL 0.5ng/mL 
 
5.3.3 Study procedure 
5.3.3.1 Screening 
A study physical performed a history and physical exam on each subject to assess for the 
presence of medical conditions. The screening took place in the department of emergency 
medicine offices on a visit separate from the experiment protocol. Body composition of the 
subject was assessed by measuring skinfolds at three sites. Blood samples were collected for 
sodium, potassium, TSH, SGOT, SGPT, alkaline phosphatase, bilirubin, blood urea nitrogen, 
creatinine and a complete blood count to exclude undiagnosed liver, hematologic and metabolic 
177 
 
disease.  Two tubes of blood have been collected (one gold top and one lavender top tube) for 
each subject. Normal lab values used by the University of Pittsburgh Medical Center 
Presbyterian Hospital lab have been accepted as the normal range. In the event a lab value is 
outside the normal range, but not clinically significant in the study physician’s opinion, the 
subjects will be allowed to repeat the lab test once. Subject had two lab tests outside the normal 
range will be excluded. Subject excluded from the study has been provided the information 
concerning their exclusion and they were referred to their primary care physician.  
 
5.3.3.2 Experiment protocol 
Prior to the protocol, subjects have been asked to refrain from caffeine, alcohol and grapefruit 
juice from 48 hours. Grapefruit juice is known to alter cytochrome P450 metabolism and 
caffeine and alcohol may alter hydration status. There is no randomization or control group since 
all the subjects will receive the same treatment. To ensure safety, a defibrillator, airway 
management supplies, ACLS medications, and reversal agents are available during the protocol. 
A study physician has been presented for the entire protocol. Upon arriving for a protocol on the 
first day, subjects will void their bladder and be weighted. All females will undergo a urine 
pregnancy test at this time. Subjects then have been prepared as follows:  
 
5.3.3.2.1 Intravenous access and blood sampling 
An 18-gauge intravenous catheter was placed in one of the subject’s hand, forearm, or 
antecubital veins using standard technique. Subjects received IV bolus of cocktail drugs. After 
the IV bolus injection, 10 mL saline was used to flush the line. Blood samples later were drawn 
from the same catheter. Blood samples (3.0mL) were collected at zero, 0.25, 0.5, 1, 2, 4, 6, 8, 10, 
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12 and 24 hours for a total of 33mL of blood taken. Since the total sampling time is 24 hours, the 
protocol started from the first day and was completed early the next day. Blood samples from 0-
12 hours has been collected on the first day, blood sample at 24 hour time point has been 
collected on the second day visit. Blood was separated by a microcentrifugation and the plasma 
was stored at -80⁰C until further analysis. Timeline of the protocol has been described in Figure 
5-3.  
 
5.3.3.2.2 Vital signs 
 Heart rate and blood pressure have been measured at the subject arrival on the first visit, 
immediately before the drug administration, 5 minutes and 10 minutes after drug administration 
and at each blood draw time point afterwards.  
 
5.3.3.2.3 Urine collection 
Total urine has been collected throughout the study, the container has been provided to the 
subjects for the overnight. The urine concentration of each specific metabolite provides 
important information of formation clearance of each probe drugs. The formation clearance is 
calculated from the concentration of the metabolite in the urine times total urine volume divided 
by the area under time plasma concentration curve.  
 
5.3.3.3 Patient safety and protocol determination 
Primary endpoints for this protocol are completed after the 24 hours blood sampling and urine 
collection or 2) if the subject request termination. The following criteria will results in early 
termination of the study as well: 1) if at any point in time of the study the subject is found to 
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have a heart rate less than 40 or greater than 150, 2) systolic blood pressure less than or equal to 
80mmHg or greater than 180mmHg, 3) any sign of arrhythmia. All subjects will be monitored 
for a minimum of 30 minute after completing the study next day. Subjects must void their 
bladder and be weighted prior to discharge.  
 
 
Figure 5-4: Timeline of the protocol (BD= blood draw). Numbers indicate hours. 
 
5.3.4 Sample Analysis 
Plasma concentrations of midazolam, esomeprazole, metoprolol and famotidine has been 
determined using UPLC/MS/MS methods described above. Briefly, a 0.20mL aliquot of plasma 
sample with four specific duterated internal standard (midazolam-d4, omprazole-d3, metoprolol-
d7, and ranitidine) was extracted from solid phase extraction column using HLB cartridges. 
Standard curve and/or QC samples were prepared and run in the same sequence.  
 
 
 
 
 
 
 
BD   BD   BD      BD        BD            BD               BD           BD      BD        BD                                          BD+ urine 
First visit 2nd visit  
0   0.25    0.5      1           2             4                6            8        10        12 hours                                      24hours 
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5.4   PK DATA ANALYSIS  
 
The primary statistical analysis has been based on best describing the complete time 
concentration curves of the each individual and their pharmacokinetics estimates. Non-
compartmental pharmacokinetic analysis has been used for estimating all probe drugs. 
Pharmacokinetic parameters (CLs, Vd, T1/2, etc) will be compared with literature reported 
values when these drugs are used in higher concentration in human study.   
 
5.4.1 Time-concentration curves 
Time concentration curves of midazolam 0-12 hours, esomeprazole 0-4 hrs, metoprolol 0-12 
hours and famotidine 0-12 hours has been showed in Figure 5-5.  All sample concentrations in 
this duration can be accurately measured by previous established analytical assays.   
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Figure 5-5: Time concentration profile of 
midazolam, esomeprazole, metoprolol and 
famotidine of Subject 1.  
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5.4.2 Non-compartmental analysis 
Non-compartmental model analysis has been performed by Winnonlin 5.2. PK parameter 
estimates of Ke, T1/2, Tmax, Cmax, AUC0-last, AUC 0-inf, Vz and CL of each probe drug have 
been listed in Table 5-6.  All AUC0-last/AUC0-inf ratio is great than 90%, indicates our sample 
time is sufficient to describe the complete elimination profile and provide accurate estimates 
from IV dose administration. Compared to multiple previous literature, there is no significant 
difference from PK estimates of subject 1 with previous literature reported PK estimates (Table 
5-7). This indicates the linear PK across the dose range from normal dose to microdose used in 
this study for midazolam, esomeprazole, metoprolol and famotidine.  
 
Table 5-6: Non-compartment model analysis for midazolam, esomeprazole, metoprolol and 
famotidine of subject 1.  
 
 Midazolam  Esomeprazole Metoprolol Famotidine 
Ke (1/hr) 0.3528 0.9577 0.1901 0.2103 
T1/2(hr) 1.965 0.7238 3.646 3.297 
Tmax (hr) 0.25 0.25 0.5 0.25 
Cmax(ng/mL) 1.035 51.92 1.244 10.11 
AUClast(hr×ng/mL) 3.046 55.40 5.155 28.55 
AUCINF(hr×ng/mL) 3.248 56.66 6.093 30.34 
Vz (mL/kg) 1023.2 216.09 5068.07 920.40 
Cl (ml/hr/kg) 360.9 206.9 963.6 193.5 
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Table 5-7: Pharmacokinetics parameters of midazolam, esomeprazole, metoprolol and 
famotidine estimated from our study and from previous literature. 
 
(Mean 
±SD) 
Author 
(Reference) 
IV Dose 
(mg) 
CLs (ml/min/kg) Vss/Vd (L/kg) T1/2 (hrs) 
Midazolam 
 
THIS STUDY 
(Persson 1987) 
(Patel 1990) 
(Allonen 1981) 
(Greenblatt 1984) 
(Greenblatt 1981) 
(Smith 1981) 
(MacGilchrist 1986) 
(Thummel 1994) 
(Malacrida 1992) 
(Majumdar 2007) 
(Hostler 2010) 
(Rogers 2002) 
(Heizmann 1983) 
 
0.1 
NA 
3.75 
0.075mg/kg 
2.5-5.0 
12.5 
5.0 
NA 
NA 
6-15mg/hr 
2.0 
6.0 
2.09±0.3 
0.15mg/kg 
 
6.02 
6.9 
7.87 
7.17±1.5 
7.8-9.4  
8.1±0.52  
6.38  
10.4±1.3 
6.5  
4.9  
6.39±0.72 
4.49±0.56 
8.1±1.31 
4.61±1.23 
 
1.02 
1.94 
NA 
NA 
1.3-2.0 
1.72±0.05 
NA 
1.15±0.15 
0.78±0.34 
0.9 
NA 
0.779±0.167 
NA 
0.717±0.16 
 
1.96 
3.1 
3.0 
2.4±0.8 
2.1-2.6 
2.5±0.2 
1.77±0.83 
1.6±0.3 
2.55±2.0 
2.3 
3.7 
1.78±0.347 
2.03±0.32 
2.29±0.42 
 
Metoprolol 
 
THIS STUDY 
(Jordo 1980) 
(Kendall 1982) 
(Regardh 1981) 
(Kelly 1985) 
 
0.5 
20 
NA 
20 
50 
16.1 
11.4±1.4  
NA 
11.6±1.6 
22.2±1.1 
5.07 
NA 
NA 
NA 
4.7±0.3 
 
3.65 
4.1±1.0 
3.3±0.7 
4.2±1.1 
2.5±0.3 
Eso/ 
omeprazole 
THIS STUDY 
(Naesdal 1986) 
(Landahl 1992) 
(Jacqz-Aigrain 1994) 
 
 
1.0 
20mg 
20mg 
NA 
3.45 
8.03±0.89 
7.14 
3.83 
0.216 
V1=0.173; V2=0.374 
NA 
0.45 
0.72 
0.57±0.059 
0.7-1.0 
0.86 
 
Famotidine THIS STUDY 
(Inotsume 1989) 
(Lin 1988) 
(Smith 1985) 
(Kroemer 1987) 
(Takabatake 1985) 
0.5 
20 mg/oral 
NA 
NA 
20mg 
20mg 
3.23 
3.86±0.33 
4.43 
NA 
             4.41 
5.89±1.79 
0.92 
NA 
NA 
NA 
1.13 
Vss=1.14 
V1=0.34±0.1 
3.3 
3.0±0.5 (SE) 
NA 
3.8 
4.0 
2.59±0.73 
NA: Data not available. To match the same unit, certain units from original literature have been converted 
(such as hour to minutes, ml/min to ml/min/kg). 
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                                      5.5 DISCUSSION AND FUTURE DIRECTION 
 
This feasibility study demonstrated in our first subject that our proposed 1) microdosage, 2) IV 
formulation, 3) study duration, and 4) UPLC/MS/MS analytical detection limits allow for the 
determination of PK parameter estimates via multiple microdosed probe drugs. Compared to 
multiple previous literature, our subject 1 data provide the preliminary evidence that all PK 
parameter estimated in a microdosing strategy is similar with high dose PK study. This study is 
descriptive in nature and will be used to determine feasibility, refine protocol and power a full 
trial of pharmacokinetic study larger sample size and in further patients’ population.  
 
Probe drug midazolam, esomeprazole and metoprolol are chosen for specific CYP3A4, 
CYP2C19 and CYP2D6 activity in human. The metabolism of these probe drugs will be highly 
dependent on the specific isoform activities. Multiple previously discussed studies have indicated  
altered metabolism or volume of distribution of midazolam in critical ill patients. Omeprazole 
metabolism is strongly correlated with CYP2C19 polymorphism. The total clearance can range 
from 1369±516 ml/hr/kg to 89.5±15.4ml/hr/kg and T1/2 ranging from 0.5±0.08 hour to 2.1±0.08 
hours, based on the specific genotype patterns (Ieiri et al., 1996). Metoprolol is a commonly used 
drug in critically ill patients, the microdosing approach will allow for both phenotypic 
assessment and also informative PK information for this common clinically administered 
medication.    
 
Famotidine is mainly excreted unchanged by the kidney. Therefore it is a probe drug for renal 
function. The renal clearance of famotidine exceeded the creatinine clearance, suggesting the 
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secretion is the major route of elimination of famotidine. The impartment of renal function may 
lead high blood concentrations of famotidine (Takabatake 1985). Total clearance of famotidine is 
strongly correlated with creatinine clearance. Previous study has suggested that the renal 
clearance of famotidine would decrease in direct proportion to the reduction in CLcr, which can 
be calculated as: CL=0.2370CLcr+3.193 (Takabatake 1985). Hypothermia effect on renal 
function is largely unknown, and is one of our future research questions.  
 
These microdoses at midazolam 0.1mg, esomeprazole 1.0mg, metoprolol 0.5mg and famotidine 
0.5mg can potential provide multiple advantages over other normal dose PK design. It will 
largely reduce the possible drug-drug interaction among the probe drugs and the drug-drug 
interaction between probe drugs and other medications. This study will prove the first important 
concept that the current microdosed design and cocktail IV approach can be used for 
phenotyping human CYP isoform CYP1A2, CYP3A4, CYP2C19 and CYP2D6 as well as renal 
secretion. This study is an important preliminary data for resubmitting the new clinical studies to 
evaluate the effect of therapeutic hypothermia on drug metabolism in cardiac arrest patients. 
 
In addition, a high dose probe cocktail study use the same experiment design may needed in the 
future to confirm the linearity PK across dose range, no drug-drug interaction and provide the 
validation with other studies or with the regular doses. 
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6.0   THE EFFECT OF THERAPEUTIC HYPOTHERMIA ON PHENYTOIN 
POPULATION PHARMACOKINETICS IN PEDIATRIC TRAUMATIC BRAIN 
INJURY PATIENTS  
Jiangquan Zhou (Population PK modeling data analysis) 
 
6.1 INTRODUCTION 
 
As an extension of our previous research with CYP probe drugs, we sought to evaluate the effect 
of therapeutic hypothermia on the disposition of clinically relevant drugs in susceptible patient 
populations.  One such patient population includes neonates undergoing therapeutic hypothermia 
following traumatic brain injury. Frequently, these patients require the prophylactic 
administration of anti-convulant medications after insult. Phenytoin is one of the most commonly 
used anti-convulsant drugs in critical care medicine. In addition, phenytoin is a drug with a 
narrow therapeutic index, which exhibits non-linear pharmacokinetics. Therefore, this study is to 
evaluate the effect of hypothermia on phenytoin population pharmacokinetics in pediatric 
patients. In this study, we have focused on applying population PK modeling and simulation 
approach to determine the population PK characteristics of phenytoin and the correlation 
between temperature and phenytoin PK parameters in pediatric TBI patients. 
 
Quite often, we observed the hypotension in rewarming patients after hypothermia treatment and 
especially in pediatric patients. A previous study has shown that hypothermia significantly 
decreased the clearance of phenytoin in traumatic brain injury patients with no change in protein 
binding during hypothermia (Iida et al., 2001). Decreased clearance maybe directly related to its 
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side effect, for example hypotension, therefore, further clinical trial and data analysis incorporate 
temperature as covariate to estimate the effect of hypothermia on phenytoin PK is necessary for 
dose regimen design and response prediction. 
 
6.1.1 Phenytoin and its PK characteristics 
Phenytoin (5,5-diphenylimidazolidine-2,4-dione) is a commonly used anticonvulsant in critical 
care medicine. It is used to control certain type of seizures, and to treat and prevent seizures that 
may begin during or after surgery to the brain or nervous system. Phenytoin acts to suppress the 
abnormal brain activity seen in seizure by reducing electrical conductance among brain cells by 
stabilizing the inactive state of voltage-gated sodium channels (Ya et al., 1986; Talwar 1990; 
White 1999; Eriksson et al., 2009). Phenytoin is also an anti-arrhythmic and a muscle relaxant 
(Carson et al., 1979; Somberg 1985; Bebin et al., 1994).  
 
Phenytoin is primarily metabolized by CYP2C9 and CYP2C19. In addition, phenytoin 
pharmacokinetics follows nonlinear elimination characteristics and saturable metabolism, an 
increase in the dose would result in a more than proportionate increase in the drug AUC, because 
the clearance of the drug decreases with an increase in the dose. Furthermore, phenytoin is a high 
protein binding drug (>90% bound to plasma albumin). Potential protein binding change could 
also alter the plasma concentration and AUC significantly. 
 
6.1.2 Michaelis-Menten kinetics   
When enzyme-catalyzed reactions are saturable, their rate of catalysis will not show a linear 
response to increasing substrate. The Michaelis-Menten kinetics model is the most commonly 
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used nonlinear model, which can be described as : V=Vmax×[S]/(Km+[S]). If the initial rate of 
the reaction is measured over a range of substrate concentrations ([S]), the reaction rate (v) 
increases as [S] increases. As [S] gets higher, the enzyme becomes saturated with substrate and 
the rate reaches Vmax, the enzyme's maximum rate. Michaelis constant (KM) is the substrate 
concentration at which the reaction rate reaches its half-maximum value (Vmax/2). The maximum 
rate of metabolism (Vmax) is dependent on the amount (or concentration) of enzymes available 
for metabolism of the drug, while KM is the concentration which produces half of Vmax and is 
inversely related to the affinity of the drug to the enzyme (the higher the affinity, the lower is 
KM).  
 
Under certain circumstances (disease states, age, and drug interactions), the Vmax and KM values 
of a drug may change (Mehvar 2001). For example, concurrent administration of carbamazepine 
or phenobarbital with phenytoin results in an increase in the Vmax of phenytoin (enzyme 
induction). Therefore, it may be necessary to increase the dosing rate of phenytoin if 
phenobarbital or carbamazepine is added to a patient's regimen. Conversely, hepatic cirrhosis 
causes a decrease in the Vmax of phenytoin, resulting in higher plasma concentrations if the same 
dose is administered. Additionally, drugs such as cimetidine or chloramphenicol cause an 
increase in the KM value of phenytoin, resulting in higher than expected plasma concentrations of 
phenytoin (Tozer et al. 1992). 
 
The goal of this study is to define the effect of therapeutic hypothermia on metabolism of this 
highly clinical relevant drug, phenytoin, and its nonlinear PK change from clinical data set. 
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Therefore, to obtain a better understanding and prediction for phenytoin time-concentration, 
response and dose regimen design during hypothermia for clinics. 
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6.2 DATA FOR PK ANALYSIS 
 
6.2.1 Subjects and dose information  
A total of 19 pediatric patients are included. Ten received hypothermia treatment and nine of 
them were normothermia control. Subject weights are within the range of 43.3±22.4kg. All 
patients received a loading dose 15.4±2.96mg/kg. The actual maintenance dosages ranged 
between 1.82-10mg/kg were given to patients for every 12 hours until the last given dose time at 
194.6±38.7 hrs based on clinical need and hospital pharmacodynamics monitoring.  
 
6.2.2 Temperature  
Time-temperature profiles of all subjects have been described in Figure 6-1. Normothermia 
temperature has been maintained at 37.1±0.6°C (Mean±SD).  Hypothermia has been maintained 
at 32-33°C for 48 hours, followed by a slow rewarming at the rate of 1 degree every 12-24 hours. 
 
6.2.3 Time-concentration profile 
All time-concentration (total) profiles have been shown in Figure 6-2, also with phenytoin dose 
regiment has been shown in Figure 6-3.  
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Figure 6-1: Body temperature in hypothermia and normothermia 
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Figure 6-2: Phenytoin time-concentration (total) of pediatric TBI patients 
 
 
Figure 6-3: Phenytoin dose regiment for hypothermia and normothermia patients 
6.3 POPULATION PK ANALYSIS 
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6.3.1 Base model 
The population pharmacokinetic model was constructed using a nonlinear mixed-effects 
approach as implemented in the NONMEM VI program (Icon, Hanover, Maryland). The 
pharmacokinetics of phenytoin generally is believed to follow the nonlinear characteristics. For 
this set of data, I tested four different structure models looking for the best fitting, and they are:  
1) one compartment first order elimination (CL, V) 
2) two compartment model first order elimination (CL, Q, V1, V2 ) 
3) one compartment model nonlinear elimination (Km, Vmax, Vd) 
4) one compartment model linear parallels with nonlinear elimination ( Km, Vm, CL,V) 
Model building process details is the same as previous section. Inter-individual variability in 
model parameters will be modeled using an exponential term. θi=θ×℮η . Residual variability, was 
evaluated using additive, proportional or a combined additive and proportional model Cobs,ij = 
Cpred,ij ×(1+εij1+ εij2), Where Cobs, ij is the jth measured observation in individual i, Cpred ij, 
is the jth model predicted value in individual i, εij is the residual error. Further refinement of the 
error model was performed if needed. The model building process and evaluation are the same as 
previous section. NONMEM subroutine ADVAN 10 was used is the building nonlinear function 
although the subroutine ADVAN 6, 9, and 13 can also be used when providing the nonlinear 
equations in the control file (Figure 6-4). 
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Figure 6-4: One or two compartment model with nonlinear or first order linear structure for 
phenytoin base model  
 
 
 
 
 
 
 
 
V2, C2 
V1, C1 
 
K21 K12 
Dose Km, Vmax 
K10, CL 
one compartment model linear elimination:  
C=C0*e
‐kt 
DCDT(1)=‐K10*C(1) 
CL=K10*V1 
 
two compartment linear elimination model:  
DCDT(1) = ‐K10*C‐K12*C(1)+K21*C(2) 
DCDT(2) = K12*C(1)‐K21*C(2) 
 
one compartment nonlinear model : 
DCDT(1) = ‐C1*VM/(KM+C1)  
 
one compartment with linear parallels with nonlinear: 
DCDT(1) = ‐C1*VM/(KM+C1)‐K10*C(1) 
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6.3.2 Covariate model and selection 
The covariate model analysis was constructed by estimating temperature (TEM/37) as a 
continuous covariate on all PK parameters. To assess whether the model with covariate 
statistically improved the fit to the data from base model, the difference between their objective 
function values, referred to as the log likelihood ratio, was calculated (detail also refer to Chapter 
3). This ratio was assumed to be chi-square distributed, which means that a reduction in 
objection function of 3.84 is considered to be significant (p<0.05, 1d.f.).  
 
6.3.3 Model evaluation 
The final covariate model was evaluated using diagnostic plots, successful minimization, 
precision for all parameters (se%) and a nonparametric bootstrap. The nonparametric bootstrap 
approach using sampling with replacement was used to assess the robustness of the model 
estimates (Parke et al., 1999). Sampling with replacement involved creating a series of datasets 
of equal size to original data set that are generated by repeatedly sampling individuals from the 
original dataset, removing these individuals and replacing them at random. The model was 
refitted to each new data set and this process was repeated 100 times. The stability of the final 
model was evaluated by examining the bootstrap median and percentiles of model parameter 
estimates from bootstrap. The Wings for NONMEM (G77 Fortran with WFN 408b) 
implementation for bootstrapping was utilized.  
 
6.3.4 Simulation 
Based on the final model estimates, simulations have been performed comparing three groups in 
normothermia, hypothermia with 96 hours rewarming and hypothermia with 48 hours 
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rewarming. Temperature covariate used in the simulation follows the original protocol, which 
has been described in three phase (induction, maintenance and rewarm). Dosage used for 
simulation is 20mg/kg for loading dose, with 2.5mg/kg every 12 hours maintaining dose. The 
total simulation duration is from 0-200 hours.  
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6.4 POPULATION PK MODEL RESULTS 
 
6.4.1 Base model selection 
Four base model structures have been tested. The OFV values and parameter estimations have 
been shown in Table 6-1. We decided to purse model 3 as it provided the best OFV value for 
estimating three parameters. In addition, this one compartment nonlinear model matches 
majority of previous literature. Therefore, this one compartmental nonlinear elimination model 
was chosen for base model structure for phenytoin. Three parameters Vmax, Km and Vd have 
been estimated in this model using ADVAN 10 subroutine in NONMEM. Two inter-individual 
variability (ω2) were chosen for Km and Vd. Residual error model used was Cobs ij=Cpred ij+ 
Err1. This base model provided an adequate description of the data, as judged by visual 
inspection of diagnostic plots as well as the standard error estimates for each parameter. Using 
one compartment nonlinear base model, we have estimated the PK parameters for normothermia, 
hypothermia patients separately and then combined data set (Table 6-2).  
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Table 6-1: All Base model estimates 
Model 1 OFV Estimates (SE%)) 
CL, V, 2etas 
Y=F+ERR(1) 
580.127 CL=0.0152 L/hr/Kg (0.231%), V=1.13 (8.42%), ETA1=0.433 
(16.2%), ETA2=0.718 (3.27%),ERR1=8.43 (110%) 
Model 2 OFV Estimates (SE%)) 
CL, V1, Q, V2, 
2etas 
Y=F+ERR(1) 
579.823 CL=0.0151(0.291%); V1=1.08 (19.5%) 
Q=0.00723 (3.55%); V2= 0.0634 (23.1%) 
ETA1=0.439 (18.3%); ETA2=0.0802 (10.5%) 
ERR1= 8.28 (144%) 
Model 3 OFV Estimates (SE%)) 
Vm, Km, Vd 
2etas (Km ,Vd); 
Y=F+ERR(1) 
576.971 Vm=0.385 (2.51%); Km=8.74 (67.1%); Vd=1.15 (7.55%); 
ETA1=1.88 (123%); ETA2=0.0512 (2.52%); ERR1=7.99 
(127%) 
Model 4 OFV Estimates (SE%)) 
CL, V, Vm, Km 
Y=F+ERR(1) 
579.446 CL=0.0152 (0.702%);V=1.13 (10.7%) 
Vm=0.0105 (511%); Km=8530 (huge) 
ETA1=0.434 (60.9%); ETA2=0.0722 (3.90%) 
ERR1=8.29 (108%) 
CL: L/hr/Kg; V: L/Kg; Vm: mg/kg/hr; Km: mg/L; Vd:L/kg 
 
 
Table 6-2: Base model estimates for normothermia and hypothermia and combined data set 
Model parameter 
Estimates (SE%) 
Normothermia  
N=9 
Hypothermia  
N=10 
Combined  
base model  N=19 
Vm (mg/kg/hr) 
Km (mg/L) 
Vd (L/kg) 
CL (L/kg/hr) 
ω 2 (Km) 
ω 2 (V1) 
η1 
0.362 (1.91%) 
5.04 (74.6%) 
1.17 (14.8%) 
0.0718  
5.70 (481%) 
0.105 (5.57%) 
7.20 (155%) 
0.542 (41.4%) 
23.2 (3220%) 
1.13 (7.49%) 
0.0234  
0.219(29.6%) 
0.011 (0.563%) 
8.99 (222%) 
0.385 (2.51%) 
8.74 (67.1%) 
1.15 (7.55%) 
0.0441 
1.88(123%) 
0.05(2.52%) 
7.99 (127%) 
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6.4.2 Covariate model 
The covariate model with temperature covariate on Km has significant reduced the OFV value 
5.58 points from the best base model mentioned above (p<0.05). Hypothermia significantly 
increased the Km of phenytoin. Hypothermia effect on Km can be described as: 
Km=13.8×(TEM/37)(-6.45), Vmax=0.458 mg/kg/hr, and Vd=1.23 L/kg.  Every one degree 
decrease from 37°C, there is expected around 19.3% Km increase for phenytoin. The individual 
Km generated have been plotted with temperature in Figure 6-5. Body temperature at 33°C, the 
Km of phenytoin will increase almost 2 fold (Table 6-3). Increased Km indicated the reduced 
affinity from phenytoin to the metabolic enzyme. Therefore, hypothermia reduced the affinity of 
the substrates to the enzyme and reduced the elimination.  
 
The covariate model with temperature covariate effect on Vmax has also significant reduced the 
OFV value 7.99 points from the best base model mentioned above (p<0.01). Hypothermia 
significantly decreased the Vmax of phenytoin. Hypothermia effect on Vmax can be described 
as: Vm=0.424× (TEM/37) (2.99), Km=11.2 mg/L, and V1=1.23 L/kg. Every one degree decrease 
from 37°C, there is expected around 7.9% Vmax decrease for phenytoin. Body temperature at 
33°C, the Vmax of phenytoin is expected to decrease 30% (Table 6-4). 
 
When tested individually, both Km and Vmax have been affected by hypothermia, however, 
when temperature has been added to both Km and Vmax at the same time, the model did not 
reduce OFV further, this indicated a Vmax-Km interactions. Based on the higher percentage 
changes per degree, we chose the temperature effect on Km to continue.  In addition, the intrinsic 
clearance of phenytoin (Vmax/Km) has then been generated, and temperature-clearance 
200 
 
relationship has been described in Figure 6-6. Hypothermia decreased the clearance of phenytoin 
in pediatric TBI patients. 
 
Table 6-3: Km change with temperature  
Baseline 
37°C 
Km  expected to 
increase to 
The change Fold increase 
36°C 
35°C 
34°C 
33°C 
32°C 
119.3% 
143.1% 
172.5% 
209.1% 
255.1% 
+19.3% 
+43.1% 
+72.5% 
+109.1% 
+155.1% 
 
Around 40% increase 
Around 70% increase 
Almost 2 fold increase 
More than 2 fold increase 
     
Km=13.8×(TEM/37) (-6.45), Temperature on Km, p<0.05; Hypothermia (lower body temperature)   
increase Km of phenytoin. 
 
Table 6-4: Vmax change with temperature  
Baseline 37°C Vmax expected to 
decrease to 
The change 
36°C 
35°C 
34°C 
33°C 
32°C 
92.1% 
84.6% 
77.6% 
70.7% 
64.7% 
-7.90% 
-15.4% 
-22.4% 
-29.3% 
-36.3% 
 
Vmax=0.424× (TEM/37) (2.99); Temperature effect on Vmax, p<0.05; Hypothermia (lower body 
temperature) decrease Vmax of phenytoin 
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Figure 6-5: Body temperature-estimated Km curve. Hypothermia increases Km of phenytoin in 
pediatric traumatic brain injury patients 
 
 
 
Figure 6-6: Body temperature-estimated clearance (Vmax/Km) curves. Hypothermia decrease 
clearance in in pediatric traumatic brain injury patients 
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6.4.3 Final model evaluation  
Estimated parameters with se% from the base model and the final model were listed in Table 6-
5. All diagnostic plots revealed that the model was consistent with the observed data (Figure 6-
7). Final model estimates for the structural and random variance parameter demonstrated larger 
inter-individual variability. The final model was assessed further by nonparametric bootstrapping 
method, the results of bootstrap estimates were consistent with NONMEM estimates which 
means the final model was relatively stable and robust (Table 6-5). Individual data with model 
fitting has also been shown in Figure 6-8. Model prediction is in great agreement with the 
individual observed data, therefore, the final model is also relatively accurate and reliable.  
 
 Table 6-5:  Population PK parameters for phenytoin in pediatric TBI patients 
Parameter 
Estimates (SE%)  
Base model Final model 
 
Bootstrap 
Median (25-75% percentile) 
Vm (mg/kg/hr) 
Km (mg/L) 
θ4(TEM/37) 
Vd (L/kg) 
ε2(Km) 
ε2(Vd) 
η1 (Err1) 
0.385 (2.51%)   
8.74 (67.1%)   
-- 
1.15 (7.55%)  
1.88 (123%) 
0.0512 (2.52%) 
7.99 (127%) 
0.458 (5.06%) 
13.8 (36.8%) 
(-6.45) (96.3%) 
1.23 (9.53%) 
1.14 (77.6%) 
0.0543 (3.08%) 
7.76 (119%) 
 0.478 (0.389-0.733) 
 22.60 (8.03-66.80) (with θ4) 
-- 
1.240 (1.12-1.39) 
-0.015 (-0.692-6.34) 
0.00429 (-0.00758-0.6830) 
7.89 (2.78-12.5) 
 
Vm: maximum rate, mg/kg/hr; Km: Michaelis constant, mg/L; Vd:  volume of distribution, L/kg TEM/37: 
temperature normalized by 37; ε2: inter-individual variability; η1: residual error 
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Figure 6-7: Goodness of fit plots for the final model of phenytoin in pediatric traumatic 
brain injury patients. The dashed lines in the upper panels are lines of unity  
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Figure 6-8: Individual time-concentration curves. The dotted points are observed values and the 
lines are model prediction value  
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6.4.4 Temperature and protein binding 
A correlation/collinearity analysis by S-plus 8.1 (TIBCO software Inc, CA) was tested for the 
possible correlation between temperature and unbound fraction (Fu). No correlation was found 
between temperature and Fu fraction, temperature did not change Fu (Figure 6-9). This result is 
consistent with previous studies which showed no protein binding change during hypothermia 
(Iida et al., 2001; Tortorici et al., 2006). Therefore, metabolism of drugs which are depends on 
hepatic enzyme activities would only be affected when hepatic enzyme activities are changed, 
regardless of high or low protein binding fraction.  
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Figure 6-9: There is no correlation between temperature and unbound fraction 
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6.4.5 Simulation 
6.4.5.1 Temperature curve 
Temperature profile used in simulation has been divided into four different periods. (Figure 6-
10): 
A): Time 0-6 hours Y= - 0.6667X+37 ( X is the time point, Y is the temperature) 
(follows protocol induction from 37-33°C in 6 hours, based on linear temperature change).  
B): Time 6-52 hour: maintain at 33°C 
C): Time 52-100 hour Y=0.0833X+28.667  
(follows protocol rewarming from 33-37°C in 48 hours, based on linear temperature change) 
or: Time 52-148 hour Y=0.0417X+30.833  
(follows protocol rewarming from 33-37°C in 96 hours, based on linear temperature change) 
D): Time 100-200 hour, maintain at 33°C 
or: Time 148-200 hour, maintain at 33°C 
 
6.4.5.2 Simulated time-concentration curves in three groups 
Based on the final model estimates, simulations for a single patient in hypothermia with 48 hrs 
rewarming, a single patient in hypothermia with 96 hrs rewarming and a single patient in 
normothermia have been done. Besides temperature covariate, phenytoin dose, study duration, 
has been provided in the following: 
1) Simulation duration 0-200 hours. 
2) Dose: 20mg/kg for loading dose, then 2.5mg/kg for every 12 hours 
The simulation results have been shown in Figure 6-11. The patients in hypothermia showed 
significant elevated concentrations at later time points compared to those in the patient of 
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normothermia. More concentrations higher than 20ng/mL are observed. Phenytoin 
concentrations in 96 hrs rewarming group are slightly higher compared to 48 hrs rewarming 
group in later time points. Therefore, this significant comparison showed that hypothermia 
prolonged the elimination of phenytoin in pediatric patients. Slower rewarming may accumulated 
more drug in the body, however may not be significant. 
 
 
 
 
 
 
 
Figure 6-10: Temperature curve used for the temperature covariate in the simulation 
 
 
 
Y= ‐0.667X+37 
Y=0.083X+28.67 until 100 hrs
Or Y=0.042X+30.83 unitl 148 hrs 
Keep 33°C until 54hrs 
Keep 37 °C until 200 hours 
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Figure 6-11: Final simulated time concentration profile from 0-200 hours. Three groups have 
been compared with the same and repeated dose regimen every 12hours (dotted line with blank 
square =normothermia; solid line with triangle=hypothermia with 48hrs rewarming; solid line 
with solid circle =hypothermia with 96hrs rewarming). Phenytoin concentrations in hypothermia 
with 48 hours rewarming and hypothermia with 96 hours rewarming group are higher than 
normothermia group. In addition, the concentrations in 96 hrs rewarming group are higher 
compared to 48 hrs rewarming group at later time points.  
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6.5 CONLUSION AND DISCUSSION 
 
The results of this study showed us hypothermia cooling for 48 hours significantly affected 
phenytoin PK in pediatric patients. Compared with previous literature, phenytoin PK estimates in 
this study is consistent with other studies (Blain et al., 1981; Berg et al., 1987; Levine et al., 
1987). During hypothermia, previous study has reported the reduced clearance of phenytoin of 
67% (Iida et al., 2001). Phenytoin is metabolized by CYP2C9 and CYP2C19. Our previous 
cardiac arrest animal data has shown hypothermia reduced the clearance of CYP2C9 substrate 
diclofenac (Chapter 3). In addition, this effect has interaction with volume of distribution. This 
data showed the reduced intrinsic clearance (Vmax/Km) of phenytoin, and hypothermia did not 
affect unbound fraction of phenytoin, therefore, the activity of CYP2C9 is likely reduced during 
hypothermia in patients.  
 
Hypothermia significantly increases Km of phenytoin. Every one degree decrease from 37°C, 
there is expected around 19.3% Km increase for phenytoin. The results indicated that 
hypothermia decreased the affinity from substrates to enzyme, and led to the decreased 
elimination and clearance. Predictive simulation also confirmed that hypothermia reduced 
phenytoin metabolism and elimination. In addition, slower rewarming at rate of 1 degree over 24 
hours resulted in higher concentrations of phenytoin in later time points compared to the group 
with rewarming rate at 1 degree over 12 hours. The results and method can be used to predict 
individual patients time concentration profile, therefore will provide the response prediction and 
appropriate drug use guidance. The specific relationship derived from population modeling can 
be used as guidance in estimating and predicting of metabolism changes and appropriate dosage 
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for drug safety and efficacy. More study used the same study design and population in different 
temperature, different dose, and different probe drugs are needed to fully validate these results.  
 
 
The net effect of these increases in drug concentrations is likely to accumulate during rewarming 
seen in the simulation. Depending on the half-life and dose frequency of the given drugs, the 
drug concentrations will remain elevated until a new steady state is established well into the 
rewarming period, whereas, full receptor response may return rapidly upon temperature 
normalization.  Phenytoin has a long half-life of around 22 hours, and 3-5 half lives of 3 to 6 
days, therefore it will take a longer rewarming time for the accumulated drug to be eliminated 
from the body.  The altered pharmacokinetics cannot be simply translated into the altered 
efficacy or toxicity since the drug response and pharmacodynamics is not available. Further 
studies on drug receptor and PK-PD relationship with temperature and diligent clinical 
monitoring are necessary.  
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7.0 SUMMARIES AND FUTURE DIRECTION 
 
 
Therapeutic hypothermia is a proven neuroprotective strategy in multiple animal models and in 
patient studies for both adults out of hospital cardiac arrest and neonates with hypoxic ischemic 
encephalopathy.  Clinical studies demonstrating neurological benefits have cooled adult patients 
to 34 to 32°C for 12 to 24 hours, whereas neonates were cooled over the same temperature range 
for up to 72 hours.  Patients who survived to the point of inpatient care are most vulnerable to 
succumb to this disease during the 24 to 72 hours in which a patient is being cooled and during 
rewarming period.  A wide array of pharmacologic agents are used in these patients, many of 
which have significant toxicities that may affect ventilator weaning, ability to assess seizure 
control, assessment of neurocognitive function, and hypotension. Furthermore, many of the 
enzymes and transporters that affect drug disposition are temperature sensitive and energy 
dependent.  Despite this potential of drug-therapy interaction, few studies have been conducted 
to evaluate the clinical effects of therapeutic hypothermia on drug metabolism and mechanisms, 
and there was little report on dosing algorithms for patients during cooling and after rewarming.  
Based on this need, it is critical for currently ongoing experiments and randomized control trials 
aimed at evaluating the efficacy of therapeutic hypothermia also include sample collection for 
assessment of drug concentrations as part of the study design.   
 
There are several conclusions can be made based on our clinical and preclinical results.   
• Mild hypothermia and cardiac arrest alter CYP activity in an isoform specific manner 
• Magnitude of the reduction is likely temperature, and extraction ratio specific 
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• Short duration hypothermia studies with hepatically eliminated drugs suggest ~11% 
reduction in clearance per °C change 
• Microdosed PK likely to be very useful in any PK design in critically ill patients 
• Therapeutic hypothermia inhibited phenytoin metabolism, Km increase ~19%  per °C  
• Effect of cooling on receptor dynamic response is unknown on current data 
 
In the current study, we did not study any flow dependent drugs.  Based on previous literature, 
similar to low extraction drugs, the metabolism of high extraction ratio drugs also appear to be 
decreased during hypothermia, although the magnitude of flow alterations is highly temperature 
dependent and is likely greater in magnitude at temperatures below 32°C.  A limited number of 
preclinical and in vitro studies suggest that active tubular secretion and drug transporter activity 
are also reduced during therapeutic hypothermia. In contrast, passive renal filtration and drug 
protein binding do not appear to be significantly altered during cooling.   
 
The aforementioned effects of therapeutic hypothermia on drug metabolism have been supported 
by clinical studies demonstrating increased drug concentrations in patients during the cooling 
period. Although drug concentrations are elevated, it is important to recognize that increased 
concentrations may or may not be translated into changes in drug response. Response to certain 
drugs, such as vecuronium was not altered during cooling; therefore, elevated concentrations 
translate into a prolonged duration of effect.  Conversely, in vitro studies have demonstrated 
significant reductions in morphine receptor response under hypothermic temperatures, thereby, 
suggesting a potential decrease in response despite increases in circulating morphine 
concentrations. Drugs with reduced drug responsivity during cooling will be particularly 
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problematic in critically ill patients because many of these drugs are dosed to clinical response.  
This results in an increased dosing despite overall decreased elimination resulting in further 
elevations in drug concentrations during cooling.   
 
Previous literature and our current study results demonstrated the need for close monitoring of 
the drugs administration not only in hypothermic condition but also in normothermic condition 
in clinical practice. The reduction in hepatic blood flow, altered gastrointestinal absorption and 
diminished intrinsic hepatic metabolic activity after cardiac arrest can directly associated with 
altered drug concentration and metabolism. The pharmacokinetics of many drugs used to treat 
heart failure and critical care patients can be significantly altered by the patients underlying 
condition. Up to now, guidelines to dosage adjustments on cardiac arrest and heart failure 
patients is incomplete, and this is tends to be overlooked in clinical practice. Further studies 
focus on cardiovascular specific drugs and patients whose conditions fluctuate widely are 
necessary.  
 
When two factors coexist and have potential interaction, for example, the hypothermia and the 
cardiac arrest factors for cardiac arrest patients receiving hypothermia, to estimate the changes of 
drug metabolism, response and make clinical adjustment is often very difficult. From our results, 
use drugs that are metabolized by CYP3A should always be cautious since both hypothermia and 
CA can affect the drug metabolism and distribution. Use drugs have narrow therapeutic windows 
should warrant a close clinically monitoring. Use drugs with a longer half life should be kept in 
mind that the accumulated drug levels may remain longer than expected. Carefully recording all 
the variables and further population modeling and simulations are needed to test and define the 
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significant variables and association. Larger sample size study is necessary to make the accurate 
estimates as well as the validation of the established model. Additionally, studies in smaller 
groups of well matched patients, evaluating probe drug concentrations will provide additional 
important information. Before a general rule can be concluded, start investigating the specific 
individual clinical relevant drugs as certain model drugs might be more relevant in clinical 
practice and safety.  
 
In closing, it is clear that a great deal of additional research is needed before a full understanding 
of the magnitude of the effects of therapeutic hypothermia on drug concentrations and responses.   
This void in our knowledge can be filled with the incorporation of drug concentration studies 
within currently ongoing clinical trials in patients receiving therapeutic hypothermia.  
Ultimately, studies should incorporate pharmacometrics tools in large patient populations to 
determine specific dosing algorithms for drugs with notable toxicities to guide clinicians in 
optimal pharmaceutical care in this highly vulnerable patient population.    
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